<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9598170</article-id><article-id pub-id-type="doi">10.3390/antibiotics11101378</article-id><article-id pub-id-type="publisher-id">antibiotics-11-01378</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Molecular Basis of Non-&#x003b2;-Lactam Antibiotics Resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9809-2921</contrib-id><name><surname>Lade</surname><given-names>Harshad</given-names></name><xref rid="af1-antibiotics-11-01378" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4668-3225</contrib-id><name><surname>Joo</surname><given-names>Hwang-Soo</given-names></name><xref rid="af2-antibiotics-11-01378" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6025-0341</contrib-id><name><surname>Kim</surname><given-names>Jae-Seok</given-names></name><xref rid="af1-antibiotics-11-01378" ref-type="aff">1</xref><xref rid="c1-antibiotics-11-01378" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Wilkinson</surname><given-names>Brian</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-antibiotics-11-01378"><label>1</label>Department of Laboratory Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul 05355, Korea</aff><aff id="af2-antibiotics-11-01378"><label>2</label>Department of Biotechnology, College of Engineering, Duksung Women&#x02019;s University, Seoul 01369, Korea</aff><author-notes><corresp id="c1-antibiotics-11-01378"><label>*</label>Correspondence: <email>jaeseok@hallym.ac.kr</email> or <email>jaeseok@kdh.or.kr</email>; Tel.: +82-2-2224-2327</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>10</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2022</year></pub-date><volume>11</volume><issue>10</issue><elocation-id>1378</elocation-id><history><date date-type="received"><day>08</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>06</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) is one of the most successful human pathogens with the potential to cause significant morbidity and mortality. MRSA has acquired resistance to almost all &#x003b2;-lactam antibiotics, including the new-generation cephalosporins, and is often also resistant to multiple other antibiotic classes. The expression of penicillin-binding protein 2a (PBP2a) is the primary basis for &#x003b2;-lactams resistance by MRSA, but it is coupled with other resistance mechanisms, conferring resistance to non-&#x003b2;-lactam antibiotics. The multiplicity of resistance mechanisms includes target modification, enzymatic drug inactivation, and decreased antibiotic uptake or efflux. This review highlights the molecular basis of resistance to non-&#x003b2;-lactam antibiotics recommended to treat MRSA infections such as macrolides, lincosamides, aminoglycosides, glycopeptides, oxazolidinones, lipopeptides, and others. A thorough understanding of the molecular and biochemical basis of antibiotic resistance in clinical isolates could help in developing promising therapies and molecular detection methods of antibiotic resistance.</p></abstract><kwd-group><kwd><italic toggle="yes">Staphylococcus aureus</italic></kwd><kwd>MRSA</kwd><kwd>antimicrobial resistance</kwd><kwd>molecular basis</kwd><kwd>macrolides</kwd><kwd>glycopeptides</kwd><kwd>lipopeptides</kwd></kwd-group><funding-group><award-group><funding-source>Korean government, Ministry of Science</funding-source><funding-source>ICT (MSIT)</funding-source><award-id>2017M3A9E4077232</award-id></award-group><award-group><funding-source>Hallym University</funding-source></award-group><funding-statement>This research was supported by the Bio and Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government, Ministry of Science and ICT (MSIT) 2017M3A9E4077232. This study was also supported by the Hallym University research fund.</funding-statement></funding-group></article-meta></front><body><sec id="sec1-antibiotics-11-01378"><title>1. Antibiotic Resistance and Human Health Risk</title><p>The discovery of penicillin by Alexander Fleming in 1928 was one of the largest triumphs of biomedical research [<xref rid="B1-antibiotics-11-01378" ref-type="bibr">1</xref>], and its introduction for clinical use in 1943 began a new era in the treatment of bacterial infection. Alexander Fleming won a Nobel Prize for the discovery of penicillin in 1945, and during his lecture, he warned that overuse of antibiotics could result in selection for resistant bacteria. True to this prediction, the extensive use of antibiotics has led to the selection and expansion of penicillin-resistant bacteria. In 1940, even before the introduction of penicillin for clinical practice, Abraham and Chain identified an enzyme (penicillinase) from <italic toggle="yes">Escherichia coli</italic> able to destroy penicillin [<xref rid="B2-antibiotics-11-01378" ref-type="bibr">2</xref>]. Following the development of penicillin, multiple classes of antibiotics were developed and launched to treat bacterial infections: macrolides, e.g., erythromycin; lincosamides, e.g., clindamycin; aminoglycosides, e.g., gentamicin; glycopeptides, e.g., vancomycin; oxazolidinones, e.g., linezolid; lipopeptides, e.g., daptomycin; tetracyclines, e.g., tetracycline; fluoroquinolones, e.g., ciprofloxacin; pyrimidines/sulfonamides, e.g., trimethoprim&#x02013;sulfamethoxazole, and others (<xref rid="antibiotics-11-01378-f001" ref-type="fig">Figure 1</xref>). Unfortunately, many bacterial pathogens associated with epidemics of human diseases have evolved resistance to almost every sequential antibiotic introduced to target it. Here, the emergence of non-&#x003b2;-lactam antibiotics resistance is exemplified in the bacterial pathogen <italic toggle="yes">Staphylococcus aureus,</italic> which causes a wide range of infectious diseases.</p><p>Antimicrobial resistance (AMR) has been observed in most bacteria but is particularly problematic in hospital-acquired infections from multidrug-resistant ESKAPE (<italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter baumannii, Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Enterobacter</italic> species) pathogens [<xref rid="B3-antibiotics-11-01378" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-11-01378" ref-type="bibr">4</xref>]. The ESKAPE pathogens are capable of escaping the bactericidal action of antibiotics and represent the paradigms for resistance, pathogenesis, and disease transmission in both hospital and community settings [<xref rid="B3-antibiotics-11-01378" ref-type="bibr">3</xref>,<xref rid="B5-antibiotics-11-01378" ref-type="bibr">5</xref>]. The emergence of antibiotic-resistant bacteria causing infectious diseases is a serious public health concern [<xref rid="B6-antibiotics-11-01378" ref-type="bibr">6</xref>]. The World Health Organization (WHO) has described antibiotic resistance as one of the serious threats to global public health, food security, and development today [<xref rid="B7-antibiotics-11-01378" ref-type="bibr">7</xref>]. A 2019 joint report by the United Nations (UN), World Health Organization (WHO), and World Organization for Animal Health (WOAH) states that if no action is taken, drug-resistant diseases could cause 10 million deaths worldwide each year by 2050 with more than $100 trillion economic output loss [<xref rid="B8-antibiotics-11-01378" ref-type="bibr">8</xref>]. The U.S. Centers for Disease Control and Prevention (CDC) estimates that more than 2.8 million infections and 35,000 deaths occur due to antimicrobial-resistant pathogens every year in the United States, with this number expected to rise as more antimicrobial-resistant strains evolve [<xref rid="B9-antibiotics-11-01378" ref-type="bibr">9</xref>]. The rise in antibiotic resistance is of concern in <italic toggle="yes">S. aureus</italic>, which has acquired resistance to almost every sequential antibiotic introduced to target it. For instance, an estimated 323,700 cases of methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) infections in hospitalized patients with 10,600 death were reported in the United States in 2017 [<xref rid="B10-antibiotics-11-01378" ref-type="bibr">10</xref>]. The spread of MRSA has emerged as a global health concern because infections with MRSA are associated with significant morbidity and mortality.</p></sec><sec id="sec2-antibiotics-11-01378"><title>2. Emergence of Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA)</title><p>The infectious diseases caused by <italic toggle="yes">S. aureus</italic> were well-treated by penicillin in the 1940s, but with the widespread use of this agent, penicillin-resistant <italic toggle="yes">S. aureus</italic> began to appear in the clinic. The first penicillin-resistant <italic toggle="yes">S. aureus</italic> infection was reported in 1942 [<xref rid="B11-antibiotics-11-01378" ref-type="bibr">11</xref>], and a penicillinase from <italic toggle="yes">S. aureus</italic> that destroys penicillin was identified in 1944 by Kirby [<xref rid="B12-antibiotics-11-01378" ref-type="bibr">12</xref>]. To combat penicillin-resistant <italic toggle="yes">S. aureus</italic> infection, methicillin (celbenin), semisynthetic &#x003b2;-lactamase-resistant penicillin was introduced to clinical practice in the United Kingdom in 1959 [<xref rid="B13-antibiotics-11-01378" ref-type="bibr">13</xref>]. In 1961, soon after the introduction of methicillin, MRSA strains were identified among clinical isolates from patients hospitalized in the United Kingdom by Patricia Jevons [<xref rid="B14-antibiotics-11-01378" ref-type="bibr">14</xref>]. Between the first reports of MRSA observed in 1961 and the 1990s, infection was common in healthcare settings (HA-MRSA) [<xref rid="B15-antibiotics-11-01378" ref-type="bibr">15</xref>]. However, by the 1990s, MRSA infections has rapidly spread in the community (CA-MRSA) [<xref rid="B16-antibiotics-11-01378" ref-type="bibr">16</xref>]. MRSA is one of the major causes of hospital-acquired infection globally and also occurs outside and independent of hospitals by CA-MRSA [<xref rid="B17-antibiotics-11-01378" ref-type="bibr">17</xref>] and, since the mid-2000s, by livestock-associated MRSA (LA-MRSA) [<xref rid="B18-antibiotics-11-01378" ref-type="bibr">18</xref>]. Several <italic toggle="yes">S. aureus</italic> clones (strains indistinguishable from each other by a variety of genetic tests) have developed into MRSA, which confer resistance to most &#x003b2;-lactam antibiotics. Furthermore, the prevalence of MRSA strains resistant to multiple non-&#x003b2;-lactam antibiotics has steadily increased and now become a major human health threat in infectious diseases [<xref rid="B19-antibiotics-11-01378" ref-type="bibr">19</xref>]. </p><p>Methicillin resistance is mediated by <italic toggle="yes">mecA</italic> gene [<xref rid="B20-antibiotics-11-01378" ref-type="bibr">20</xref>], acquired by horizontal transfer of a mobile genetic element staphylococcal cassette chromosome <italic toggle="yes">mec</italic> (SCC<italic toggle="yes">mec</italic>) [<xref rid="B21-antibiotics-11-01378" ref-type="bibr">21</xref>]. The <italic toggle="yes">mecA</italic> gene encodes an alternative penicillin-binding protein 2a that has a low affinity for &#x003b2;-lactam antibiotics [<xref rid="B22-antibiotics-11-01378" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-11-01378" ref-type="bibr">23</xref>], resulting in resistance to this entire class. PBP2a enables <italic toggle="yes">S. aureus</italic> to maintain cell wall synthesis when other PBPs are inhibited by &#x003b2;-lactams [<xref rid="B24-antibiotics-11-01378" ref-type="bibr">24</xref>]. MRSA strains, besides being resistant to nearly all &#x003b2;-lactams, are often resistant to antibiotics of other classes such as macrolides, lincosamides, aminoglycosides, glycopeptides, oxazolidinones, and lipopeptides [<xref rid="B25-antibiotics-11-01378" ref-type="bibr">25</xref>,<xref rid="B26-antibiotics-11-01378" ref-type="bibr">26</xref>]. For example, complicated urinary tract infections (cUTIs) caused by MRSA are commonly treated with vancomycin [<xref rid="B27-antibiotics-11-01378" ref-type="bibr">27</xref>], but strains with decreased susceptibility, designated as vancomycin-intermediate <italic toggle="yes">S. aureus</italic> (VISA)m emerged in 1996 [<xref rid="B28-antibiotics-11-01378" ref-type="bibr">28</xref>]. Furthermore, clindamycin (discovered in 1966) has been generally used to treat skin and soft-tissue infection (SSTI) caused by CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>], and strains with clindamycin resistance were reported in 1968 [<xref rid="B30-antibiotics-11-01378" ref-type="bibr">30</xref>]. </p></sec><sec id="sec3-antibiotics-11-01378"><title>3. Molecular Basis of Non-&#x003b2;-Lactams Resistance</title><p><italic toggle="yes">S. aureus</italic> has developed numerous mechanisms to neutralize the effect of antibiotics. Antibiotic resistance is commonly associated with the acquisition of resistance genes or mutations affecting central biochemical processes. MRSA confers resistance to non-&#x003b2;-lactam antibiotics by various mechanisms, such as (i) target modification, (ii) mutation of target, (iii) drug inactivation by enzymes, and (iv) decreased antibiotic uptake or efflux (<xref rid="antibiotics-11-01378-f002" ref-type="fig">Figure 2</xref>). </p><sec id="sec3dot1-antibiotics-11-01378"><title>3.1. Target Modification</title><p>Antibiotics work by binding to a cellular target so that an essential biochemical process is blocked. An alteration of the target structure prevents antibiotic binding, or it binds weakly, and thus acts as a self-resistance mechanism. The ribosome is a complex molecular machine associated with protein synthesis, and alteration of the drug-binding site through modification of rRNA results in resistance to ribosome-targeting antibiotics. For example, modification of the bacterial ribosome by 23S rRNA methyltransferase [<xref rid="B40-antibiotics-11-01378" ref-type="bibr">40</xref>] prevents the binding of macrolides to ribosomal targets [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>]. Methylation of 23S rRNA by chloramphenicol-florfenicol resistance (<italic toggle="yes">cfr</italic>) gene encoded rRNA methyltransferase alters the drug-binging site 50S ribosomal subunit [<xref rid="B41-antibiotics-11-01378" ref-type="bibr">41</xref>], thus reducing the ability of chloramphenicol and clindamycin antibiotics to inhibit the ribosomes translational activity. RNA methyltransferase, the gene product of <italic toggle="yes">cfr</italic> from <italic toggle="yes">S. sciuri</italic> [<xref rid="B42-antibiotics-11-01378" ref-type="bibr">42</xref>] targets nucleotide A2503 of 23S rRNA and inhibits ribose methylation at nucleotide C2498, thereby causing resistance to chloramphenicol, florfenicol, and clindamycin in <italic toggle="yes">S. aureus</italic> laboratory strain [<xref rid="B42-antibiotics-11-01378" ref-type="bibr">42</xref>].</p></sec><sec id="sec3dot2-antibiotics-11-01378"><title>3.2. Mutation of Target</title><p>Chromosomal mutations that drive antibiotic resistance often arise within the genes that encode targets. Mutation of the target plays a major role in the development of resistance across distinct antibiotics such as mutations in the DNA topoisomerase IV and DNA gyrase with fluoroquinolones [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>], alterations to RNA polymerase with high-level resistance to rifampicin [<xref rid="B43-antibiotics-11-01378" ref-type="bibr">43</xref>], and ribosomal mutations (<italic toggle="yes">tetM</italic> and <italic toggle="yes">tetO</italic>) with tetracyclines [<xref rid="B44-antibiotics-11-01378" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-11-01378" ref-type="bibr">45</xref>]. Mutations in the chromosomal genes <italic toggle="yes">grlA</italic> (referred to as <italic toggle="yes">parC</italic> in other bacteria) (encoding DNA topoisomerase IV subunit A) [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>,<xref rid="B46-antibiotics-11-01378" ref-type="bibr">46</xref>] and <italic toggle="yes">gyrA</italic> (encoding an essential enzyme DNA gyrase subunit A) [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>] are the primary mechanisms of fluoroquinolones resistance in <italic toggle="yes">S. aureus</italic>. The two enzymes are associated with the overlapping and opening of the double-stranded DNA during replication. Mutations of the <italic toggle="yes">grlA</italic> gene affect the amino acid codons Ser80, Glu84, and Ala116 of GrlA enzyme subunit [<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>,<xref rid="B46-antibiotics-11-01378" ref-type="bibr">46</xref>], whereas <italic toggle="yes">gyrA</italic> gene mutations affect the amino acid codons Ser84, Ser85, and Glu88 of GyrA enzyme subunit [<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B47-antibiotics-11-01378" ref-type="bibr">47</xref>] in the quinolone-resistance-determining region (QRDR). The changes in amino acids, particularly those in certain regions of each GrlA and GyrA enzyme subunit called the QRDR, decrease the binding affinity of enzymes and make them less sensitive to inhibition by fluoroquinolones. Nearly all quinolone-resistant <italic toggle="yes">S. aureus</italic> strains substitute Ser84 of GyrA with Leu or, in some other strains, Ser80 of GrlA with Phe [<xref rid="B48-antibiotics-11-01378" ref-type="bibr">48</xref>,<xref rid="B49-antibiotics-11-01378" ref-type="bibr">49</xref>].</p></sec><sec id="sec3dot3-antibiotics-11-01378"><title>3.3. Drug Inactivation by Enzymes</title><p>The enzymatic modification that renders antibiotics of decreased affinity for their main target 16S rRNA is the most prevalent mechanism of aminoglycosides resistance in <italic toggle="yes">S. aureus</italic> [<xref rid="B50-antibiotics-11-01378" ref-type="bibr">50</xref>]. AMEs catalyze the modification at &#x02013;OH or &#x02013;NH2 groups of the 2-deoxystreptamine nucleus or the sugar moieties of aminoglycosides [<xref rid="B51-antibiotics-11-01378" ref-type="bibr">51</xref>]. Resistance to the aminoglycoside antibiotics gentamicin, tobramycin, and kanamycin is generally mediated by a bifunctional AME AAC(6&#x02032;)/APH(2&#x02033;) encoded by <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) gene that specifies 6&#x02032;-acetyltransferase [AAC(6&#x02032;)] and 2&#x02033;-phosphotransferase [APH(2&#x02033;)] aminoglycoside-modifying activities [<xref rid="B36-antibiotics-11-01378" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-11-01378" ref-type="bibr">37</xref>]. Esterases encoded by <italic toggle="yes">ere</italic> genes [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>] and phosphotransferases encoded by <italic toggle="yes">mph</italic> genes [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>] confer resistance to erythromycin and other 14-, 15-, and 16-membered macrolides in <italic toggle="yes">S. aureus</italic>. Thiol-S-transferase (encoded by <italic toggle="yes">fosB</italic> gene) catalyzes the inactivation of fosfomycin [<xref rid="B53-antibiotics-11-01378" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-11-01378" ref-type="bibr">54</xref>], which is used to treat UTIs.</p></sec><sec id="sec3dot4-antibiotics-11-01378"><title>3.4. Decreased Antibiotic Uptake or Efflux</title><p>Resistance can develop either by decreasing the permeability of the cell membrane or by increasing the efflux of antibiotics from the cell through changes in membrane permeability [<xref rid="B55-antibiotics-11-01378" ref-type="bibr">55</xref>]. NorA, QacA/B, and Smr (Staphylococcal multidrug resistance, also known as QacC/D) are multidrug efflux membrane proteins found mainly in <italic toggle="yes">S. aureus</italic> clinical isolates [<xref rid="B56-antibiotics-11-01378" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-11-01378" ref-type="bibr">57</xref>]. NorA (encoded by <italic toggle="yes">norA</italic> gene) is a chromosomally encoded multidrug efflux pump protein of the core genome of <italic toggle="yes">S. aureus</italic> [<xref rid="B58-antibiotics-11-01378" ref-type="bibr">58</xref>] associated with resistance to fluoroquinolones, tetracyclines, and several antiseptics (chlorhexidine digluconate, cetrimide, benzalkonium chloride) [<xref rid="B59-antibiotics-11-01378" ref-type="bibr">59</xref>]. The <italic toggle="yes">qacA</italic> and <italic toggle="yes">qacB</italic> genes encode an efflux pump protein that has been associated with increased resistance to fluoroquinolones and chlorhexidine tolerance [<xref rid="B60-antibiotics-11-01378" ref-type="bibr">60</xref>,<xref rid="B61-antibiotics-11-01378" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-11-01378" ref-type="bibr">62</xref>]. Furthermore, mutations in genes encoding efflux pumps make the antibiotic export more efficient. For example, mutations in the bacterial DNA can lead the bacteria to produce more of a certain efflux pump. In staphylococci, the tetracyclines resistance is mediated by Tet efflux pumps TetA(K) and TetA(L), which are members of the major facilitator superfamily (MFS) transporters with 14 transmembrane domains. TetK is encoded by the small multicopy plasmid pT181 and is integrated within the chromosomal SCC<italic toggle="yes">mec</italic>III cassette of MRSA strains [<xref rid="B63-antibiotics-11-01378" ref-type="bibr">63</xref>].</p></sec></sec><sec id="sec4-antibiotics-11-01378"><title>4. MRSA Resistance to Non-&#x003b2;-Lactams</title><p>Since 1961, the incidence of MRSA resistance to &#x003b2;-lactam antibiotics including new-generation cephalosporins is increasing worldwide [<xref rid="B64-antibiotics-11-01378" ref-type="bibr">64</xref>]. MRSA strains become additionally resistant to antibiotics of multiple non-&#x003b2;-lactam classes such as macrolides, aminoglycosides, glycopeptides, oxazolidinone, lipopeptide, pyrimidine/sulfonamide, and others. This is because MRSA strains often harbor genes that convey resistance to antibiotics of multiple non-&#x003b2;-lactam classes. Antibiotic resistance is mediated through several distinct mechanisms, most of which are quite well-understood [<xref rid="B65-antibiotics-11-01378" ref-type="bibr">65</xref>]. Depending on the antimicrobial class, <italic toggle="yes">S. aureus</italic> can utilize different mechanisms to resist the antibiotic effect. In this review, we included the approved non-&#x003b2;-lactam antibiotics currently used for the management of patients with MRSA infections, which are suggested as per the evidence-based guidelines prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA) [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>] and United Kingdom (UK) guidelines produced following a review of the published literature (2007&#x02013;2018) [<xref rid="B27-antibiotics-11-01378" ref-type="bibr">27</xref>]. A summary of the currently used non-&#x003b2;-lactam antibiotic mechanisms of action and molecular bases of resistance in <italic toggle="yes">S. aureus</italic> is presented in <xref rid="antibiotics-11-01378-t001" ref-type="table">Table 1</xref>. A better understanding of the molecular basis of antibiotic resistance could help in the development of novel drugs that suppress MRSA in multiple ways and molecular detection methods of antibiotic resistance.</p><sec id="sec4dot1-antibiotics-11-01378"><title>4.1. Macrolides (Erythromycin)</title><p>Erythromycin, a macrolide antibiotic discovered in 1952, has been used for the treatment of SSTIs caused by MRSA [<xref rid="B66-antibiotics-11-01378" ref-type="bibr">66</xref>]. Macrolide antibiotics inhibit protein synthesis by targeting the bacterial ribosome. They bind to bacterial 23S rRNA on the 50S ribosome subunit and stop protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and assembly of the 50S ribosomal subunit [<xref rid="B68-antibiotics-11-01378" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-11-01378" ref-type="bibr">69</xref>]. Macrolide molecules may also affect the functional properties of the catalytic center of the ribosome, leading to inhibition of translation or a change in the reading frame, resulting in the abnormal synthesis of the polypeptide chain [<xref rid="B222-antibiotics-11-01378" ref-type="bibr">222</xref>]. Macrolides have a broad spectrum of activity against both gram-positive and gram-negative bacteria.</p><p><italic toggle="yes">S. aureus</italic> resistance to erythromycin was first observed in 1955, following its introduction in 1952 [<xref rid="B67-antibiotics-11-01378" ref-type="bibr">67</xref>]. In <italic toggle="yes">S. aureus</italic>, the resistance to macrolides, lincosamides, and streptogramin B (MLS<sub>B</sub>) antibiotics correlates with the resistance to methicillin [<xref rid="B223-antibiotics-11-01378" ref-type="bibr">223</xref>]. MRSA strains showing resistance to MLS<sub>B</sub> are usually determined by the presence of 23S rRNA methyltransferase encoding <italic toggle="yes">ermA</italic> or <italic toggle="yes">ermC</italic> genes, whereas MSSA strains show resistance by <italic toggle="yes">ermC</italic>, followed by <italic toggle="yes">ermB</italic>, genes [<xref rid="B70-antibiotics-11-01378" ref-type="bibr">70</xref>]. The MLS<sub>B</sub> resistance can be inducible or constitutive and is not related to the type of <italic toggle="yes">erm</italic> genes.</p><p>The main mechanisms leading to macrolide resistance in <italic toggle="yes">S. aureus</italic> are (i) modification of the bacterial ribosome by <italic toggle="yes">erm</italic>-gene-encoded 23S rRNA methyltransferase [<xref rid="B70-antibiotics-11-01378" ref-type="bibr">70</xref>], which leads to a conformational change in the ribosome, thus preventing the binding of macrolides to ribosomal target [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>]; (ii) active efflux of macrolides from the cell by ATP-binding cassette family (ABC-F) transporters encoded by <italic toggle="yes">msr</italic>A and <italic toggle="yes">msr</italic>B genes, protecting the bacterial ribosome from antibiotic-mediated inhibition [<xref rid="B72-antibiotics-11-01378" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-11-01378" ref-type="bibr">73</xref>]; (iii) enzymatic inactivation of the macrolides by phosphotransferases (encoded by <italic toggle="yes">mph</italic> genes) [<xref rid="B74-antibiotics-11-01378" ref-type="bibr">74</xref>] and esterase (encoded by <italic toggle="yes">ere</italic> genes), which prevent binding to target site [<xref rid="B74-antibiotics-11-01378" ref-type="bibr">74</xref>]. Indeed, the major genes associated with macrolides resistance in <italic toggle="yes">S. aureus</italic> include <italic toggle="yes">ermA</italic> [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>], <italic toggle="yes">ermB</italic>, <italic toggle="yes">ermC</italic> [<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>], <italic toggle="yes">ermY</italic> [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>], <italic toggle="yes">msr</italic>(F) [<xref rid="B71-antibiotics-11-01378" ref-type="bibr">71</xref>], <italic toggle="yes">msrA</italic> [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>,<xref rid="B72-antibiotics-11-01378" ref-type="bibr">72</xref>], <italic toggle="yes">msrB</italic>, <italic toggle="yes">ereA</italic>, <italic toggle="yes">ereB</italic>, <italic toggle="yes">mphB</italic>, and <italic toggle="yes">mphC</italic> [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>].</p></sec><sec id="sec4dot2-antibiotics-11-01378"><title>4.2. Lincosamide (Clindamycin)</title><p>Clindamycin, a lincosamide antibiotic approved in 1966, has been used for the treatment of SSTIs caused by CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>]. Clindamycin in MLS<sub>B</sub> family of antibiotics serves as an alternative to treat both MSSA and MRSA infections due to its excellent pharmacokinetic properties. It inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit and impedes both the assembly of ribosomes and the translation process [<xref rid="B75-antibiotics-11-01378" ref-type="bibr">75</xref>]. It impairs peptide chain initiation and stimulates the dissociation of peptidyl-tRNA from ribosomes.</p><p>The widespread use of clindamycin has led to the emergence of resistant strains; the first report of clindamycin resistance in <italic toggle="yes">S. aureus</italic> appeared in 1968 [<xref rid="B30-antibiotics-11-01378" ref-type="bibr">30</xref>]. Resistance to clindamycin generally occurs through ribosomal target site modification mediated by <italic toggle="yes">erm</italic> genes [<xref rid="B70-antibiotics-11-01378" ref-type="bibr">70</xref>], which can be expressed either constitutively (<sub>c</sub>MLS<sub>B</sub> phenotype) or inducibly (<sub>i</sub>MLS<sub>B</sub> phenotype) [<xref rid="B40-antibiotics-11-01378" ref-type="bibr">40</xref>,<xref rid="B76-antibiotics-11-01378" ref-type="bibr">76</xref>]. The <italic toggle="yes">ermB, ermC</italic>, and <italic toggle="yes">ermA</italic> genes code for rRNA methylase, which methylates and alters the drug target site 23S rRNA, thus preventing the binding of MLS<sub>B</sub> antibiotics [<xref rid="B77-antibiotics-11-01378" ref-type="bibr">77</xref>]. Furthermore, resistance to clindamycin occurs through target site modification by <italic toggle="yes">cfr</italic>-gene-encoded rRNA methyltransferase [<xref rid="B41-antibiotics-11-01378" ref-type="bibr">41</xref>], which methylates an adenine residue of the 23S rRNA in the 50S ribosomal subunit, resulting in altered antibiotic binding sites within the ribosome. The emergence of multidrug-resistant CA-MRSA strains carrying plasmid pUSA03 (codes for resistance to clindamycin and mupirocin), predominant among isolates from men who have sex with men (MSM), is on the rise in Boston and San Francisco [<xref rid="B224-antibiotics-11-01378" ref-type="bibr">224</xref>]. Transformation of a large plasmid pSCFS3 that carried the two chloramphenicol- and florfenicol-resistance genes <italic toggle="yes">cfr</italic> and <italic toggle="yes">fexA</italic> from porcine <italic toggle="yes">S. aureus</italic> strain into <italic toggle="yes">S. aureus</italic> RN4220 mediated high-level clindamycin resistance (MIC 256 &#x003bc;g/mL) in addition to chloramphenicol&#x02013;florfenicol resistance (MICs for both &#x02265; 128 &#x003bc;g/mL) [<xref rid="B42-antibiotics-11-01378" ref-type="bibr">42</xref>].</p></sec><sec id="sec4dot3-antibiotics-11-01378"><title>4.3. Aminoglycosides (Gentamicin)</title><p>Gentamicin, an aminoglycoside antibiotic, was approved by the U.S. FDA in 1971 for the treatment of sepsis in newborns, septicemia, and UTI caused by MRSA. Gentamicin acts by binding to the 16S rRNA helix at the mRNA&#x02013;tRNA decoding center of bacterial 30S ribosome subunit [<xref rid="B80-antibiotics-11-01378" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-11-01378" ref-type="bibr">81</xref>], thereby causing inaccurate induction and inhibition of translation, disrupting bacterial protein synthesis [<xref rid="B82-antibiotics-11-01378" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-11-01378" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-11-01378" ref-type="bibr">84</xref>].</p><p>Resistance to aminoglycosides is usually mediated by aminoglycoside-modifying enzyme (AME) AAC(6&#x02032;)/APH(2&#x02033;) in <italic toggle="yes">S. aureus</italic> [<xref rid="B85-antibiotics-11-01378" ref-type="bibr">85</xref>]. The AMEs inactivate aminoglycosides by <italic toggle="yes">N</italic>-acetylation (<italic toggle="yes">N</italic>-acetyl transferases, AAC), <italic toggle="yes">O</italic>-phosphorylation (aminoglycoside phosphotransferases, APH), or <italic toggle="yes">O</italic>-adenylation (aminoglycoside nucleotidinyl transferases, ANT) of amino or hydroxyl groups of antibiotics [<xref rid="B51-antibiotics-11-01378" ref-type="bibr">51</xref>]. Gentamicin-resistant <italic toggle="yes">S. aureus</italic> was first reported in 1975 [<xref rid="B78-antibiotics-11-01378" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-11-01378" ref-type="bibr">79</xref>]. The <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;<italic toggle="yes">)</italic>-gene-encoded bifunctional AME AAC(6&#x02032;)/APH(2&#x02033;) specifies both 6&#x02032;-acetyltransferase (AAC(6&#x02032;))- and 2&#x02033;-phosphotransferase (APH(2&#x02033;))-aminoglycoside-modifying activities [<xref rid="B36-antibiotics-11-01378" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-11-01378" ref-type="bibr">37</xref>]. The <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) gene is the most prevalent in aminoglycoside-resistant <italic toggle="yes">S. aureus</italic> isolates [<xref rid="B86-antibiotics-11-01378" ref-type="bibr">86</xref>,<xref rid="B225-antibiotics-11-01378" ref-type="bibr">225</xref>].</p><p>Arbekacin is a semisynthetic aminoglycoside antibiotic derived from kanamycin. Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approved arbekacin for the treatment of pneumonia caused by MRSA in 1990 [<xref rid="B87-antibiotics-11-01378" ref-type="bibr">87</xref>]. It is not used clinically in the USA. Arbekacin binds to the four nucleotides of the 16S rRNA and one amino acid of protein S12 to interfere with the decoding site around nucleotide 1400 in the 16S rRNA of the 30S ribosome subunit [<xref rid="B89-antibiotics-11-01378" ref-type="bibr">89</xref>]. This site interacts with the wobble base of tRNA, which leads to the misreading of mRNA, such that incorrect amino acids are inserted into the proteins. These error-filled proteins are nonfunctional or even toxic. A single base alteration at site G1126A of the <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) gene, resulting in one amino acid substitution S376N in the phosphorylation catalytic motif of AAC(6&#x02032;)/APH(2&#x02033;), has been reported to be associated with arbekacin resistance in MRSA strain PRC104 [<xref rid="B90-antibiotics-11-01378" ref-type="bibr">90</xref>]. Moreover, MRSA strain KU5801, which has additional &#x003b2;-lactam-inducible arbekacin resistance, was reported in Japan due to an antagonistic mechanism [<xref rid="B91-antibiotics-11-01378" ref-type="bibr">91</xref>] by which the integration of Tn4001-IS257 hybrid structure that contained the <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) gene cointegrated into a region downstream of the <italic toggle="yes">blaZ</italic> gene. A previous study found that all 17 MRSA strains belonging to <italic toggle="yes">coa</italic>-RFLP type M22 possessed the <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) gene, but 70.1% were resistant to arbekacin [<xref rid="B88-antibiotics-11-01378" ref-type="bibr">88</xref>], whereas of the 363 MRSA type L21 strains, 5.5% were arbekacin-resistant, despite about half (41.9%) of them carrying the <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) gene. This suggests that AAC(6&#x02032;)/APH(2&#x02033;) mediate arbekacin resistance, but there is not a single mechanism among MRSA type L21 strains [<xref rid="B88-antibiotics-11-01378" ref-type="bibr">88</xref>]. AAC(6&#x02032;)/APH(2&#x02033;) has the capability of 6&#x02032;-<italic toggle="yes">N</italic>-acetylation and/or 2&#x02033;-<italic toggle="yes">O</italic>-phosphorylation of arbekacin that contains 6&#x02032;-NH<sub>2</sub> and/or 2&#x02033;-OH [<xref rid="B37-antibiotics-11-01378" ref-type="bibr">37</xref>,<xref rid="B92-antibiotics-11-01378" ref-type="bibr">92</xref>].</p></sec><sec id="sec4dot4-antibiotics-11-01378"><title>4.4. Glycopeptides (Vancomycin)</title><p>Vancomycin, a glycopeptide antibiotic, was introduced in 1958 for the treatment of severe gram-positive bacterial infections, including MRSA [<xref rid="B226-antibiotics-11-01378" ref-type="bibr">226</xref>]. Vancomycin has long been considered the last-line antibiotic to treat serious infections, such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, sepsis, and severe SSTI due to both HA-MRSA and CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>]. Vancomycin inhibits bacterial cell wall synthesis by targeting the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan [<xref rid="B227-antibiotics-11-01378" ref-type="bibr">227</xref>,<xref rid="B228-antibiotics-11-01378" ref-type="bibr">228</xref>]. It forms hydrogen bonds with D-Ala-D-Ala termini moieties of the peptidoglycan precursor lipid II, resulting in conformational alteration that inhibits the incorporation of <italic toggle="yes">N</italic>-acetylmuramic acid (NAM)- and <italic toggle="yes">N</italic>-acetylglucosamine (NAG)-peptide subunits into the growing peptidoglycan chain, thereby inhibiting bacterial cell wall biosynthesis [<xref rid="B95-antibiotics-11-01378" ref-type="bibr">95</xref>,<xref rid="B229-antibiotics-11-01378" ref-type="bibr">229</xref>]. This alters bacterial membrane integrity and increases its permeability, which ultimately leads to bacterial death [<xref rid="B229-antibiotics-11-01378" ref-type="bibr">229</xref>]. The Clinical and Laboratory Standards Institute (CLSI) has classified <italic toggle="yes">S. aureus</italic> isolates as vancomycin-susceptible <italic toggle="yes">S. aureus</italic> (VSSA; MIC &#x02264; 2 &#x003bc;g/mL), vancomycin-intermediate <italic toggle="yes">S. aureus</italic> (VISA; MIC of 4&#x02013;8 &#x003bc;g/mL), and vancomycin-resistant <italic toggle="yes">S. aureus</italic> (VRSA; MIC &#x02265; 16 &#x003bc;g/mL) [<xref rid="B146-antibiotics-11-01378" ref-type="bibr">146</xref>].</p><p>While human infections with MRSA are commonly treated with vancomycin, VISA started appearing in the 1990s [<xref rid="B28-antibiotics-11-01378" ref-type="bibr">28</xref>]. The first <italic toggle="yes">S. aureus</italic> clinical strain with reduced vancomycin susceptibility (MIC 8 &#x003bc;g/mL) was reported in Japan in 1996 [<xref rid="B28-antibiotics-11-01378" ref-type="bibr">28</xref>]. The gradual mutations within genes encoding two-component regulatory systems (TCSs) such as WalKR [<xref rid="B104-antibiotics-11-01378" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-11-01378" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-11-01378" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-11-01378" ref-type="bibr">107</xref>], VraSR [<xref rid="B108-antibiotics-11-01378" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-11-01378" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-11-01378" ref-type="bibr">110</xref>], or GraSR [<xref rid="B107-antibiotics-11-01378" ref-type="bibr">107</xref>,<xref rid="B109-antibiotics-11-01378" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-11-01378" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-11-01378" ref-type="bibr">111</xref>,<xref rid="B112-antibiotics-11-01378" ref-type="bibr">112</xref>] are predominantly involved in cell wall biosynthesis and are associated with VISA. WalKR is essential for the regulation of cell wall metabolism-associated genes and particularly as a regulator of peptidoglycan synthesis at the time of cross-bridge hydrolysis [<xref rid="B230-antibiotics-11-01378" ref-type="bibr">230</xref>,<xref rid="B231-antibiotics-11-01378" ref-type="bibr">231</xref>,<xref rid="B232-antibiotics-11-01378" ref-type="bibr">232</xref>]. GraSR system is involved in cell envelope modifications through regulation of the <italic toggle="yes">dlt</italic> operon and <italic toggle="yes">mprF/fmtC</italic> genes that are linked to teichoic acid alanylation and alteration of cell wall charge [<xref rid="B97-antibiotics-11-01378" ref-type="bibr">97</xref>]. Mutations within the <italic toggle="yes">graSR</italic> are associated with modified expression of global regulators Rot (repressor of toxins) [<xref rid="B233-antibiotics-11-01378" ref-type="bibr">233</xref>] and accessory gene regulator (Agr) [<xref rid="B234-antibiotics-11-01378" ref-type="bibr">234</xref>], which lead to VISA. Regulator mutation in TCS <italic toggle="yes">walKR</italic> and truncating mutation in proteolytic regulatory gene <italic toggle="yes">clpP</italic> in laboratory-derived VISA strain N315LR5P1 leads to 1 to 2 mg/L raised vancomycin resistance [<xref rid="B113-antibiotics-11-01378" ref-type="bibr">113</xref>]. Furthermore, the mutation in <italic toggle="yes">rpoB</italic> gene encoding the DNA-dependent RNA polymerase &#x003b2;-subunit results in increased cell wall thickness and thereby increased resistance to vancomycin [<xref rid="B99-antibiotics-11-01378" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-11-01378" ref-type="bibr">100</xref>]. Recently, single-nucleotide polymorphisms (SNPs) in the <italic toggle="yes">capB</italic> (E58K) gene (encoding tyrosine kinase) and <italic toggle="yes">lytN</italic> (I16V) gene (encoding <italic toggle="yes">N</italic>-acetylmuramyl-L-alanine amidase) have been shown to cause increased <italic toggle="yes">S. aureus</italic> resistance to vancomycin in the absence of <italic toggle="yes">van</italic> genes [<xref rid="B101-antibiotics-11-01378" ref-type="bibr">101</xref>].</p><p>The occurrence of VRSA infections in clinical settings remains rare [<xref rid="B235-antibiotics-11-01378" ref-type="bibr">235</xref>], which could be due to the antagonistic effects of <italic toggle="yes">mecA</italic> and <italic toggle="yes">vanA</italic> resistance determinants [<xref rid="B236-antibiotics-11-01378" ref-type="bibr">236</xref>]. The development of VRSA strains occurred through horizontal gene transfer (HGT) of the <italic toggle="yes">vanA</italic> gene by transposon Tn<italic toggle="yes">1546</italic> from vancomycin-resistant <italic toggle="yes">Enterococcus faecalis</italic> [<xref rid="B237-antibiotics-11-01378" ref-type="bibr">237</xref>]. The <italic toggle="yes">vanA</italic> gene cluster that encodes D-Ala:D-Lac ligases alters the dipeptide terminus of peptidoglycan precursors from D-Ala-D-Ala to D-Ala-D-lactate (D-Ala-D-Lac) [<xref rid="B95-antibiotics-11-01378" ref-type="bibr">95</xref>,<xref rid="B238-antibiotics-11-01378" ref-type="bibr">238</xref>], which has substantially lower binding affinity for vancomycin and thus fails to inhibit cell wall synthesis in <italic toggle="yes">S. aureus</italic> [<xref rid="B102-antibiotics-11-01378" ref-type="bibr">102</xref>]. The first <italic toggle="yes">vanA</italic>-mediated high-level VRSA (MIC &#x02265; 32 &#x000b5;g/mL) clinical strain was recovered in Michigan, the USA in 2002 [<xref rid="B239-antibiotics-11-01378" ref-type="bibr">239</xref>]. Furthermore, the first <italic toggle="yes">vanA</italic>-mediated methicillin-resistant VRSA (MIC &#x0003e; 256 &#x000b5;g/mL) strain in Europe was isolated from a patient in Portugal in 2013 [<xref rid="B240-antibiotics-11-01378" ref-type="bibr">240</xref>].</p></sec><sec id="sec4dot5-antibiotics-11-01378"><title>4.5. Oxazolidinones (Linezolid)</title><p>Linezolid is the first fully synthetic oxazolidinone antibiotic approved by the U.S. FDA in 2000 for the treatment of acute bacterial skin and skin structure infections (ABSSSI), pneumonia, bone and joint infections (BJI), and catheter-related bacteremia caused by gram-positive bacteria with activity against MRSA [<xref rid="B120-antibiotics-11-01378" ref-type="bibr">120</xref>,<xref rid="B241-antibiotics-11-01378" ref-type="bibr">241</xref>]. Linezolid inhibits bacterial protein synthesis by binding to the domain V region of the 23S rRNA of the 50S ribosome subunit and preventing the complex formation with <italic toggle="yes">N</italic>-formyl methionyl&#x02013;tRNA (tRNA<sup>fMet</sup>), mRNA, and the 30S ribosome subunit [<xref rid="B120-antibiotics-11-01378" ref-type="bibr">120</xref>,<xref rid="B122-antibiotics-11-01378" ref-type="bibr">122</xref>]. The clinical breakpoint of linezolid for MRSA is 8&#x02009;&#x003bc;g/mL.</p><p>MRSA clinical isolates with resistance to linezolid were first reported in 2001 [<xref rid="B121-antibiotics-11-01378" ref-type="bibr">121</xref>]. Further, new oxazolidinone antibiotics such as tedizolid, radezolid, and contezolid with superior efficacy were developed, but MRSA clones with resistance to these antibiotics also evolved [<xref rid="B242-antibiotics-11-01378" ref-type="bibr">242</xref>]. Linezolid resistance in MRSA was due to the acquisition of <italic toggle="yes">cfr</italic> gene, encoding 23S rRNA methyltransferase enzyme [<xref rid="B125-antibiotics-11-01378" ref-type="bibr">125</xref>], which alters adenosine at position 2503 in 23S rRNA in the large ribosomal subunit [<xref rid="B126-antibiotics-11-01378" ref-type="bibr">126</xref>]. A T2500A mutation in the <italic toggle="yes">23S rRNA</italic> gene and loss of a single copy of rRNA has been reported to be associated with linezolid resistance in sequential <italic toggle="yes">S. aureus</italic> isolates [<xref rid="B127-antibiotics-11-01378" ref-type="bibr">127</xref>]. Furthermore, the mutation of domain V of the 23S rRNA [<xref rid="B121-antibiotics-11-01378" ref-type="bibr">121</xref>] and mutation of the ribosomal proteins near the linezolid binding site in the ribosomal peptidyl transferase center [<xref rid="B128-antibiotics-11-01378" ref-type="bibr">128</xref>] results in linezolid resistance in MRSA. Multiple MRSA clones with two mutations in the ribosomal protein uL3 exhibited resistance to linezolid, with a two-fold higher MIC than the clinical breakpoint [<xref rid="B243-antibiotics-11-01378" ref-type="bibr">243</xref>].</p></sec><sec id="sec4dot6-antibiotics-11-01378"><title>4.6. Lipopeptides (Daptomycin)</title><p>Daptomycin, a cyclic lipopeptide antibiotic approved by the U.S. FDA in 2003, has in vitro bactericidal activity against many gram-positive bacteria. It was approved for the treatment of bacteremia and endocarditis caused by <italic toggle="yes">S. aureus</italic> [<xref rid="B244-antibiotics-11-01378" ref-type="bibr">244</xref>] and has now become the main alternative to vancomycin for serious MRSA infections [<xref rid="B245-antibiotics-11-01378" ref-type="bibr">245</xref>]. Daptomycin exhibits bactericidal activity by targeting membrane phospholipid phosphatidylglycerol as well as bactoprenyl-coupled cell wall precursors such as lipid II in a calcium-dependent manner [<xref rid="B246-antibiotics-11-01378" ref-type="bibr">246</xref>]. In addition, daptomycin affects the localization of cell wall synthesis enzymes like MurG, further interfering with cell wall synthesis [<xref rid="B137-antibiotics-11-01378" ref-type="bibr">137</xref>,<xref rid="B138-antibiotics-11-01378" ref-type="bibr">138</xref>].</p><p>Since no resistant breakpoint for daptomycin has been officially established, the term nonsusceptible is used by some researchers over resistant. <italic toggle="yes">S. aureus</italic> strains with MIC &#x02264; 1 &#x003bc;g/mL are referred as daptomycin-susceptible (DAP-S) [<xref rid="B145-antibiotics-11-01378" ref-type="bibr">145</xref>] and strains with MIC &#x0003e;1 &#x003bc;g/mL as daptomycin-nonsusceptible [<xref rid="B146-antibiotics-11-01378" ref-type="bibr">146</xref>]. The first daptomycin-nonsusceptible <italic toggle="yes">S. aureus</italic> isolates have been reported from a patient treated with daptomycin for bacteremia in Boston in 2004 [<xref rid="B135-antibiotics-11-01378" ref-type="bibr">135</xref>]. Even before the daptomycin approval, the daptomycin-nonsusceptible <italic toggle="yes">S. aureus</italic> mutants were observed after passage through increasing concentrations of daptomycin [<xref rid="B247-antibiotics-11-01378" ref-type="bibr">247</xref>]. Although the development of daptomycin-nonsusceptible <italic toggle="yes">S. aureus</italic> remains rare, there have been steady reports of the emergence of daptomycin-nonsusceptible MRSA strains (MIC of &#x0003e;1 &#x003bc;g/mL) during treatment with daptomycin [<xref rid="B248-antibiotics-11-01378" ref-type="bibr">248</xref>,<xref rid="B249-antibiotics-11-01378" ref-type="bibr">249</xref>,<xref rid="B250-antibiotics-11-01378" ref-type="bibr">250</xref>,<xref rid="B251-antibiotics-11-01378" ref-type="bibr">251</xref>].</p><p>The development of daptomycin-nonsusceptible <italic toggle="yes">S. aureus</italic> occurs from the stepwise and multifactorial process that involves cell membrane and cell wall alterations [<xref rid="B136-antibiotics-11-01378" ref-type="bibr">136</xref>,<xref rid="B142-antibiotics-11-01378" ref-type="bibr">142</xref>,<xref rid="B252-antibiotics-11-01378" ref-type="bibr">252</xref>]. The most common resistance mechanism includes the alteration of the surface charge of cells which results in the repulsion of anionic daptomycin molecules [<xref rid="B142-antibiotics-11-01378" ref-type="bibr">142</xref>]. This primarily occurs due to the acquisition of gain-of-function mutations in <italic toggle="yes">mprF</italic> gene encoding a membrane-bound protein MprF called lysyl&#x02013;phosphatidyl glycerol synthetase [<xref rid="B253-antibiotics-11-01378" ref-type="bibr">253</xref>]. MprF is a bifunctional protein that facilitates both the lysinylation of phosphatidylglycerol, i.e., transfer of negatively charged phosphatidylglycerol to positively charged lysyl&#x02013;phosphatidylglycerol and the translocation of lysyl&#x02013;phosphatidylglycerol to the outer leaflet of the membrane [<xref rid="B136-antibiotics-11-01378" ref-type="bibr">136</xref>,<xref rid="B144-antibiotics-11-01378" ref-type="bibr">144</xref>,<xref rid="B253-antibiotics-11-01378" ref-type="bibr">253</xref>,<xref rid="B254-antibiotics-11-01378" ref-type="bibr">254</xref>]. Furthermore, the <italic toggle="yes">dlt</italic> operon regulates the alanylation of wall teichoic acid, and mutation in the <italic toggle="yes">dlt</italic> operon leads to an increase in cell surface positive charge, which reduces the daptomycin susceptibility through charge-mediated repulsion [<xref rid="B233-antibiotics-11-01378" ref-type="bibr">233</xref>,<xref rid="B255-antibiotics-11-01378" ref-type="bibr">255</xref>]. Mutations in various genes including those associated with the cell membrane (<italic toggle="yes">mprF</italic>), cell wall (<italic toggle="yes">dltABCD</italic>), and RNA polymerase subunits (<italic toggle="yes">rpoC</italic> and <italic toggle="yes">rpoB</italic>) [<xref rid="B99-antibiotics-11-01378" ref-type="bibr">99</xref>] have been described to play an important role in daptomycin susceptibility [<xref rid="B143-antibiotics-11-01378" ref-type="bibr">143</xref>,<xref rid="B252-antibiotics-11-01378" ref-type="bibr">252</xref>,<xref rid="B256-antibiotics-11-01378" ref-type="bibr">256</xref>,<xref rid="B257-antibiotics-11-01378" ref-type="bibr">257</xref>]. Daptomycin resistance also occurs due to mutations in <italic toggle="yes">yycH</italic> and <italic toggle="yes">yycI</italic> genes, leading to loss of protein functions and downregulated the WalKR and the downstream players Atl and amidase Sle1, including the autolysin Atl and amidase Sle1 which are essential for cell wall synthesis [<xref rid="B141-antibiotics-11-01378" ref-type="bibr">141</xref>]. Mutations of the TCSs like WalKR, VraSR, or GraSR that directly or indirectly control the transcription of several genes encoding proteins involved in cell wall synthesis and permeability have been also associated with daptomycin susceptibility in <italic toggle="yes">S. aureus</italic> [<xref rid="B142-antibiotics-11-01378" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-11-01378" ref-type="bibr">143</xref>]. GraSR regulates the expression of genes encoding peptidoglycan hydrolases lysyl&#x02013;phosphatidylglycerol synthase and flippase, MprF, and the DltABCD system, which modifies teichoic acids with D-alanine [<xref rid="B233-antibiotics-11-01378" ref-type="bibr">233</xref>,<xref rid="B258-antibiotics-11-01378" ref-type="bibr">258</xref>,<xref rid="B259-antibiotics-11-01378" ref-type="bibr">259</xref>].</p></sec><sec id="sec4dot7-antibiotics-11-01378"><title>4.7. Fluoroquinolone (Ciprofloxacin)</title><p>Ciprofloxacin, a second-generation synthetic antibiotic of the fluoroquinolone class is active against a broad range of gram-positive and gram-negative bacteria. It was approved by the U.S. FDA in 1987 to treat UTIs caused by both MRSA and MSSA. Ciprofloxacin targets bacterial DNA topoisomerase IV and DNA gyrase enzymes which contributes to the relaxation of positive supercoils during DNA replication [<xref rid="B176-antibiotics-11-01378" ref-type="bibr">176</xref>], thus preventing DNA replication and eventually bacterial death [<xref rid="B177-antibiotics-11-01378" ref-type="bibr">177</xref>,<xref rid="B178-antibiotics-11-01378" ref-type="bibr">178</xref>].</p><p>The ciprofloxacin-resistant <italic toggle="yes">S. aureus</italic> isolates were described soon after the introduction of the agent into clinical practice [<xref rid="B260-antibiotics-11-01378" ref-type="bibr">260</xref>]. Resistance to fluoroquinolones including ciprofloxacin typically arises as a result of the (i) point mutations in the <italic toggle="yes">grlA</italic>/<italic toggle="yes">grlB</italic> genes encoding the subunits of DNA topoisomerase IV and <italic toggle="yes">gyrA/gyrB</italic> genes encoding the subunits of DNA gyrase [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B261-antibiotics-11-01378" ref-type="bibr">261</xref>], and (ii) decreased intracellular accumulation and/or active efflux of the drug by membrane-integrated transporter proteins (e.g., NorA) [<xref rid="B262-antibiotics-11-01378" ref-type="bibr">262</xref>]. Challenging the <italic toggle="yes">S. aureus</italic> isolates with the ciprofloxacin elevated the <italic toggle="yes">norA</italic> expression, which potentiates the evolution by increasing the fitness benefit provided by DNA topoisomerase mutations [<xref rid="B179-antibiotics-11-01378" ref-type="bibr">179</xref>]. The initial target mutations occur more frequently in <italic toggle="yes">grlA</italic> gene, whereas additional mutations are found in <italic toggle="yes">gyrA</italic> gene in highly fluoroquinolone-resistant <italic toggle="yes">S. aureus</italic> strains [<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>]. Mutational changes result in amino acid substitutions in the QRDR of GrlA and GyrA proteins. The GyrA Ser84Leu and GrlA Ser80Phe mutation caused a two-fold increase in minimum bactericidal concentration (MBC) of fluoroquinolone antibiotic DW286 than its corresponding MIC [<xref rid="B49-antibiotics-11-01378" ref-type="bibr">49</xref>,<xref rid="B263-antibiotics-11-01378" ref-type="bibr">263</xref>].</p><p>Efflux pump-mediated fluoroquinolone resistance is due to the extrusion of an intracellular drug into the external environment [<xref rid="B57-antibiotics-11-01378" ref-type="bibr">57</xref>,<xref rid="B264-antibiotics-11-01378" ref-type="bibr">264</xref>]. Efflux pumps are usually expressed at low or nondetectable levels but upregulated upon exposure to certain antimicrobials including fluoroquinolones [<xref rid="B57-antibiotics-11-01378" ref-type="bibr">57</xref>,<xref rid="B264-antibiotics-11-01378" ref-type="bibr">264</xref>]. Several efflux pumps have been identified in <italic toggle="yes">S. aureus</italic>, including chromosomally encoded NorA, NorB, NorC, MdeA, MepA, SepA, and SdrM and plasmid-encoded QacA/B, QacG, QacH, QacJ, and Smr [<xref rid="B265-antibiotics-11-01378" ref-type="bibr">265</xref>]. However, the NorA, QacA, and Smr proteins are considered major players in multidrug resistance in <italic toggle="yes">S. aureus</italic> [<xref rid="B56-antibiotics-11-01378" ref-type="bibr">56</xref>,<xref rid="B57-antibiotics-11-01378" ref-type="bibr">57</xref>,<xref rid="B61-antibiotics-11-01378" ref-type="bibr">61</xref>,<xref rid="B62-antibiotics-11-01378" ref-type="bibr">62</xref>]. The chromosomal gene <italic toggle="yes">norA</italic> was first identified in fluoroquinolone-resistant <italic toggle="yes">S. aureus</italic> isolate in Japan in 1986 [<xref rid="B266-antibiotics-11-01378" ref-type="bibr">266</xref>]. NorA is a 388 amino acid protein with 12 transmembrane segments (TMS) which belongs to the Major Facilitator Superfamily (MFS) of secondary transporters [<xref rid="B59-antibiotics-11-01378" ref-type="bibr">59</xref>]. NorA is also involved in resistance to several structurally different compounds including ethidium bromide dye, quaternary ammonium compounds (disinfectants), and other antimicrobials [<xref rid="B262-antibiotics-11-01378" ref-type="bibr">262</xref>,<xref rid="B267-antibiotics-11-01378" ref-type="bibr">267</xref>,<xref rid="B268-antibiotics-11-01378" ref-type="bibr">268</xref>].</p></sec><sec id="sec4dot8-antibiotics-11-01378"><title>4.8. Pyrimidines/Sulfonamides (Trimethoprim-Sulfamethoxazole)</title><p>Trimethoprim (TMP; 2,4-diamino-5-(3&#x02032;,4&#x02032;,5&#x02032;-trimethoxybenzyl)pyrimidine)/sulfamethoxazole (SMX; 3-(p-aminophenyl sulfonamido)-5-methylisoxazole), also known as co-trimoxazole, is a combination of trimethoprim and sulfamethoxazole class drugs that have been used to treat UTIs, uncomplicated SSTIs, and BJIs caused by CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>,<xref rid="B269-antibiotics-11-01378" ref-type="bibr">269</xref>,<xref rid="B270-antibiotics-11-01378" ref-type="bibr">270</xref>,<xref rid="B271-antibiotics-11-01378" ref-type="bibr">271</xref>]. TMP inhibits bacterial dihydrofolate reductase (DHFR), an enzyme that catalyzes nicotinamide adenine dinucleotide phosphate (NADPH)-dependent conversion of dihydrofolate (DHF) to tetrahydrofolate (THF) [<xref rid="B272-antibiotics-11-01378" ref-type="bibr">272</xref>,<xref rid="B273-antibiotics-11-01378" ref-type="bibr">273</xref>]. TMP is more specific to <italic toggle="yes">S. aureus</italic> DHFR (SaDHFR) than to human DHFR, which particularly inhibits bacterial folic acid synthesis [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>]. SMX is a structural analog of para-aminobenzoic acid (PABA), a substrate important for bacterial folic acid synthesis [<xref rid="B274-antibiotics-11-01378" ref-type="bibr">274</xref>]. SMX binds to dihydropteroate synthase (DHPS) which catalyzes the conversion of PABA to dihydropteroate (DHP) during the THF formation [<xref rid="B269-antibiotics-11-01378" ref-type="bibr">269</xref>]. The inhibition of DHPS leads to defective thymidine biosynthesis and thus reduces or inhibits bacterial folic acid synthesis [<xref rid="B275-antibiotics-11-01378" ref-type="bibr">275</xref>]. In general, TMP&#x02013;SMX has a greater effect as a combination because synergistically they inhibit two consecutive steps in nucleic acid and protein synthesis which are critical for the growth and cell division of bacteria [<xref rid="B276-antibiotics-11-01378" ref-type="bibr">276</xref>].</p><p>The widespread use of TMP&#x02013;SMX for the treatment of staphylococcal infections leads to the emergence of resistance in both MSSA and MRSA [<xref rid="B277-antibiotics-11-01378" ref-type="bibr">277</xref>,<xref rid="B278-antibiotics-11-01378" ref-type="bibr">278</xref>,<xref rid="B279-antibiotics-11-01378" ref-type="bibr">279</xref>]. <italic toggle="yes">S. aureus</italic> shows resistance to TMP&#x02013;SMX due to the mutation of chromosomal gene <italic toggle="yes">dfrB</italic> encoding SaDHFR and resistance genes that encode variant DHFRs [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>,<xref rid="B193-antibiotics-11-01378" ref-type="bibr">193</xref>,<xref rid="B194-antibiotics-11-01378" ref-type="bibr">194</xref>,<xref rid="B195-antibiotics-11-01378" ref-type="bibr">195</xref>], which is the target of TMP [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>]. A single amino acid substitution at position 98 (Phe98 to Tyr98) in SaDHFR encoded by <italic toggle="yes">dfrB</italic> led to the intermediate-level TMP resistance (MIC &#x02264;256 mg/L) in <italic toggle="yes">S. aureus</italic> [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>]. In contrast, acquired plasmid-borne <italic toggle="yes">dfrA</italic> (also known as <italic toggle="yes">dfrS1</italic>) encoding type S1 DHFR mediates high-level TMP resistance (MIC &#x02265;512 mg/L). The <italic toggle="yes">dfrA</italic>, <italic toggle="yes">dfrB</italic>, <italic toggle="yes">dfrG</italic>, and <italic toggle="yes">dfrK</italic> are important TMP resistance genes known to occur in staphylococci including MRSA [<xref rid="B191-antibiotics-11-01378" ref-type="bibr">191</xref>,<xref rid="B192-antibiotics-11-01378" ref-type="bibr">192</xref>]. <italic toggle="yes">S. aureus</italic> exposed to sub-MIC of TMP-SMX for 14 days resulted in resistant strains due to the F98Y mutation in DHFR encoded by the <italic toggle="yes">dfrB</italic> gene [<xref rid="B280-antibiotics-11-01378" ref-type="bibr">280</xref>]. Mutations in the <italic toggle="yes">dfrB</italic> and <italic toggle="yes">dfrA</italic> have been reported as major determinants of TMP resistance in <italic toggle="yes">S. aureus</italic> clinical isolates [<xref rid="B281-antibiotics-11-01378" ref-type="bibr">281</xref>,<xref rid="B282-antibiotics-11-01378" ref-type="bibr">282</xref>]. The <italic toggle="yes">dfrG</italic> gene encoding the TMP-resistant DHFR enzyme was rarely identified in <italic toggle="yes">S. aureus</italic> clinical isolates [<xref rid="B190-antibiotics-11-01378" ref-type="bibr">190</xref>,<xref rid="B283-antibiotics-11-01378" ref-type="bibr">283</xref>] but mediates TMP resistance [<xref rid="B190-antibiotics-11-01378" ref-type="bibr">190</xref>,<xref rid="B195-antibiotics-11-01378" ref-type="bibr">195</xref>].</p></sec><sec id="sec4dot9-antibiotics-11-01378"><title>4.9. Mupirocin</title><p>Mupirocin was discovered in 1971 [<xref rid="B197-antibiotics-11-01378" ref-type="bibr">197</xref>] but marketed for clinical use in the UK in 1985 and US in 1988 [<xref rid="B198-antibiotics-11-01378" ref-type="bibr">198</xref>]. It was widely used as a decolonizing agent during the emergence of the CA-MRSA epidemic in the United States in the 1990s. Currently, mupirocin remains the best option for the treatment of MRSA nasal decolonization and SSTI [<xref rid="B27-antibiotics-11-01378" ref-type="bibr">27</xref>,<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>]. Mupirocin competitively inhibits bacterial isoleucyl t-RNA synthetase, an enzyme encoded by the chromosomal <italic toggle="yes">ileS</italic> gene that promotes the conversion of isoleucine and tRNA to isoleucyl&#x02013;tRNA, leading to the inhibition of protein and RNA synthesis [<xref rid="B201-antibiotics-11-01378" ref-type="bibr">201</xref>].</p><p>Resistance to mupirocin among <italic toggle="yes">S. aureus</italic> clinical isolates was first reported in 1987 [<xref rid="B199-antibiotics-11-01378" ref-type="bibr">199</xref>,<xref rid="B200-antibiotics-11-01378" ref-type="bibr">200</xref>]. The high-level mupirocin resistance (MIC &#x0003e; 500 &#x003bc;g/mL) by <italic toggle="yes">S. aureus</italic> is generally mediated by the expression of plasmid-encoded <italic toggle="yes">mupA</italic> gene [<xref rid="B205-antibiotics-11-01378" ref-type="bibr">205</xref>,<xref rid="B206-antibiotics-11-01378" ref-type="bibr">206</xref>], which encodes an alternate isoleucyl&#x02013;tRNA synthetase enzyme [<xref rid="B208-antibiotics-11-01378" ref-type="bibr">208</xref>]. Moreover, the <italic toggle="yes">mupB</italic> gene (3102 bp) is also associated with high-level mupirocin resistance in <italic toggle="yes">S. aureus</italic>, which shares 65.5% sequence identity with <italic toggle="yes">mupA</italic> and 45.5% with <italic toggle="yes">ileS</italic> gene [<xref rid="B207-antibiotics-11-01378" ref-type="bibr">207</xref>]. The low-level mupirocin resistance (MIC 8&#x02013;256&#x02009;&#x003bc;g/mL) is usually associated with point mutations in the chromosomally encoded <italic toggle="yes">ileS</italic> gene [<xref rid="B205-antibiotics-11-01378" ref-type="bibr">205</xref>], which result in V588F or V631F alterations in the native isoleucyl&#x02013;tRNA synthetase [<xref rid="B202-antibiotics-11-01378" ref-type="bibr">202</xref>,<xref rid="B203-antibiotics-11-01378" ref-type="bibr">203</xref>,<xref rid="B204-antibiotics-11-01378" ref-type="bibr">204</xref>]. In addition, low-level mupirocin resistance was confirmed by the chromosomal location of <italic toggle="yes">mupA</italic> gene [<xref rid="B284-antibiotics-11-01378" ref-type="bibr">284</xref>] in some <italic toggle="yes">S. aureus</italic> strains from different geographic areas [<xref rid="B285-antibiotics-11-01378" ref-type="bibr">285</xref>].</p></sec><sec id="sec4dot10-antibiotics-11-01378"><title>4.10. Fosfomycin</title><p>Fosfomycin discovered in 1969 [<xref rid="B210-antibiotics-11-01378" ref-type="bibr">210</xref>], is a phosphonic acid derivative from cultures of Streptomyces spp. It is a broad-spectrum antibiotic used primarily for the treatment of UTIs caused by multidrug-resistant pathogens including MRSA. Fosfomycin interferes with bacterial cell wall synthesis via irreversibly inhibiting the cytosolic enzyme UDP-<italic toggle="yes">N</italic>-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the addition of phosphoenolpyruvate to UDP-<italic toggle="yes">N</italic>-acetylglucosamine (UDP-GlcNAc) to form UDP-<italic toggle="yes">N</italic>-acetylmuramic acid (UDP-MurNAc) [<xref rid="B211-antibiotics-11-01378" ref-type="bibr">211</xref>].</p><p>Resistance to fosfomycin has been occurring among MRSA clinical isolates either by chromosome-associated defective transport proteins or plasmid-mediated fosfomycin-inactivating enzymes [<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>]. GlpT and UhpT transporter proteins mediated the uptake of fosfomycin into bacterial cells. Mutations in GlpT (Trp137/Arg) (encoded by <italic toggle="yes">glpT</italic> gene) [<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>] and UhpT (encoded by <italic toggle="yes">uhpT</italic> gene) [<xref rid="B214-antibiotics-11-01378" ref-type="bibr">214</xref>] reduce the permeability and subsequently prevent fosfomycin from invading the bacterium [<xref rid="B212-antibiotics-11-01378" ref-type="bibr">212</xref>,<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>]. In addition, the mutation in <italic toggle="yes">murA</italic> gene encoding UDP-<italic toggle="yes">N</italic>-acetylglucosamine enolpyruvyl transferase reduces affinity for fosfomycin [<xref rid="B215-antibiotics-11-01378" ref-type="bibr">215</xref>], conferring various degrees of drug resistance. The fosfomycin-inactivating enzyme thiol-S-transferase (encoded by <italic toggle="yes">fosB</italic> gene) [<xref rid="B53-antibiotics-11-01378" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-11-01378" ref-type="bibr">54</xref>] catalyzes the inactivation of fosfomycin antibiotic in <italic toggle="yes">S. aureus</italic> [<xref rid="B53-antibiotics-11-01378" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-11-01378" ref-type="bibr">54</xref>]. FosY protein, a putative bacillithiol transferase (encoded by <italic toggle="yes">fosY</italic> gene present on a genomic island) which shares 65.9&#x02013;77.5% amino acid identity with FosB and FosD, respectively, confers resistance to fosfomycin in clonal complex 1 (CC1) MRSA isolate from China [<xref rid="B217-antibiotics-11-01378" ref-type="bibr">217</xref>]. The chromosomally encoded major facilitator superfamily efflux transporter Tet38 (encoded by <italic toggle="yes">tet38</italic> gene) of <italic toggle="yes">S. aureus</italic> acts as an efflux transporter of fosfomycin, which is affected by glycerol-3-phosphate (G3P) [<xref rid="B216-antibiotics-11-01378" ref-type="bibr">216</xref>].</p></sec><sec id="sec4dot11-antibiotics-11-01378"><title>4.11. Rifampin</title><p>Rifampin was discovered in 1965, introduced for clinical therapy in Italy in 1968, and approved in the United States in 1971 [<xref rid="B218-antibiotics-11-01378" ref-type="bibr">218</xref>]. It is used in combination therapy (adjunctive with vancomycin) for the treatment of serious <italic toggle="yes">S. aureus</italic> infections such as endocarditis and BJI [<xref rid="B27-antibiotics-11-01378" ref-type="bibr">27</xref>]. Rifampicin inhibits transcription via binding to the &#x003b2;-subunit of bacterial DNA-dependent RNA polymerase (encoded by <italic toggle="yes">rpoB</italic> gene), leading to suppression of RNA synthesis and subsequent cell death [<xref rid="B219-antibiotics-11-01378" ref-type="bibr">219</xref>,<xref rid="B220-antibiotics-11-01378" ref-type="bibr">220</xref>].</p><p>Unfortunately, the frequency of rifampicin-resistant <italic toggle="yes">S. aureus</italic> isolates has increased in recent times [<xref rid="B286-antibiotics-11-01378" ref-type="bibr">286</xref>]. The high-level resistance to rifampin in <italic toggle="yes">S. aureus</italic> is associated with mutations in an extremely conserved region of the RNA polymerase &#x003b2;-subunit called the rifampin resistance-determining region (RRDR) that resulted in an amino acid substitution Gln468/Arg, His481/Tyr, and Arg484/His [<xref rid="B43-antibiotics-11-01378" ref-type="bibr">43</xref>]. Furthermore, the mutation in <italic toggle="yes">rpoB</italic> gene (N967I) causes the amino acid substitution Asn967/Ile in the &#x003b2;-subunit of RNA polymerase [<xref rid="B221-antibiotics-11-01378" ref-type="bibr">221</xref>]. It is also demonstrated that mutations in <italic toggle="yes">rpoB</italic> gene of VISA strain Mu50 are associated with the alteration of vancomycin susceptibility [<xref rid="B100-antibiotics-11-01378" ref-type="bibr">100</xref>]. Mutations within the <italic toggle="yes">rpoB</italic> gene of clinical <italic toggle="yes">S. aureus</italic> isolates are associated with a decrease in daptomycin susceptibility, thus giving a daptomycin non-susceptible (DNS) phenotype [<xref rid="B252-antibiotics-11-01378" ref-type="bibr">252</xref>,<xref rid="B287-antibiotics-11-01378" ref-type="bibr">287</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-antibiotics-11-01378"><title>5. Conclusions</title><p>The evolution and spread of MRSA has become a major concern for public health. MRSA strains are intrinsically resistant to almost all &#x003b2;-lactam antibiotics by an acquired <italic toggle="yes">mecA</italic> encoded PBP2a, which can continue peptidoglycan crosslinking in the face of a challenge by &#x003b2;-lactams. Furthermore, MRSA strains are often also resistant to currently used multiple non-&#x003b2;-lactam antibiotics such as erythromycin, clindamycin, gentamicin, linezolid, tetracycline, fusidic acid, ciprofloxacin, ozenoxacin, TMX&#x02013;SMX, and others. The selective pressure exerted by antibiotics use has led <italic toggle="yes">S. aureus</italic> to develop resistance against one or more antibiotics simultaneously. MRSA can become resistant to non-&#x003b2;-lactam antibiotics through different mechanisms including modification of the antibiotic target, enzymatic inactivation of antibiotics, and/or decreased antibiotic uptake or efflux. This is mainly directed by the acquisition of resistant genes by HGT and genetic mutations owing to the selective pressure of antibiotics. Therefore, revealing molecular determinants that confer resistance to antibiotics in clinical isolates as well as laboratory strains is important for the development of molecular detection methods of antibiotic resistance and designing novel strategies to control MRSA infections.</p><p>Antibiotic combination therapy is currently used for treating some MRSA infections, such as ceftaroline plus daptomycin for refractory bacteremia and daptomycin plus rifampicin for biofilm-related infections. However, the continuous emergence of antibiotic-resistant bacteria has highlighted the need for the development of new antibiotics and the identification of novel drug targets to tackle AMR and optimal management of MRSA infections.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, H.L., H.-S.J. and J.-S.K.; writing&#x02014;original draft preparation, H.L.; writing&#x02014;review and editing, H.L., H.-S.J. and J.-S.K.; funding acquisition, J.-S.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-11-01378"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fleming</surname><given-names>A.</given-names></name>
</person-group><article-title>On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. injluenzae</article-title><source>Br. J. Exp. Pathol.</source><year>1929</year><volume>10</volume><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1093/clinids/2.1.129</pub-id></element-citation></ref><ref id="B2-antibiotics-11-01378"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abraham</surname><given-names>E.P.</given-names></name>
<name><surname>Chain</surname><given-names>E.</given-names></name>
</person-group><article-title>An enzyme from bacteria able to destroy penicillin</article-title><source>Nature</source><year>1940</year><volume>146</volume><fpage>837</fpage><pub-id pub-id-type="doi">10.1038/146837a0</pub-id></element-citation></ref><ref id="B3-antibiotics-11-01378"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Oliveira</surname><given-names>D.M.P.</given-names></name>
<name><surname>Forde</surname><given-names>B.M.</given-names></name>
<name><surname>Kidd</surname><given-names>T.J.</given-names></name>
<name><surname>Harris</surname><given-names>P.N.A.</given-names></name>
<name><surname>Schembri</surname><given-names>M.A.</given-names></name>
<name><surname>Beatson</surname><given-names>S.A.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Walker</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Antimicrobial Resistance in ESKAPE Pathogens</article-title><source>Clin. Microbiol. Rev.</source><year>2020</year><volume>33</volume><fpage>e00181-19</fpage><pub-id pub-id-type="doi">10.1128/CMR.00181-19</pub-id><pub-id pub-id-type="pmid">32404435</pub-id></element-citation></ref><ref id="B4-antibiotics-11-01378"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boucher</surname><given-names>H.W.</given-names></name>
<name><surname>Talbot</surname><given-names>G.H.</given-names></name>
<name><surname>Bradley</surname><given-names>J.S.</given-names></name>
<name><surname>Edwards</surname><given-names>J.E.</given-names></name>
<name><surname>Gilbert</surname><given-names>D.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
<name><surname>Scheld</surname><given-names>M.</given-names></name>
<name><surname>Spellberg</surname><given-names>B.</given-names></name>
<name><surname>Bartlett</surname><given-names>J.</given-names></name>
</person-group><article-title>Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>48</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1086/595011</pub-id><?supplied-pmid 19035777?><pub-id pub-id-type="pmid">19035777</pub-id></element-citation></ref><ref id="B5-antibiotics-11-01378"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pendleton</surname><given-names>J.N.</given-names></name>
<name><surname>Gorman</surname><given-names>S.P.</given-names></name>
<name><surname>Gilmore</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Clinical relevance of the ESKAPE pathogens</article-title><source>Expert Rev. Anti. Infect. Ther.</source><year>2013</year><volume>11</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1586/eri.13.12</pub-id><pub-id pub-id-type="pmid">23458769</pub-id></element-citation></ref><ref id="B6-antibiotics-11-01378"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>K.</given-names></name>
</person-group><article-title>Platforms for antibiotic discovery</article-title><source>Nat. Rev. Drug Discov.</source><year>2013</year><volume>12</volume><fpage>371</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1038/nrd3975</pub-id><pub-id pub-id-type="pmid">23629505</pub-id></element-citation></ref><ref id="B7-antibiotics-11-01378"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Antimicrobial Resistance</source><publisher-name>WHO</publisher-name><publisher-loc>Geneva, Switzerlnad</publisher-loc><year>2021</year></element-citation></ref><ref id="B8-antibiotics-11-01378"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>O&#x02019;Neill</surname><given-names>J.</given-names></name>
</person-group><source>Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance</source><publisher-name>Wellcome Trust</publisher-name><publisher-loc>London, UK</publisher-loc><year>2016</year></element-citation></ref><ref id="B9-antibiotics-11-01378"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (U.S.)</collab>
</person-group><source>Antibiotic Resistance Threats in the United States, 2019</source><publisher-name>Centers for Disease Control and Prevention (U.S.)</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B10-antibiotics-11-01378"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (U.S.)</collab>
</person-group><source>Methicillin-Resistant Staphylococcus Aureus, 2019</source><publisher-name>Centers for Disease Control and Prevention (U.S.)</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B11-antibiotics-11-01378"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rammelkamp</surname><given-names>C.H.</given-names></name>
<name><surname>Maxon</surname><given-names>T.</given-names></name>
</person-group><article-title>Resistance of Staphylococcus aureus to the Action of Penicillin</article-title><source>Exp. Biol. Med.</source><year>1942</year><volume>51</volume><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.3181/00379727-51-13986</pub-id></element-citation></ref><ref id="B12-antibiotics-11-01378"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirby</surname><given-names>W.M.M.</given-names></name>
</person-group><article-title>Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci</article-title><source>Science</source><year>1944</year><volume>99</volume><fpage>452</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1126/science.99.2579.452</pub-id><pub-id pub-id-type="pmid">17798398</pub-id></element-citation></ref><ref id="B13-antibiotics-11-01378"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knox</surname><given-names>R.</given-names></name>
</person-group><article-title>A New Penicillin (BRL 1241) Active Against Penicillin-resistant</article-title><source>Staphylococci. BMJ</source><year>1960</year><volume>2</volume><fpage>690</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1136/bmj.2.5200.690</pub-id><pub-id pub-id-type="pmid">14410240</pub-id></element-citation></ref><ref id="B14-antibiotics-11-01378"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jevons</surname><given-names>M.P.</given-names></name>
</person-group><article-title>&#x0201c;Celbenin&#x0201d;&#x02014;Resistant</article-title><source>Staphylococci. Br. Med. J.</source><year>1961</year><volume>1</volume><fpage>124</fpage><pub-id pub-id-type="doi">10.1136/bmj.1.5219.124-a</pub-id></element-citation></ref><ref id="B15-antibiotics-11-01378"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>N.A.</given-names></name>
<name><surname>Sharma-Kuinkel</surname><given-names>B.K.</given-names></name>
<name><surname>Maskarinec</surname><given-names>S.A.</given-names></name>
<name><surname>Eichenberger</surname><given-names>E.M.</given-names></name>
<name><surname>Shah</surname><given-names>P.P.</given-names></name>
<name><surname>Carugati</surname><given-names>M.</given-names></name>
<name><surname>Holland</surname><given-names>T.L.</given-names></name>
<name><surname>Fowler</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>203</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0147-4</pub-id><?supplied-pmid 30737488?><pub-id pub-id-type="pmid">30737488</pub-id></element-citation></ref><ref id="B16-antibiotics-11-01378"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tenover</surname><given-names>F.C.</given-names></name>
<name><surname>McDougal</surname><given-names>L.K.</given-names></name>
<name><surname>Goering</surname><given-names>R.V.</given-names></name>
<name><surname>Killgore</surname><given-names>G.</given-names></name>
<name><surname>Projan</surname><given-names>S.J.</given-names></name>
<name><surname>Patel</surname><given-names>J.B.</given-names></name>
<name><surname>Dunman</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States</article-title><source>J. Clin. Microbiol.</source><year>2006</year><volume>44</volume><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1128/JCM.44.1.108-118.2006</pub-id><pub-id pub-id-type="pmid">16390957</pub-id></element-citation></ref><ref id="B17-antibiotics-11-01378"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>David</surname><given-names>M.Z.</given-names></name>
<name><surname>Daum</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Community-associated methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>: Epidemiology and clinical consequences of an emerging epidemic</article-title><source>Clin. Microbiol. Rev.</source><year>2010</year><volume>23</volume><fpage>616</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1128/CMR.00081-09</pub-id><?supplied-pmid 20610826?><pub-id pub-id-type="pmid">20610826</pub-id></element-citation></ref><ref id="B18-antibiotics-11-01378"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lakhundi</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>K.</given-names></name>
</person-group><article-title>Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic>: Molecular Characterization, Evolution, and Epidemiology</article-title><source>Clin. Microbiol. Rev.</source><year>2018</year><volume>31</volume><fpage>e00020-18</fpage><pub-id pub-id-type="doi">10.1128/CMR.00020-18</pub-id><?supplied-pmid 30209034?><pub-id pub-id-type="pmid">30209034</pub-id></element-citation></ref><ref id="B19-antibiotics-11-01378"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chambers</surname><given-names>H.F.</given-names></name>
<name><surname>DeLeo</surname><given-names>F.R.</given-names></name>
</person-group><article-title>Waves of resistance: <italic toggle="yes">Staphylococcus aureus</italic> in the antibiotic era</article-title><source>Nat. Rev. Microbiol.</source><year>2009</year><volume>7</volume><fpage>629</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2200</pub-id><?supplied-pmid 19680247?><pub-id pub-id-type="pmid">19680247</pub-id></element-citation></ref><ref id="B20-antibiotics-11-01378"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuhashi</surname><given-names>M.</given-names></name>
<name><surname>Song</surname><given-names>M.D.</given-names></name>
<name><surname>Ishino</surname><given-names>F.</given-names></name>
<name><surname>Wachi</surname><given-names>M.</given-names></name>
<name><surname>Doi</surname><given-names>M.</given-names></name>
<name><surname>Inoue</surname><given-names>M.</given-names></name>
<name><surname>Ubukata</surname><given-names>K.</given-names></name>
<name><surname>Yamashita</surname><given-names>N.</given-names></name>
<name><surname>Konno</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Bacteriol.</source><year>1986</year><volume>167</volume><fpage>975</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1128/jb.167.3.975-980.1986</pub-id><?supplied-pmid 3638304?><pub-id pub-id-type="pmid">3638304</pub-id></element-citation></ref><ref id="B21-antibiotics-11-01378"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katayama</surname><given-names>Y.</given-names></name>
<name><surname>Ito</surname><given-names>T.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>A New Class of Genetic Element, <italic toggle="yes">Staphylococcus</italic> Cassette Chromosome mec, Encodes Methicillin Resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>1549</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.6.1549-1555.2000</pub-id><pub-id pub-id-type="pmid">10817707</pub-id></element-citation></ref><ref id="B22-antibiotics-11-01378"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartman</surname><given-names>B.J.</given-names></name>
<name><surname>Tomasz</surname><given-names>A.</given-names></name>
</person-group><article-title>Low-affinity penicillin-binding protein associated with beta-lactam resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Bacteriol.</source><year>1984</year><volume>158</volume><fpage>513</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1128/jb.158.2.513-516.1984</pub-id><?supplied-pmid 6563036?><pub-id pub-id-type="pmid">6563036</pub-id></element-citation></ref><ref id="B23-antibiotics-11-01378"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Utsui</surname><given-names>Y.</given-names></name>
<name><surname>Yokota</surname><given-names>T.</given-names></name>
</person-group><article-title>Role of an altered penicillin-binding protein in methicillin- and cephem-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1985</year><volume>28</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1128/AAC.28.3.397</pub-id><pub-id pub-id-type="pmid">3878127</pub-id></element-citation></ref><ref id="B24-antibiotics-11-01378"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuda</surname><given-names>C.</given-names></name>
<name><surname>Suvorov</surname><given-names>M.</given-names></name>
<name><surname>Vakulenko</surname><given-names>S.B.</given-names></name>
<name><surname>Mobashery</surname><given-names>S.</given-names></name>
</person-group><article-title>The Basis for Resistance to &#x003b2;-Lactam Antibiotics by Penicillin-binding Protein 2a of Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>40802</fpage><lpage>40806</lpage><pub-id pub-id-type="doi">10.1074/jbc.M403589200</pub-id><pub-id pub-id-type="pmid">15226303</pub-id></element-citation></ref><ref id="B25-antibiotics-11-01378"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watkins</surname><given-names>R.R.</given-names></name>
<name><surname>Holubar</surname><given-names>M.</given-names></name>
<name><surname>David</surname><given-names>M.Z.</given-names></name>
</person-group><article-title>Antimicrobial resistance in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> to newer antimicrobial agents</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e01216-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.01216-19</pub-id><?supplied-pmid 31527033?><pub-id pub-id-type="pmid">31527033</pub-id></element-citation></ref><ref id="B26-antibiotics-11-01378"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lade</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>J.-S.</given-names></name>
</person-group><article-title>Bacterial Targets of Antibiotics in Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>398</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10040398</pub-id><pub-id pub-id-type="pmid">33917043</pub-id></element-citation></ref><ref id="B27-antibiotics-11-01378"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>N.M.</given-names></name>
<name><surname>Goodman</surname><given-names>A.L.</given-names></name>
<name><surname>Horner</surname><given-names>C.</given-names></name>
<name><surname>Jenkins</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Treatment of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA): Updated guidelines from the UK</article-title><source>JAC Antimicrob. Resist.</source><year>2021</year><volume>3</volume><fpage>dlaa114</fpage><pub-id pub-id-type="doi">10.1093/jacamr/dlaa114</pub-id><pub-id pub-id-type="pmid">34223066</pub-id></element-citation></ref><ref id="B28-antibiotics-11-01378"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> clinical strain with reduced vancomycin susceptibility</article-title><source>J. Antimicrob. Chemother.</source><year>1997</year><volume>40</volume><fpage>135</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/jac/40.1.135</pub-id><pub-id pub-id-type="pmid">9249217</pub-id></element-citation></ref><ref id="B29-antibiotics-11-01378"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Bayer</surname><given-names>A.</given-names></name>
<name><surname>Cosgrove</surname><given-names>S.E.</given-names></name>
<name><surname>Daum</surname><given-names>R.S.</given-names></name>
<name><surname>Fridkin</surname><given-names>S.K.</given-names></name>
<name><surname>Gorwitz</surname><given-names>R.J.</given-names></name>
<name><surname>Kaplan</surname><given-names>S.L.</given-names></name>
<name><surname>Karchmer</surname><given-names>A.W.</given-names></name>
<name><surname>Levine</surname><given-names>D.P.</given-names></name>
<name><surname>Murray</surname><given-names>B.E.</given-names></name>
<etal/>
</person-group><article-title>Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Infections in Adults and Children</article-title><source>Clin. Infect. Dis.</source><year>2011</year><volume>52</volume><fpage>e18</fpage><lpage>e55</lpage><pub-id pub-id-type="doi">10.1093/cid/ciq146</pub-id><pub-id pub-id-type="pmid">21208910</pub-id></element-citation></ref><ref id="B30-antibiotics-11-01378"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGehee</surname><given-names>R.F.R.</given-names></name>
<name><surname>Barre</surname><given-names>F.F.</given-names></name>
<name><surname>Finland</surname><given-names>M.</given-names></name>
</person-group><article-title>Resistance of <italic toggle="yes">Staphylococcus aureus</italic> to lincomycin, clinimycin, and erythromycin</article-title><source>Antimicrob. Agents Chemother.</source><year>1968</year><volume>8</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">5735385</pub-id></element-citation></ref><ref id="B31-antibiotics-11-01378"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>M.C.</given-names></name>
<name><surname>Sutcliffe</surname><given-names>J.</given-names></name>
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
<name><surname>Jensen</surname><given-names>L.B.</given-names></name>
<name><surname>Rood</surname><given-names>J.</given-names></name>
<name><surname>Seppala</surname><given-names>H.</given-names></name>
</person-group><article-title>Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants</article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>2823</fpage><lpage>2830</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.12.2823</pub-id><pub-id pub-id-type="pmid">10582867</pub-id></element-citation></ref><ref id="B32-antibiotics-11-01378"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weisblum</surname><given-names>B.</given-names></name>
</person-group><article-title>Erythromycin resistance by ribosome modification</article-title><source>Antimicrob. Agents Chemother.</source><year>1995</year><volume>39</volume><fpage>577</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.3.577</pub-id><pub-id pub-id-type="pmid">7793855</pub-id></element-citation></ref><ref id="B33-antibiotics-11-01378"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitz</surname><given-names>F.-J.</given-names></name>
<name><surname>Jones</surname><given-names>M.E.</given-names></name>
<name><surname>Hofmann</surname><given-names>B.</given-names></name>
<name><surname>Hansen</surname><given-names>B.</given-names></name>
<name><surname>Scheuring</surname><given-names>S.</given-names></name>
<name><surname>L&#x000fc;ckefahr</surname><given-names>M.</given-names></name>
<name><surname>Fluit</surname><given-names>A.</given-names></name>
<name><surname>Verhoef</surname><given-names>J.</given-names></name>
<name><surname>Hadding</surname><given-names>U.</given-names></name>
<name><surname>Heinz</surname><given-names>H.-P.</given-names></name>
<etal/>
</person-group><article-title>Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of <italic toggle="yes">Staphylococcus aureus</italic> and Effects of Mutations on Ciprofloxacin MIC</article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>1249</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.5.1249</pub-id><pub-id pub-id-type="pmid">9593159</pub-id></element-citation></ref><ref id="B34-antibiotics-11-01378"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrero</surname><given-names>L.</given-names></name>
<name><surname>Cameron</surname><given-names>B.</given-names></name>
<name><surname>Crouzet</surname><given-names>J.</given-names></name>
</person-group><article-title>Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1995</year><volume>39</volume><fpage>1554</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.7.1554</pub-id><pub-id pub-id-type="pmid">7492103</pub-id></element-citation></ref><ref id="B35-antibiotics-11-01378"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>E.Y.</given-names></name>
<name><surname>Trucksis</surname><given-names>M.</given-names></name>
<name><surname>Hooper</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1996</year><volume>40</volume><fpage>1881</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1128/AAC.40.8.1881</pub-id><pub-id pub-id-type="pmid">8843298</pub-id></element-citation></ref><ref id="B36-antibiotics-11-01378"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaffe</surname><given-names>H.W.</given-names></name>
<name><surname>Sweeney</surname><given-names>H.M.</given-names></name>
<name><surname>Weinstein</surname><given-names>R.A.</given-names></name>
<name><surname>Kabins</surname><given-names>S.A.</given-names></name>
<name><surname>Nathan</surname><given-names>C.</given-names></name>
<name><surname>Cohen</surname><given-names>S.</given-names></name>
</person-group><article-title>Structural and phenotypic varieties of gentamicin resistance plasmids in hospital strains of <italic toggle="yes">Staphylococcus aureus</italic> and coagulase-negative staphylococci</article-title><source>Antimicrob. Agents Chemother.</source><year>1982</year><volume>21</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1128/AAC.21.5.773</pub-id><pub-id pub-id-type="pmid">7103456</pub-id></element-citation></ref><ref id="B37-antibiotics-11-01378"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ubukata</surname><given-names>K.</given-names></name>
<name><surname>Yamashita</surname><given-names>N.</given-names></name>
<name><surname>Gotoh</surname><given-names>A.</given-names></name>
<name><surname>Konno</surname><given-names>M.</given-names></name>
</person-group><article-title>Purification and characterization of aminoglycoside-modifying enzymes from <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Staphylococcus epidermidis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1984</year><volume>25</volume><fpage>754</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1128/AAC.25.6.754</pub-id><pub-id pub-id-type="pmid">6331299</pub-id></element-citation></ref><ref id="B38-antibiotics-11-01378"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasanvand</surname><given-names>A.</given-names></name>
<name><surname>Ghafourian</surname><given-names>S.</given-names></name>
<name><surname>Taherikalani</surname><given-names>M.</given-names></name>
<name><surname>Jalilian</surname><given-names>F.</given-names></name>
<name><surname>Sadeghifard</surname><given-names>N.</given-names></name>
<name><surname>Pakzad</surname><given-names>I.</given-names></name>
</person-group><article-title>Antiseptic Resistance in Methicillin Sensitive and Methicillin Resistant <italic toggle="yes">Staphylococcus aureus</italic> Isolates from Some Major Hospitals, Iran</article-title><source>Recent Pat. Antiinfect. Drug Discov.</source><year>2015</year><volume>10</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.2174/1574891X10666150623093259</pub-id><pub-id pub-id-type="pmid">26100979</pub-id></element-citation></ref><ref id="B39-antibiotics-11-01378"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taheri</surname><given-names>N.</given-names></name>
<name><surname>Ardebili</surname><given-names>A.</given-names></name>
<name><surname>Amouzandeh-Nobaveh</surname><given-names>A.</given-names></name>
<name><surname>Ghaznavi-Rad</surname><given-names>E.</given-names></name>
</person-group><article-title>Frequency of Antiseptic Resistance Among <italic toggle="yes">Staphylococcus aureus</italic> and Coagulase-Negative <italic toggle="yes">Staphylococci</italic> Isolated From a University Hospital in Central Iran</article-title><source>Oman Med. J.</source><year>2016</year><volume>31</volume><fpage>426</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.5001/omj.2016.86</pub-id><pub-id pub-id-type="pmid">27974958</pub-id></element-citation></ref><ref id="B40-antibiotics-11-01378"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mlynarczyk-Bonikowska</surname><given-names>B.</given-names></name>
<name><surname>Kowalewski</surname><given-names>C.</given-names></name>
<name><surname>Krolak-Ulinska</surname><given-names>A.</given-names></name>
<name><surname>Marusza</surname><given-names>W.</given-names></name>
</person-group><article-title>Molecular Mechanisms of Drug Resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>8088</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23158088</pub-id><pub-id pub-id-type="pmid">35897667</pub-id></element-citation></ref><ref id="B41-antibiotics-11-01378"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsai</surname><given-names>K.</given-names></name>
<name><surname>Stojkovi&#x00107;</surname><given-names>V.</given-names></name>
<name><surname>Noda-Garcia</surname><given-names>L.</given-names></name>
<name><surname>Young</surname><given-names>I.D.</given-names></name>
<name><surname>Myasnikov</surname><given-names>A.G.</given-names></name>
<name><surname>Kleinman</surname><given-names>J.</given-names></name>
<name><surname>Palla</surname><given-names>A.</given-names></name>
<name><surname>Floor</surname><given-names>S.N.</given-names></name>
<name><surname>Frost</surname><given-names>A.</given-names></name>
<name><surname>Fraser</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Directed evolution of the rRNA methylating enzyme Cfr reveals molecular basis of antibiotic resistance</article-title><source>Elife</source><year>2022</year><volume>11</volume><fpage>e70017</fpage><pub-id pub-id-type="doi">10.7554/eLife.70017</pub-id><pub-id pub-id-type="pmid">35015630</pub-id></element-citation></ref><ref id="B42-antibiotics-11-01378"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kehrenberg</surname><given-names>C.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
<name><surname>Jacobsen</surname><given-names>L.</given-names></name>
<name><surname>Hansen</surname><given-names>L.H.</given-names></name>
<name><surname>Vester</surname><given-names>B.</given-names></name>
</person-group><article-title>A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: Methylation of 23S ribosomal RNA at A2503</article-title><source>Mol. Microbiol.</source><year>2005</year><volume>57</volume><fpage>1064</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04754.x</pub-id><pub-id pub-id-type="pmid">16091044</pub-id></element-citation></ref><ref id="B43-antibiotics-11-01378"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aubry-Damon</surname><given-names>H.</given-names></name>
<name><surname>Soussy</surname><given-names>C.J.</given-names></name>
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
</person-group><article-title>Characterization of mutations in the rpoB gene that confer rifampin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>2590</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.10.2590</pub-id><pub-id pub-id-type="pmid">9756760</pub-id></element-citation></ref><ref id="B44-antibiotics-11-01378"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chopra</surname><given-names>I.</given-names></name>
<name><surname>Roberts</surname><given-names>M.</given-names></name>
</person-group><article-title>Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2001</year><volume>65</volume><fpage>232</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1128/MMBR.65.2.232-260.2001</pub-id><pub-id pub-id-type="pmid">11381101</pub-id></element-citation></ref><ref id="B45-antibiotics-11-01378"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Tetracycline resistance determinants: Mechanisms of action, regulation of expression, genetic mobility, and distribution</article-title><source>FEMS Microbiol. Rev.</source><year>1996</year><volume>19</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.1996.tb00251.x</pub-id><?supplied-pmid 8916553?><pub-id pub-id-type="pmid">8916553</pub-id></element-citation></ref><ref id="B46-antibiotics-11-01378"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrero</surname><given-names>L.</given-names></name>
<name><surname>Cameron</surname><given-names>B.</given-names></name>
<name><surname>Manse</surname><given-names>B.</given-names></name>
<name><surname>Lagneaux</surname><given-names>D.</given-names></name>
<name><surname>Crouzet</surname><given-names>J.</given-names></name>
<name><surname>Famechon</surname><given-names>A.</given-names></name>
<name><surname>Blanche</surname><given-names>F.</given-names></name>
</person-group><article-title>Cloning and primary structure of <italic toggle="yes">Staphylococcus aureus</italic> DNA topoisomerase IV: A primary target of fluoroquinolones</article-title><source>Mol. Microbiol.</source><year>1994</year><volume>13</volume><fpage>641</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1994.tb00458.x</pub-id><?supplied-pmid 7997176?><pub-id pub-id-type="pmid">7997176</pub-id></element-citation></ref><ref id="B47-antibiotics-11-01378"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ito</surname><given-names>H.</given-names></name>
<name><surname>Yoshida</surname><given-names>H.</given-names></name>
<name><surname>Bogaki-Shonai</surname><given-names>M.</given-names></name>
<name><surname>Niga</surname><given-names>T.</given-names></name>
<name><surname>Hattori</surname><given-names>H.</given-names></name>
<name><surname>Nakamura</surname><given-names>S.</given-names></name>
</person-group><article-title>Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1994</year><volume>38</volume><fpage>2014</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.9.2014</pub-id><?supplied-pmid 7811012?><pub-id pub-id-type="pmid">7811012</pub-id></element-citation></ref><ref id="B48-antibiotics-11-01378"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
<name><surname>Igarashi</surname><given-names>M.</given-names></name>
<name><surname>Morimoto</surname><given-names>Y.</given-names></name>
<name><surname>Baba</surname><given-names>T.</given-names></name>
<name><surname>Umekita</surname><given-names>M.</given-names></name>
<name><surname>Akamatsu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Curing bacteria of antibiotic resistance: Reverse antibiotics, a novel class of antibiotics in nature</article-title><source>Int. J. Antimicrob. Agents</source><year>2012</year><volume>39</volume><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.02.007</pub-id><pub-id pub-id-type="pmid">22534508</pub-id></element-citation></ref><ref id="B49-antibiotics-11-01378"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yun</surname><given-names>H.-J.</given-names></name>
<name><surname>Min</surname><given-names>Y.-H.</given-names></name>
<name><surname>Jo</surname><given-names>Y.W.</given-names></name>
<name><surname>Shim</surname><given-names>M.-J.</given-names></name>
<name><surname>Choi</surname><given-names>E.-C.</given-names></name>
</person-group><article-title>Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against <italic toggle="yes">Staphylococcus aureus</italic> strains with defined mutations in DNA gyrase and topoisomerase IV</article-title><source>Int. J. Antimicrob. Agents</source><year>2005</year><volume>25</volume><fpage>334</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.11.013</pub-id><?supplied-pmid 15784314?><pub-id pub-id-type="pmid">15784314</pub-id></element-citation></ref><ref id="B50-antibiotics-11-01378"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaw</surname><given-names>K.J.</given-names></name>
<name><surname>Rather</surname><given-names>P.N.</given-names></name>
<name><surname>Hare</surname><given-names>R.S.</given-names></name>
<name><surname>Miller</surname><given-names>G.H.</given-names></name>
</person-group><article-title>Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes</article-title><source>Microbiol. Rev.</source><year>1993</year><volume>57</volume><fpage>138</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1128/mr.57.1.138-163.1993</pub-id><pub-id pub-id-type="pmid">8385262</pub-id></element-citation></ref><ref id="B51-antibiotics-11-01378"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramirez</surname><given-names>M.S.</given-names></name>
<name><surname>Tolmasky</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Aminoglycoside modifying enzymes</article-title><source>Drug Resist. Updat.</source><year>2010</year><volume>13</volume><fpage>151</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2010.08.003</pub-id><?supplied-pmid 20833577?><pub-id pub-id-type="pmid">20833577</pub-id></element-citation></ref><ref id="B52-antibiotics-11-01378"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuoka</surname><given-names>M.</given-names></name>
<name><surname>Inoue</surname><given-names>M.</given-names></name>
<name><surname>Endo</surname><given-names>Y.</given-names></name>
<name><surname>Nakajima</surname><given-names>Y.</given-names></name>
</person-group><article-title>Characteristic expression of three genes, msr (A), mph (C) and erm (Y), that confer resistance to macrolide antibiotics on <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>FEMS Microbiol. Lett.</source><year>2003</year><volume>220</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/S0378-1097(03)00134-4</pub-id><pub-id pub-id-type="pmid">12670694</pub-id></element-citation></ref><ref id="B53-antibiotics-11-01378"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>M.K.</given-names></name>
<name><surname>Keithly</surname><given-names>M.E.</given-names></name>
<name><surname>Goodman</surname><given-names>M.C.</given-names></name>
<name><surname>Hammer</surname><given-names>N.D.</given-names></name>
<name><surname>Cook</surname><given-names>P.D.</given-names></name>
<name><surname>Jagessar</surname><given-names>K.L.</given-names></name>
<name><surname>Harp</surname><given-names>J.</given-names></name>
<name><surname>Skaar</surname><given-names>E.P.</given-names></name>
<name><surname>Armstrong</surname><given-names>R.N.</given-names></name>
</person-group><article-title>Structure and function of the genomically encoded fosfomycin resistance enzyme, FosB, from <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Biochemistry</source><year>2014</year><volume>53</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1021/bi4015852</pub-id><pub-id pub-id-type="pmid">24447055</pub-id></element-citation></ref><ref id="B54-antibiotics-11-01378"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
</person-group><article-title>Characterization of Fosfomycin Resistance Gene, fosB, in Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Isolates</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0154829</elocation-id><pub-id pub-id-type="pmid">27144405</pub-id></element-citation></ref><ref id="B55-antibiotics-11-01378"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kapoor</surname><given-names>G.</given-names></name>
<name><surname>Saigal</surname><given-names>S.</given-names></name>
<name><surname>Elongavan</surname><given-names>A.</given-names></name>
</person-group><article-title>Action and resistance mechanisms of antibiotics: A guide for clinicians</article-title><source>J. Anaesthesiol. Clin. Pharmacol.</source><year>2017</year><volume>33</volume><fpage>300</fpage><pub-id pub-id-type="doi">10.4103/joacp.JOACP_349_15</pub-id><?supplied-pmid 29109626?><pub-id pub-id-type="pmid">29109626</pub-id></element-citation></ref><ref id="B56-antibiotics-11-01378"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foster</surname><given-names>T.J.</given-names></name>
</person-group><article-title>The remarkably multifunctional fibronectin binding proteins of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2016</year><volume>35</volume><fpage>1923</fpage><lpage>1931</lpage><pub-id pub-id-type="doi">10.1007/s10096-016-2763-0</pub-id><?supplied-pmid 27604831?><pub-id pub-id-type="pmid">27604831</pub-id></element-citation></ref><ref id="B57-antibiotics-11-01378"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jang</surname><given-names>S.</given-names></name>
</person-group><article-title>Multidrug efflux pumps in <italic toggle="yes">Staphylococcus aureus</italic> and their clinical implications</article-title><source>J. Microbiol.</source><year>2016</year><volume>54</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s12275-016-5159-z</pub-id><pub-id pub-id-type="pmid">26727895</pub-id></element-citation></ref><ref id="B58-antibiotics-11-01378"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaatz</surname><given-names>G.W.</given-names></name>
<name><surname>Seo</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Inducible NorA-mediated multidrug resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1995</year><volume>39</volume><fpage>2650</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.12.2650</pub-id><?supplied-pmid 8592996?><pub-id pub-id-type="pmid">8592996</pub-id></element-citation></ref><ref id="B59-antibiotics-11-01378"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>S.S.</given-names></name>
<name><surname>Sobkowiak</surname><given-names>B.</given-names></name>
<name><surname>Parreira</surname><given-names>R.</given-names></name>
<name><surname>Edgeworth</surname><given-names>J.D.</given-names></name>
<name><surname>Viveiros</surname><given-names>M.</given-names></name>
<name><surname>Clark</surname><given-names>T.G.</given-names></name>
<name><surname>Couto</surname><given-names>I.</given-names></name>
</person-group><article-title>Genetic diversity of norA, coding for a main efflux pump of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Front. Genet.</source><year>2019</year><volume>10</volume><fpage>710</fpage><pub-id pub-id-type="doi">10.3389/fgene.2018.00710</pub-id><?supplied-pmid 30687388?><pub-id pub-id-type="pmid">31428138</pub-id></element-citation></ref><ref id="B60-antibiotics-11-01378"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>S.I.</given-names></name>
<name><surname>Lee</surname><given-names>Y.-M.</given-names></name>
<name><surname>Park</surname><given-names>K.-H.</given-names></name>
<name><surname>Ryu</surname><given-names>B.-H.</given-names></name>
<name><surname>Hong</surname><given-names>K.-W.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Bae</surname><given-names>I.-G.</given-names></name>
<name><surname>Cho</surname><given-names>O.-H.</given-names></name>
</person-group><article-title>Clinical and Molecular Characteristics of qacA- and qacB-Positive Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Causing Bloodstream Infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e02157-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.02157-18</pub-id><pub-id pub-id-type="pmid">30718251</pub-id></element-citation></ref><ref id="B61-antibiotics-11-01378"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noguchi</surname><given-names>N.</given-names></name>
<name><surname>Suwa</surname><given-names>J.</given-names></name>
<name><surname>Narui</surname><given-names>K.</given-names></name>
<name><surname>Sasatsu</surname><given-names>M.</given-names></name>
<name><surname>Ito</surname><given-names>T.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
<name><surname>Song</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes qacA/B and smr of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> isolated in Asia during 1998 and 1999</article-title><source>J. Med. Microbiol.</source><year>2005</year><volume>54</volume><fpage>557</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.45902-0</pub-id><pub-id pub-id-type="pmid">15888465</pub-id></element-citation></ref><ref id="B62-antibiotics-11-01378"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakaminami</surname><given-names>H.</given-names></name>
<name><surname>Takadama</surname><given-names>S.</given-names></name>
<name><surname>Okita</surname><given-names>M.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Noguchi</surname><given-names>N.</given-names></name>
</person-group><article-title>Fast-acting bactericidal activity of olanexidine gluconate against qacA/B-positive methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Med. Microbiol.</source><year>2019</year><volume>68</volume><fpage>957</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000979</pub-id><?supplied-pmid 31050633?><pub-id pub-id-type="pmid">31050633</pub-id></element-citation></ref><ref id="B63-antibiotics-11-01378"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guay</surname><given-names>G.G.</given-names></name>
<name><surname>Khan</surname><given-names>S.A.</given-names></name>
<name><surname>Rothstein</surname><given-names>D.M.</given-names></name>
</person-group><article-title>The tet(K) Gene of Plasmid pT181 of <italic toggle="yes">Staphylococcus aureus</italic> Encodes an Efflux Protein That Contains 14 Transmembrane Helices</article-title><source>Plasmid</source><year>1993</year><volume>30</volume><fpage>163</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1006/plas.1993.1045</pub-id><pub-id pub-id-type="pmid">8234490</pub-id></element-citation></ref><ref id="B64-antibiotics-11-01378"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>A.S.</given-names></name>
<name><surname>de Lencastre</surname><given-names>H.</given-names></name>
<name><surname>Garau</surname><given-names>J.</given-names></name>
<name><surname>Kluytmans</surname><given-names>J.</given-names></name>
<name><surname>Malhotra-Kumar</surname><given-names>S.</given-names></name>
<name><surname>Peschel</surname><given-names>A.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
</person-group><article-title>Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Nat. Rev. Dis. Prim.</source><year>2018</year><volume>4</volume><fpage>18033</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.33</pub-id><pub-id pub-id-type="pmid">29849094</pub-id></element-citation></ref><ref id="B65-antibiotics-11-01378"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wright</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Q&#x00026;A: Antibiotic resistance: Where does it come from and what can we do about it?</article-title><source>BMC Biol.</source><year>2010</year><volume>8</volume><elocation-id>123</elocation-id><pub-id pub-id-type="pmid">20887638</pub-id></element-citation></ref><ref id="B66-antibiotics-11-01378"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McGuire</surname><given-names>J.M.</given-names></name>
<name><surname>Bunch</surname><given-names>R.L.</given-names></name>
<name><surname>Anderson</surname><given-names>R.C.</given-names></name>
<name><surname>Boaz</surname><given-names>H.E.</given-names></name>
<name><surname>Flynn</surname><given-names>E.H.</given-names></name>
<name><surname>Powell</surname><given-names>H.M.</given-names></name>
<name><surname>Smith</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Ilotycin, a new antibiotic</article-title><source>Antibiot. Chemother.</source><year>1952</year><volume>2</volume><fpage>281</fpage><lpage>283</lpage></element-citation></ref><ref id="B67-antibiotics-11-01378"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>MacCabe</surname><given-names>A.F.</given-names></name>
<name><surname>Gould</surname><given-names>J.C.</given-names></name>
</person-group><article-title>The Epidemiology of an Erythromycin Resistant <italic toggle="yes">Staphylococcus</italic></article-title><source>Scott. Med. J.</source><year>1956</year><volume>1</volume><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1177/003693305600100701</pub-id><?supplied-pmid 13351658?><pub-id pub-id-type="pmid">13351658</pub-id></element-citation></ref><ref id="B68-antibiotics-11-01378"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Champney</surname><given-names>W.S.</given-names></name>
<name><surname>Burdine</surname><given-names>R.</given-names></name>
</person-group><article-title>Macrolide antibiotics inhibit 50S ribosomal subunit assembly in <italic toggle="yes">Bacillus subtilis</italic> and <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1995</year><volume>39</volume><fpage>2141</fpage><lpage>2144</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.9.2141</pub-id><pub-id pub-id-type="pmid">8540733</pub-id></element-citation></ref><ref id="B69-antibiotics-11-01378"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dinos</surname><given-names>G.P.</given-names></name>
</person-group><article-title>The macrolide antibiotic renaissance</article-title><source>Br. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>2967</fpage><lpage>2983</lpage><pub-id pub-id-type="doi">10.1111/bph.13936</pub-id><pub-id pub-id-type="pmid">28664582</pub-id></element-citation></ref><ref id="B70-antibiotics-11-01378"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miklasi&#x00144;ska-Majdanik</surname><given-names>M.</given-names></name>
</person-group><article-title>Mechanisms of Resistance to Macrolide Antibiotics among <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1406</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10111406</pub-id><pub-id pub-id-type="pmid">34827344</pub-id></element-citation></ref><ref id="B71-antibiotics-11-01378"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwendener</surname><given-names>S.</given-names></name>
<name><surname>Don&#x000e0;</surname><given-names>V.</given-names></name>
<name><surname>Perreten</surname><given-names>V.</given-names></name>
</person-group><article-title>The Novel Macrolide Resistance Genes mef (D), msr (F), and msr (H) Are Present on Resistance Islands in <italic toggle="yes">Macrococcus canis</italic>, <italic toggle="yes">Macrococcus caseolyticus</italic>, and <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e00160-20</fpage><pub-id pub-id-type="doi">10.1128/AAC.00160-20</pub-id><pub-id pub-id-type="pmid">32122903</pub-id></element-citation></ref><ref id="B72-antibiotics-11-01378"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ross</surname><given-names>J.I.</given-names></name>
<name><surname>Eady</surname><given-names>E.A.</given-names></name>
<name><surname>Cove</surname><given-names>J.H.</given-names></name>
<name><surname>Cunliffe</surname><given-names>W.J.</given-names></name>
<name><surname>Baumberg</surname><given-names>S.</given-names></name>
<name><surname>Wootton</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Inducible erythromycin resistance in staphlyococci is encoded by a member of the ATP-binding transport super-gene family</article-title><source>Mol. Microbiol.</source><year>1990</year><volume>4</volume><fpage>1207</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1990.tb00696.x</pub-id><pub-id pub-id-type="pmid">2233255</pub-id></element-citation></ref><ref id="B73-antibiotics-11-01378"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fe&#x000df;ler</surname><given-names>A.T.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
</person-group><article-title>Mobile macrolide resistance genes in staphylococci</article-title><source>Plasmid</source><year>2018</year><volume>99</volume><fpage>2</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.plasmid.2018.05.001</pub-id><pub-id pub-id-type="pmid">29807043</pub-id></element-citation></ref><ref id="B74-antibiotics-11-01378"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leclercq</surname><given-names>R.</given-names></name>
</person-group><article-title>Mechanisms of Resistance to Macrolides and Lincosamides: Nature of the Resistance Elements and Their Clinical Implications</article-title><source>Clin. Infect. Dis.</source><year>2002</year><volume>34</volume><fpage>482</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1086/324626</pub-id><pub-id pub-id-type="pmid">11797175</pub-id></element-citation></ref><ref id="B75-antibiotics-11-01378"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sp&#x000ed;&#x0017e;ek</surname><given-names>J.</given-names></name>
<name><surname>&#x00158;ezanka</surname><given-names>T.</given-names></name>
</person-group><article-title>Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications</article-title><source>Biochem. Pharmacol.</source><year>2017</year><volume>133</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2016.12.001</pub-id><pub-id pub-id-type="pmid">27940264</pub-id></element-citation></ref><ref id="B76-antibiotics-11-01378"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhuang</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>F.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>Shen</surname><given-names>P.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Distribution of erm genes among MRSA isolates with resistance to clindamycin in a Chinese teaching hospital</article-title><source>Infect. Genet. Evol.</source><year>2021</year><volume>96</volume><fpage>105127</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.105127</pub-id><pub-id pub-id-type="pmid">34718190</pub-id></element-citation></ref><ref id="B77-antibiotics-11-01378"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blair</surname><given-names>J.M.A.</given-names></name>
<name><surname>Webber</surname><given-names>M.A.</given-names></name>
<name><surname>Baylay</surname><given-names>A.J.</given-names></name>
<name><surname>Ogbolu</surname><given-names>D.O.</given-names></name>
<name><surname>Piddock</surname><given-names>L.J.V.</given-names></name>
</person-group><article-title>Molecular mechanisms of antibiotic resistance</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id><pub-id pub-id-type="pmid">25435309</pub-id></element-citation></ref><ref id="B78-antibiotics-11-01378"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soussy</surname><given-names>C.J.</given-names></name>
<name><surname>Bouanchaud</surname><given-names>D.H.</given-names></name>
<name><surname>Fouace</surname><given-names>J.</given-names></name>
<name><surname>Dublanchet</surname><given-names>A.</given-names></name>
<name><surname>Duval</surname><given-names>J.</given-names></name>
</person-group><article-title>A gentamycin resistance plasmid in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Ann. Microbiol.</source><year>1975</year><volume>126</volume><fpage>91</fpage><lpage>94</lpage></element-citation></ref><ref id="B79-antibiotics-11-01378"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Porthouse</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>D.F.</given-names></name>
<name><surname>Smith</surname><given-names>R.G.</given-names></name>
<name><surname>Rogers</surname><given-names>T.</given-names></name>
</person-group><article-title>Gentamicin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Lancet</source><year>1976</year><volume>307</volume><fpage>20</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(76)92912-3</pub-id></element-citation></ref><ref id="B80-antibiotics-11-01378"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schluenzen</surname><given-names>F.</given-names></name>
<name><surname>Tocilj</surname><given-names>A.</given-names></name>
<name><surname>Zarivach</surname><given-names>R.</given-names></name>
<name><surname>Harms</surname><given-names>J.</given-names></name>
<name><surname>Gluehmann</surname><given-names>M.</given-names></name>
<name><surname>Janell</surname><given-names>D.</given-names></name>
<name><surname>Bashan</surname><given-names>A.</given-names></name>
<name><surname>Bartels</surname><given-names>H.</given-names></name>
<name><surname>Agmon</surname><given-names>I.</given-names></name>
<name><surname>Franceschi</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Structure of Functionally Activated Small Ribosomal Subunit at 3.3 &#x000c5; Resolution</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00084-2</pub-id><pub-id pub-id-type="pmid">11007480</pub-id></element-citation></ref><ref id="B81-antibiotics-11-01378"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wimberly</surname><given-names>B.T.</given-names></name>
<name><surname>Brodersen</surname><given-names>D.E.</given-names></name>
<name><surname>Clemons</surname><given-names>W.M.</given-names></name>
<name><surname>Morgan-Warren</surname><given-names>R.J.</given-names></name>
<name><surname>Carter</surname><given-names>A.P.</given-names></name>
<name><surname>Vonrhein</surname><given-names>C.</given-names></name>
<name><surname>Hartsch</surname><given-names>T.</given-names></name>
<name><surname>Ramakrishnan</surname><given-names>V.</given-names></name>
</person-group><article-title>Structure of the 30S ribosomal subunit</article-title><source>Nature</source><year>2000</year><volume>407</volume><fpage>327</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/35030006</pub-id><pub-id pub-id-type="pmid">11014182</pub-id></element-citation></ref><ref id="B82-antibiotics-11-01378"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carter</surname><given-names>A.P.</given-names></name>
<name><surname>Clemons</surname><given-names>W.M.</given-names></name>
<name><surname>Brodersen</surname><given-names>D.E.</given-names></name>
<name><surname>Morgan-Warren</surname><given-names>R.J.</given-names></name>
<name><surname>Wimberly</surname><given-names>B.T.</given-names></name>
<name><surname>Ramakrishnan</surname><given-names>V.</given-names></name>
</person-group><article-title>Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics</article-title><source>Nature</source><year>2000</year><volume>407</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1038/35030019</pub-id><pub-id pub-id-type="pmid">11014183</pub-id></element-citation></ref><ref id="B83-antibiotics-11-01378"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magnet</surname><given-names>S.</given-names></name>
<name><surname>Blanchard</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Molecular Insights into Aminoglycoside Action and Resistance</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>477</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1021/cr0301088</pub-id><pub-id pub-id-type="pmid">15700953</pub-id></element-citation></ref><ref id="B84-antibiotics-11-01378"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotra</surname><given-names>L.P.</given-names></name>
<name><surname>Haddad</surname><given-names>J.</given-names></name>
<name><surname>Mobashery</surname><given-names>S.</given-names></name>
</person-group><article-title>Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter Resistance</article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>3249</fpage><lpage>3256</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.12.3249-3256.2000</pub-id><pub-id pub-id-type="pmid">11083623</pub-id></element-citation></ref><ref id="B85-antibiotics-11-01378"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rouch</surname><given-names>D.A.</given-names></name>
<name><surname>Byrne</surname><given-names>M.E.</given-names></name>
<name><surname>Kong</surname><given-names>Y.C.</given-names></name>
<name><surname>Skurray</surname><given-names>R.A.</given-names></name>
</person-group><article-title>The aacA-aphD gentamicin and kanamycin resistance determinant of Tn4001 from <italic toggle="yes">Staphylococcus aureus</italic>: Expression and nucleotide sequence analysis</article-title><source>J. Gen. Microbiol.</source><year>1987</year><volume>133</volume><fpage>3039</fpage><lpage>3052</lpage><pub-id pub-id-type="doi">10.1099/00221287-133-11-3039</pub-id><?supplied-pmid 2833561?><pub-id pub-id-type="pmid">2833561</pub-id></element-citation></ref><ref id="B86-antibiotics-11-01378"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ida</surname><given-names>T.</given-names></name>
<name><surname>Okamoto</surname><given-names>R.</given-names></name>
<name><surname>Shimauchi</surname><given-names>C.</given-names></name>
<name><surname>Okubo</surname><given-names>T.</given-names></name>
<name><surname>Kuga</surname><given-names>A.</given-names></name>
<name><surname>Inoue</surname><given-names>M.</given-names></name>
</person-group><article-title>Identification of aminoglycoside-modifying enzymes by susceptibility testing: Epidemiology of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> in Japan</article-title><source>J. Clin. Microbiol.</source><year>2001</year><volume>39</volume><fpage>3115</fpage><lpage>3121</lpage><pub-id pub-id-type="doi">10.1128/JCM.39.9.3115-3121.2001</pub-id><?supplied-pmid 11526138?><pub-id pub-id-type="pmid">11526138</pub-id></element-citation></ref><ref id="B87-antibiotics-11-01378"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>M.</given-names></name>
<name><surname>Nonoyama</surname><given-names>M.</given-names></name>
<name><surname>Okamoto</surname><given-names>R.I.T.</given-names></name>
</person-group><article-title>Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>&#x02014;PubMed</article-title><source>Drugs Exp. Clin. Res.</source><year>1994</year><volume>20</volume><fpage>233</fpage><lpage>239</lpage><?supplied-pmid 7758395?><pub-id pub-id-type="pmid">7758395</pub-id></element-citation></ref><ref id="B88-antibiotics-11-01378"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuchizaki</surname><given-names>N.</given-names></name>
<name><surname>Ishino</surname><given-names>K.</given-names></name>
<name><surname>Saito</surname><given-names>F.</given-names></name>
<name><surname>Ishikawa</surname><given-names>J.</given-names></name>
<name><surname>Nakajima</surname><given-names>M.</given-names></name>
<name><surname>Hotta</surname><given-names>K.</given-names></name>
</person-group><article-title>Trends of Arbekacin-resistant MRSA Strains in Japanese Hospitals (1979 to 2000)</article-title><source>J. Antibiot.</source><year>2006</year><volume>59</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/ja.2006.32</pub-id></element-citation></ref><ref id="B89-antibiotics-11-01378"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>N.</given-names></name>
<name><surname>Matsunaga</surname><given-names>K.</given-names></name>
<name><surname>Hirata</surname><given-names>A.</given-names></name>
<name><surname>Matsuhisa</surname><given-names>Y.</given-names></name>
<name><surname>Nishimura</surname><given-names>T.</given-names></name>
</person-group><article-title>Mechanism of action of habekacin, a novel amino acid-containing aminoglycoside antibiotic</article-title><source>Antimicrob. Agents Chemother.</source><year>1983</year><volume>24</volume><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1128/AAC.24.5.797</pub-id><pub-id pub-id-type="pmid">6362557</pub-id></element-citation></ref><ref id="B90-antibiotics-11-01378"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishino</surname><given-names>K.</given-names></name>
<name><surname>Ishikawa</surname><given-names>J.</given-names></name>
<name><surname>Ikeda</surname><given-names>Y.</given-names></name>
<name><surname>Hotta</surname><given-names>K.</given-names></name>
</person-group><article-title>Characterization of a Bifunctional Aminoglycoside-Modifying Enzyme with Novel Substrate Specificity and Its Gene from a Clinical Isolate of Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> with High Arbekacin Resistance</article-title><source>J. Antibiot.</source><year>2004</year><volume>57</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.57.679</pub-id></element-citation></ref><ref id="B91-antibiotics-11-01378"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ida</surname><given-names>T.</given-names></name>
<name><surname>Okamoto</surname><given-names>R.</given-names></name>
<name><surname>Nonoyama</surname><given-names>M.</given-names></name>
<name><surname>Irinoda</surname><given-names>K.</given-names></name>
<name><surname>Kurazono</surname><given-names>M.</given-names></name>
<name><surname>Inoue</surname><given-names>M.</given-names></name>
</person-group><article-title>Antagonism between Aminoglycosides and &#x003b2;-Lactams in a Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Isolate Involves Induction of an Aminoglycoside-Modifying Enzyme</article-title><source>Antimicrob. Agents Chemother.</source><year>2002</year><volume>46</volume><fpage>1516</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1128/AAC.46.5.1516-1521.2002</pub-id><pub-id pub-id-type="pmid">11959590</pub-id></element-citation></ref><ref id="B92-antibiotics-11-01378"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondo</surname><given-names>S.</given-names></name>
<name><surname>Tamura</surname><given-names>A.</given-names></name>
<name><surname>Gomi</surname><given-names>S.</given-names></name>
<name><surname>Ikeda</surname><given-names>Y.</given-names></name>
<name><surname>Takeuchi</surname><given-names>T.</given-names></name>
<name><surname>Mitsuhashi</surname><given-names>S.</given-names></name>
</person-group><article-title>Structures of enzymatically modified products of arbekacin by methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Antibiot.</source><year>1993</year><volume>46</volume><fpage>310</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.46.310</pub-id></element-citation></ref><ref id="B93-antibiotics-11-01378"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
</person-group><article-title>Arbekacin: Another novel agent for treating infections due to methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> and multidrug-resistant Gram-negative pathogens</article-title><source>Clin. Pharmacol. Adv. Appl.</source><year>2014</year><volume>6</volume><fpage>139</fpage><pub-id pub-id-type="doi">10.2147/CPAA.S44377</pub-id></element-citation></ref><ref id="B94-antibiotics-11-01378"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (CDC)</collab>
</person-group><article-title><italic toggle="yes">Staphylococcus aureus</italic> resistant to vancomycin&#x02014;United States, 2002</article-title><source>MMWR Morb. Mortal Wkly. Rep.</source><year>2002</year><volume>51</volume><fpage>565</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">12139181</pub-id></element-citation></ref><ref id="B95-antibiotics-11-01378"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>P.E.</given-names></name>
</person-group><article-title>Structure, biochemistry and mechanism of action of glycopeptide antibiotics</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>1989</year><volume>8</volume><fpage>943</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1007/BF01967563</pub-id><?supplied-pmid 2532132?><pub-id pub-id-type="pmid">2532132</pub-id></element-citation></ref><ref id="B96-antibiotics-11-01378"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parenti</surname><given-names>F.</given-names></name>
</person-group><article-title>Structure and mechanism of action of teicoplanin</article-title><source>J. Hosp. Infect.</source><year>1986</year><volume>7</volume><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/0195-6701(86)90011-3</pub-id><pub-id pub-id-type="pmid">2871101</pub-id></element-citation></ref><ref id="B97-antibiotics-11-01378"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>McGuinness</surname><given-names>W.A.</given-names></name>
<name><surname>Malachowa</surname><given-names>N.</given-names></name>
<name><surname>DeLeo</surname><given-names>F.R.</given-names></name>
</person-group><article-title>Vancomycin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>The Year in Infection</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2005</year><volume>Volume 90</volume><fpage>133</fpage><lpage>152</lpage></element-citation></ref><ref id="B98-antibiotics-11-01378"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>S.</given-names></name>
<name><surname>Sievert</surname><given-names>D.M.</given-names></name>
<name><surname>Hageman</surname><given-names>J.C.</given-names></name>
<name><surname>Boulton</surname><given-names>M.L.</given-names></name>
<name><surname>Tenover</surname><given-names>F.C.</given-names></name>
<name><surname>Downes</surname><given-names>F.P.</given-names></name>
<name><surname>Shah</surname><given-names>S.</given-names></name>
<name><surname>Rudrik</surname><given-names>J.T.</given-names></name>
<name><surname>Pupp</surname><given-names>G.R.</given-names></name>
<name><surname>Brown</surname><given-names>W.J.</given-names></name>
<etal/>
</person-group><article-title>Infection with Vancomycin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Containing the vanA Resistance Gene</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1342</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa025025</pub-id><pub-id pub-id-type="pmid">12672861</pub-id></element-citation></ref><ref id="B99-antibiotics-11-01378"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Isii</surname><given-names>T.</given-names></name>
<name><surname>Fukuda</surname><given-names>M.</given-names></name>
<name><surname>Ochiai</surname><given-names>T.</given-names></name>
<name><surname>Neoh</surname><given-names>H.M.</given-names></name>
<name><surname>Da Cunha Camargo</surname><given-names>I.L.B.</given-names></name>
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Shoji</surname><given-names>M.</given-names></name>
<name><surname>Hishinuma</surname><given-names>T.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>5222</fpage><lpage>5233</lpage><pub-id pub-id-type="doi">10.1128/AAC.00437-10</pub-id><pub-id pub-id-type="pmid">20837752</pub-id></element-citation></ref><ref id="B100-antibiotics-11-01378"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Katayama</surname><given-names>Y.</given-names></name>
<name><surname>Kozue</surname><given-names>K.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Impact of rpoB mutations on reduced vancomycin susceptibility in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Clin. Microbiol.</source><year>2011</year><volume>49</volume><fpage>2680</fpage><lpage>2684</lpage><pub-id pub-id-type="doi">10.1128/JCM.02144-10</pub-id><pub-id pub-id-type="pmid">21525224</pub-id></element-citation></ref><ref id="B101-antibiotics-11-01378"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamaguchi</surname><given-names>T.</given-names></name>
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Okamura</surname><given-names>S.</given-names></name>
<name><surname>Miura</surname><given-names>Y.</given-names></name>
<name><surname>Tsukimori</surname><given-names>A.</given-names></name>
<name><surname>Nakamura</surname><given-names>I.</given-names></name>
<name><surname>Ito</surname><given-names>N.</given-names></name>
<name><surname>Masuya</surname><given-names>A.</given-names></name>
<name><surname>Shiina</surname><given-names>T.</given-names></name>
<name><surname>Matsumoto</surname><given-names>T.</given-names></name>
</person-group><article-title>Evolution and single-nucleotide polymorphisms in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> strains with reduced susceptibility to vancomycin and daptomycin, based on determination of the complete genome</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>3585</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1128/AAC.05159-14</pub-id><pub-id pub-id-type="pmid">25779584</pub-id></element-citation></ref><ref id="B102-antibiotics-11-01378"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gardete</surname><given-names>S.</given-names></name>
<name><surname>Tomasz</surname><given-names>A.</given-names></name>
</person-group><article-title>Mechanisms of vancomycin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Clin. Investig.</source><year>2014</year><volume>124</volume><fpage>2836</fpage><lpage>2840</lpage><pub-id pub-id-type="pmid">24983424</pub-id></element-citation></ref><ref id="B103-antibiotics-11-01378"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arthur</surname><given-names>M.</given-names></name>
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
</person-group><article-title>Genetics and mechanisms of glycopeptide resistance in <italic toggle="yes">Enterococci</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>1563</fpage><lpage>1571</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.8.1563</pub-id><pub-id pub-id-type="pmid">8215264</pub-id></element-citation></ref><ref id="B104-antibiotics-11-01378"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>Q.</given-names></name>
<name><surname>Shang</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>72</volume><fpage>dkw518</fpage><pub-id pub-id-type="doi">10.1093/jac/dkw518</pub-id></element-citation></ref><ref id="B105-antibiotics-11-01378"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Suna</surname><given-names>B.</given-names></name>
</person-group><article-title>Mechanism of reduced vancomycin susceptibility conferred by walK mutation in community-acquired methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> strain mw2</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>1352</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1128/AAC.04290-14</pub-id><pub-id pub-id-type="pmid">25451044</pub-id></element-citation></ref><ref id="B106-antibiotics-11-01378"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howden</surname><given-names>B.P.</given-names></name>
<name><surname>McEvoy</surname><given-names>C.R.E.</given-names></name>
<name><surname>Allen</surname><given-names>D.L.</given-names></name>
<name><surname>Chua</surname><given-names>K.</given-names></name>
<name><surname>Gao</surname><given-names>W.</given-names></name>
<name><surname>Harrison</surname><given-names>P.F.</given-names></name>
<name><surname>Bell</surname><given-names>J.</given-names></name>
<name><surname>Coombs</surname><given-names>G.</given-names></name>
<name><surname>Bennett-Wood</surname><given-names>V.</given-names></name>
<name><surname>Porter</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Evolution of Multidrug Resistance during <italic toggle="yes">Staphylococcus aureus</italic> Infection Involves Mutation of the Essential Two Component Regulator WalKR</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1002359</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002359</pub-id><pub-id pub-id-type="pmid">22102812</pub-id></element-citation></ref><ref id="B107-antibiotics-11-01378"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hafer</surname><given-names>C.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Kornblum</surname><given-names>J.</given-names></name>
<name><surname>Lowy</surname><given-names>F.D.</given-names></name>
<name><surname>Uhlemann</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>5845</fpage><lpage>5851</lpage><pub-id pub-id-type="doi">10.1128/AAC.01139-12</pub-id><?supplied-pmid 22948864?><pub-id pub-id-type="pmid">22948864</pub-id></element-citation></ref><ref id="B108-antibiotics-11-01378"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gardete</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>C.</given-names></name>
<name><surname>Hartmann</surname><given-names>B.M.</given-names></name>
<name><surname>Mwangi</surname><given-names>M.</given-names></name>
<name><surname>Roux</surname><given-names>C.M.</given-names></name>
<name><surname>Dunman</surname><given-names>P.M.</given-names></name>
<name><surname>Chambers</surname><given-names>H.F.</given-names></name>
<name><surname>Tomasz</surname><given-names>A.</given-names></name>
</person-group><article-title>Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) Strain of Clonal Type USA300</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><elocation-id>e1002505</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002505</pub-id><?supplied-pmid 22319446?><pub-id pub-id-type="pmid">22319446</pub-id></element-citation></ref><ref id="B109-antibiotics-11-01378"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Doddangoudar</surname><given-names>V.C.</given-names></name>
<name><surname>O&#x02019;Donoghue</surname><given-names>M.M.</given-names></name>
<name><surname>Chong</surname><given-names>E.Y.C.</given-names></name>
<name><surname>Tsang</surname><given-names>D.N.C.</given-names></name>
<name><surname>Boost</surname><given-names>M.V.</given-names></name>
</person-group><article-title>Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>2101</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1093/jac/dks171</pub-id><pub-id pub-id-type="pmid">22643192</pub-id></element-citation></ref><ref id="B110-antibiotics-11-01378"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Neoh</surname><given-names>H.M.</given-names></name>
<name><surname>Shoji</surname><given-names>M.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>1231</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1128/AAC.01173-08</pub-id><pub-id pub-id-type="pmid">19124662</pub-id></element-citation></ref><ref id="B111-antibiotics-11-01378"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neoh</surname><given-names>H.M.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Yuzawa</surname><given-names>H.</given-names></name>
<name><surname>Takeuchi</surname><given-names>F.</given-names></name>
<name><surname>Matsuo</surname><given-names>M.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Mutated response regulator graR is responsible for phenotypic conversion of <italic toggle="yes">Staphylococcus aureus</italic> from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance</article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1128/AAC.00534-07</pub-id><pub-id pub-id-type="pmid">17954695</pub-id></element-citation></ref><ref id="B112-antibiotics-11-01378"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howden</surname><given-names>B.P.</given-names></name>
<name><surname>Stinear</surname><given-names>T.P.</given-names></name>
<name><surname>Allen</surname><given-names>D.L.</given-names></name>
<name><surname>Johnson</surname><given-names>P.D.R.</given-names></name>
<name><surname>Ward</surname><given-names>P.B.</given-names></name>
<name><surname>Davies</surname><given-names>J.K.</given-names></name>
</person-group><article-title>Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>3755</fpage><lpage>3762</lpage><pub-id pub-id-type="doi">10.1128/AAC.01613-07</pub-id><pub-id pub-id-type="pmid">18644967</pub-id></element-citation></ref><ref id="B113-antibiotics-11-01378"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shoji</surname><given-names>M.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Iizuka</surname><given-names>R.</given-names></name>
<name><surname>Komoto</surname><given-names>A.</given-names></name>
<name><surname>Neoh</surname><given-names>H.M.</given-names></name>
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Hishinuma</surname><given-names>T.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>walK and clpP mutations confer reduced vancomycin susceptibility in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>3870</fpage><lpage>3881</lpage><pub-id pub-id-type="doi">10.1128/AAC.01563-10</pub-id><pub-id pub-id-type="pmid">21628539</pub-id></element-citation></ref><ref id="B114-antibiotics-11-01378"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ito</surname><given-names>T.</given-names></name>
<name><surname>Okuma</surname><given-names>K.</given-names></name>
<name><surname>Ma</surname><given-names>X.X.</given-names></name>
<name><surname>Yuzawa</surname><given-names>H.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Insights on antibiotic resistance of <italic toggle="yes">Staphylococcus aureus</italic> from its whole genome: Genomic island SCC</article-title><source>Drug Resist. Update</source><year>2003</year><volume>6</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S1368-7646(03)00003-7</pub-id></element-citation></ref><ref id="B115-antibiotics-11-01378"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glupczynski</surname><given-names>Y.</given-names></name>
<name><surname>Lagast</surname><given-names>H.</given-names></name>
<name><surname>Van der Auwera</surname><given-names>P.</given-names></name>
<name><surname>Thys</surname><given-names>J.P.</given-names></name>
<name><surname>Crokaert</surname><given-names>F.</given-names></name>
<name><surname>Yourassowsky</surname><given-names>E.</given-names></name>
<name><surname>Meunier-Carpentier</surname><given-names>F.</given-names></name>
<name><surname>Klastersky</surname><given-names>J.</given-names></name>
<name><surname>Kains</surname><given-names>J.P.</given-names></name>
<name><surname>Serruys-Schoutens</surname><given-names>E.</given-names></name>
</person-group><article-title>Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria</article-title><source>Antimicrob. Agents Chemother.</source><year>1986</year><volume>29</volume><fpage>52</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1128/AAC.29.1.52</pub-id><pub-id pub-id-type="pmid">2942100</pub-id></element-citation></ref><ref id="B116-antibiotics-11-01378"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manuel</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Detection of teicoplanin resistance in UK EMRSA-17 strains</article-title><source>J. Antimicrob. Chemother.</source><year>2002</year><volume>50</volume><fpage>1089</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1093/jac/dkf213</pub-id><?supplied-pmid 12461040?><pub-id pub-id-type="pmid">12461040</pub-id></element-citation></ref><ref id="B117-antibiotics-11-01378"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bakthavatchalam</surname><given-names>Y.D.</given-names></name>
<name><surname>Babu</surname><given-names>P.</given-names></name>
<name><surname>Munusamy</surname><given-names>E.</given-names></name>
<name><surname>Dwarakanathan</surname><given-names>H.T.</given-names></name>
<name><surname>Rupali</surname><given-names>P.</given-names></name>
<name><surname>Zervos</surname><given-names>M.</given-names></name>
<name><surname>Victor</surname><given-names>P.J.</given-names></name>
<name><surname>Veeraraghavan</surname><given-names>B.</given-names></name>
</person-group><article-title>Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>: A first report from South India</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0227009</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0227009</pub-id><?supplied-pmid 31887179?><pub-id pub-id-type="pmid">31887179</pub-id></element-citation></ref><ref id="B118-antibiotics-11-01378"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brandenberger</surname><given-names>M.</given-names></name>
<name><surname>Tschierske</surname><given-names>M.</given-names></name>
<name><surname>Giachino</surname><given-names>P.</given-names></name>
<name><surname>Wada</surname><given-names>A.</given-names></name>
<name><surname>Berger-B&#x000e4;chi</surname><given-names>B.</given-names></name>
</person-group><article-title>Inactivation of a novel three-cistronic operon tcaR-tcaA-tcaB increases teicoplanin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Biochim. Biophys. Acta Gen. Subj.</source><year>2000</year><volume>1523</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/S0304-4165(00)00133-1</pub-id></element-citation></ref><ref id="B119-antibiotics-11-01378"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maki</surname><given-names>H.</given-names></name>
<name><surname>McCallum</surname><given-names>N.</given-names></name>
<name><surname>Bischoff</surname><given-names>M.</given-names></name>
<name><surname>Wada</surname><given-names>A.</given-names></name>
<name><surname>Berger-B&#x000e4;chi</surname><given-names>B.</given-names></name>
</person-group><article-title>tcaA inactivation increases glycopeptide resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>1953</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.6.1953-1959.2004</pub-id><pub-id pub-id-type="pmid">15155184</pub-id></element-citation></ref><ref id="B120-antibiotics-11-01378"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moellering</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Linezolid: The first oxazolidinone antimicrobial</article-title><source>Ann. Intern. Med.</source><year>2003</year><volume>138</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-138-2-200301210-00015</pub-id><?supplied-pmid 12529096?><pub-id pub-id-type="pmid">12529096</pub-id></element-citation></ref><ref id="B121-antibiotics-11-01378"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsiodras</surname><given-names>S.</given-names></name>
<name><surname>Gold</surname><given-names>H.S.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
<name><surname>Wennersten</surname><given-names>C.</given-names></name>
<name><surname>Venkataraman</surname><given-names>L.</given-names></name>
<name><surname>Moellering</surname><given-names>R.C.</given-names></name>
<name><surname>Ferraro</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Linezolid resistance in a clinical isolate of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>207</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)05410-1</pub-id><pub-id pub-id-type="pmid">11476839</pub-id></element-citation></ref><ref id="B122-antibiotics-11-01378"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swaney</surname><given-names>S.M.</given-names></name>
<name><surname>Aoki</surname><given-names>H.</given-names></name>
<name><surname>Ganoza</surname><given-names>M.C.</given-names></name>
<name><surname>Shinabarger</surname><given-names>D.L.</given-names></name>
</person-group><article-title>The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria</article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>3251</fpage><lpage>3255</lpage><pub-id pub-id-type="doi">10.1128/AAC.42.12.3251</pub-id><pub-id pub-id-type="pmid">9835522</pub-id></element-citation></ref><ref id="B123-antibiotics-11-01378"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arias</surname><given-names>C.A.</given-names></name>
<name><surname>Vallejo</surname><given-names>M.</given-names></name>
<name><surname>Reyes</surname><given-names>J.</given-names></name>
<name><surname>Panesso</surname><given-names>D.</given-names></name>
<name><surname>Moreno</surname><given-names>J.</given-names></name>
<name><surname>Casta&#x000f1;eda</surname><given-names>E.</given-names></name>
<name><surname>Villegas</surname><given-names>M.V.</given-names></name>
<name><surname>Murray</surname><given-names>B.E.</given-names></name>
<name><surname>Quinn</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase</article-title><source>J. Clin. Microbiol.</source><year>2008</year><volume>46</volume><fpage>892</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1128/JCM.01886-07</pub-id><pub-id pub-id-type="pmid">18174304</pub-id></element-citation></ref><ref id="B124-antibiotics-11-01378"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Endimiani</surname><given-names>A.</given-names></name>
<name><surname>Blackford</surname><given-names>M.</given-names></name>
<name><surname>Dasenbrook</surname><given-names>E.C.</given-names></name>
<name><surname>Reed</surname><given-names>M.D.</given-names></name>
<name><surname>Bajaksouszian</surname><given-names>S.</given-names></name>
<name><surname>Hujer</surname><given-names>A.M.</given-names></name>
<name><surname>Rudin</surname><given-names>S.D.</given-names></name>
<name><surname>Hujer</surname><given-names>K.M.</given-names></name>
<name><surname>Perreten</surname><given-names>V.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
<etal/>
</person-group><article-title>Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>1684</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1128/AAC.01308-10</pub-id><pub-id pub-id-type="pmid">21263048</pub-id></element-citation></ref><ref id="B125-antibiotics-11-01378"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iguchi</surname><given-names>S.</given-names></name>
<name><surname>Mizutani</surname><given-names>T.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
<name><surname>Kikuchi</surname><given-names>K.</given-names></name>
</person-group><article-title>Rapid Acquisition of Linezolid Resistance in Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic>: Role of Hypermutation and Homologous Recombination</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0155512</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0155512</pub-id><?supplied-pmid 27182700?><pub-id pub-id-type="pmid">27182700</pub-id></element-citation></ref><ref id="B126-antibiotics-11-01378"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toh</surname><given-names>S.-M.</given-names></name>
<name><surname>Xiong</surname><given-names>L.</given-names></name>
<name><surname>Arias</surname><given-names>C.A.</given-names></name>
<name><surname>Villegas</surname><given-names>M.V.</given-names></name>
<name><surname>Lolans</surname><given-names>K.</given-names></name>
<name><surname>Quinn</surname><given-names>J.</given-names></name>
<name><surname>Mankin</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> resistant to the synthetic antibiotic linezolid</article-title><source>Mol. Microbiol.</source><year>2007</year><volume>64</volume><fpage>1506</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05744.x</pub-id><?supplied-pmid 17555436?><pub-id pub-id-type="pmid">17555436</pub-id></element-citation></ref><ref id="B127-antibiotics-11-01378"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meka</surname><given-names>V.G.</given-names></name>
<name><surname>Pillai</surname><given-names>S.K.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Wennersten</surname><given-names>C.</given-names></name>
<name><surname>Venkataraman</surname><given-names>L.</given-names></name>
<name><surname>DeGirolami</surname><given-names>P.C.</given-names></name>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
<name><surname>Moellering</surname><given-names>R.C.</given-names><suffix>Jr.</suffix></name>
<name><surname>Gold</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Linezolid Resistance in Sequential <italic toggle="yes">Staphylococcus aureus</italic> Isolates Associated with a T2500A Mutation in the 23S rRNA Gene and Loss of a Single Copy of rRNA</article-title><source>J. Infect. Dis.</source><year>2004</year><volume>190</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1086/421471</pub-id><pub-id pub-id-type="pmid">15216466</pub-id></element-citation></ref><ref id="B128-antibiotics-11-01378"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Locke</surname><given-names>J.B.</given-names></name>
<name><surname>Hilgers</surname><given-names>M.</given-names></name>
<name><surname>Shaw</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Novel ribosomal mutations in <italic toggle="yes">Staphylococcus aureus</italic> strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700)</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>5265</fpage><lpage>5274</lpage><pub-id pub-id-type="doi">10.1128/AAC.00871-09</pub-id><pub-id pub-id-type="pmid">19752277</pub-id></element-citation></ref><ref id="B129-antibiotics-11-01378"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhanel</surname><given-names>G.G.</given-names></name>
<name><surname>Love</surname><given-names>R.</given-names></name>
<name><surname>Adam</surname><given-names>H.</given-names></name>
<name><surname>Golden</surname><given-names>A.</given-names></name>
<name><surname>Zelenitsky</surname><given-names>S.</given-names></name>
<name><surname>Schweizer</surname><given-names>F.</given-names></name>
<name><surname>Gorityala</surname><given-names>B.</given-names></name>
<name><surname>Lagac&#x000e9;-Wiens</surname><given-names>P.R.S.</given-names></name>
<name><surname>Rubinstein</surname><given-names>E.</given-names></name>
<name><surname>Walkty</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens</article-title><source>Drugs</source><year>2015</year><volume>75</volume><fpage>253</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0352-7</pub-id><?supplied-pmid 25673021?><pub-id pub-id-type="pmid">25673021</pub-id></element-citation></ref><ref id="B130-antibiotics-11-01378"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kisgen</surname><given-names>J.J.</given-names></name>
<name><surname>Mansour</surname><given-names>H.</given-names></name>
<name><surname>Unger</surname><given-names>N.R.</given-names></name>
<name><surname>Childs</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Tedizolid: A new oxazolidinone antimicrobial</article-title><source>Am. J. Heal. Pharm.</source><year>2014</year><volume>71</volume><fpage>621</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.2146/ajhp130482</pub-id><?supplied-pmid 24688035?><pub-id pub-id-type="pmid">24688035</pub-id></element-citation></ref><ref id="B131-antibiotics-11-01378"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>T.</given-names></name>
<name><surname>Penewit</surname><given-names>K.</given-names></name>
<name><surname>Waalkes</surname><given-names>A.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Salipante</surname><given-names>S.J.</given-names></name>
<name><surname>Nath</surname><given-names>A.</given-names></name>
<name><surname>Werth</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>292</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa422</pub-id><?supplied-pmid 33057715?><pub-id pub-id-type="pmid">33057715</pub-id></element-citation></ref><ref id="B132-antibiotics-11-01378"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freitas</surname><given-names>A.R.</given-names></name>
<name><surname>Dilek</surname><given-names>A.R.</given-names></name>
<name><surname>Peixe</surname><given-names>L.</given-names></name>
<name><surname>Novais</surname><given-names>C.</given-names></name>
</person-group><article-title>Dissemination of Staphylococcus epidermidis ST22 With Stable, High-Level Resistance to Linezolid and Tedizolid in the Greek-Turkish Region (2008&#x02013;2016)</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2018</year><volume>39</volume><fpage>492</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1017/ice.2018.5</pub-id><?supplied-pmid 29427999?><pub-id pub-id-type="pmid">29427999</pub-id></element-citation></ref><ref id="B133-antibiotics-11-01378"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoy</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Contezolid: First Approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>1587</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01576-0</pub-id><pub-id pub-id-type="pmid">34365606</pub-id></element-citation></ref><ref id="B134-antibiotics-11-01378"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Cai</surname><given-names>C.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Shi</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>N.</given-names></name>
<name><surname>Zheng</surname><given-names>S.</given-names></name>
<name><surname>Qian</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
</person-group><article-title>In vitro Activity of Contezolid Against Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic>, Vancomycin-Resistant <italic toggle="yes">Enterococcus</italic>, and Strains With Linezolid Resistance Genes From China</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><fpage>2408</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.729900</pub-id><?supplied-pmid 34489919?><pub-id pub-id-type="pmid">34489919</pub-id></element-citation></ref><ref id="B135-antibiotics-11-01378"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mangili</surname><given-names>A.</given-names></name>
<name><surname>Bica</surname><given-names>I.</given-names></name>
<name><surname>Snydman</surname><given-names>D.R.</given-names></name>
<name><surname>Hamer</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Daptomycin-Resistant, Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Bacteremia</article-title><source>Clin. Infect. Dis.</source><year>2005</year><volume>40</volume><fpage>1058</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1086/428616</pub-id><?supplied-pmid 15825002?><pub-id pub-id-type="pmid">15825002</pub-id></element-citation></ref><ref id="B136-antibiotics-11-01378"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
<name><surname>Schneider</surname><given-names>T.</given-names></name>
<name><surname>Sahl</surname><given-names>H.G.</given-names></name>
</person-group><article-title>Mechanisms of daptomycin resistance in <italic toggle="yes">Staphylococcus aureus</italic>: Role of the cell membrane and cell wall</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2013</year><volume>1277</volume><fpage>139</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06819.x</pub-id><pub-id pub-id-type="pmid">23215859</pub-id></element-citation></ref><ref id="B137-antibiotics-11-01378"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller</surname><given-names>A.</given-names></name>
<name><surname>Wenzel</surname><given-names>M.</given-names></name>
<name><surname>Strahl</surname><given-names>H.</given-names></name>
<name><surname>Grein</surname><given-names>F.</given-names></name>
<name><surname>Saaki</surname><given-names>T.N.V.</given-names></name>
<name><surname>Kohl</surname><given-names>B.</given-names></name>
<name><surname>Siersma</surname><given-names>T.</given-names></name>
<name><surname>Bandow</surname><given-names>J.E.</given-names></name>
<name><surname>Sahl</surname><given-names>H.G.</given-names></name>
<name><surname>Schneider</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E7077</fpage><lpage>E7086</lpage><pub-id pub-id-type="doi">10.1073/pnas.1611173113</pub-id><pub-id pub-id-type="pmid">27791134</pub-id></element-citation></ref><ref id="B138-antibiotics-11-01378"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pogliano</surname><given-names>J.</given-names></name>
<name><surname>Pogliano</surname><given-names>N.</given-names></name>
<name><surname>Silverman</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins</article-title><source>J. Bacteriol.</source><year>2012</year><volume>194</volume><fpage>4494</fpage><lpage>4504</lpage><pub-id pub-id-type="doi">10.1128/JB.00011-12</pub-id><?supplied-pmid 22661688?><pub-id pub-id-type="pmid">22661688</pub-id></element-citation></ref><ref id="B139-antibiotics-11-01378"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Kreiswirth</surname><given-names>B.N.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Yeaman</surname><given-names>M.R.</given-names></name>
<name><surname>Xiong</surname><given-names>Y.Q.</given-names></name>
<name><surname>Sawa</surname><given-names>A.</given-names></name>
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Enhanced Expression of dltABCD Is Associated with the Development of Daptomycin Nonsusceptibility in a Clinical Endocarditis Isolate of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Infect. Dis.</source><year>2009</year><volume>200</volume><fpage>1916</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1086/648473</pub-id><pub-id pub-id-type="pmid">19919306</pub-id></element-citation></ref><ref id="B140-antibiotics-11-01378"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cafiso</surname><given-names>V.</given-names></name>
<name><surname>Bertuccio</surname><given-names>T.</given-names></name>
<name><surname>Purrello</surname><given-names>S.</given-names></name>
<name><surname>Campanile</surname><given-names>F.</given-names></name>
<name><surname>Mammina</surname><given-names>C.</given-names></name>
<name><surname>Sartor</surname><given-names>A.</given-names></name>
<name><surname>Raglio</surname><given-names>A.</given-names></name>
<name><surname>Stefani</surname><given-names>S.</given-names></name>
</person-group><article-title>dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Int. J. Antimicrob. Agents</source><year>2014</year><volume>43</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.10.001</pub-id><pub-id pub-id-type="pmid">24183798</pub-id></element-citation></ref><ref id="B141-antibiotics-11-01378"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sulaiman</surname><given-names>J.E.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Lam</surname><given-names>H.</given-names></name>
</person-group><article-title>Mutation in the Two-Component System Regulator YycH Leads to Daptomycin Tolerance in Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> upon Evolution with a Population Bottleneck</article-title><source>Microbiol. Spectr.</source><year>2022</year><volume>10</volume><fpage>e01687-22</fpage><pub-id pub-id-type="doi">10.1128/spectrum.01687-22</pub-id></element-citation></ref><ref id="B142-antibiotics-11-01378"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tran</surname><given-names>T.T.</given-names></name>
<name><surname>Munita</surname><given-names>J.M.</given-names></name>
<name><surname>Arias</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Mechanisms of drug resistance: Daptomycin resistance</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2015</year><volume>1354</volume><fpage>32</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1111/nyas.12948</pub-id><?supplied-pmid 26495887?><pub-id pub-id-type="pmid">26495887</pub-id></element-citation></ref><ref id="B143-antibiotics-11-01378"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>S.</given-names></name>
<name><surname>Cuirolo</surname><given-names>A.X.</given-names></name>
<name><surname>Plata</surname><given-names>K.B.</given-names></name>
<name><surname>Riosa</surname><given-names>S.</given-names></name>
<name><surname>Silverman</surname><given-names>J.A.</given-names></name>
<name><surname>Rubio</surname><given-names>A.</given-names></name>
<name><surname>Rosato</surname><given-names>R.R.</given-names></name>
<name><surname>Rosato</surname><given-names>A.E.</given-names></name>
</person-group><article-title>VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1128/AAC.00432-10</pub-id><pub-id pub-id-type="pmid">21986832</pub-id></element-citation></ref><ref id="B144-antibiotics-11-01378"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>W.R.</given-names></name>
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
<name><surname>Arias</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Mechanism of Action and Resistance to Daptomycin in <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Enterococci</italic></article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a026997</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a026997</pub-id><?supplied-pmid 27580748?><pub-id pub-id-type="pmid">27580748</pub-id></element-citation></ref><ref id="B145-antibiotics-11-01378"><label>145.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CLSI</collab>
</person-group><source>Performance Standards for Antimicrobial Susceptibility Testing</source><edition>28th ed.</edition><comment>CLSI supplement M100</comment><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2018</year><isbn>1-56238-838-X</isbn></element-citation></ref><ref id="B146-antibiotics-11-01378"><label>146.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CLSI</collab>
</person-group><source>Performance Standards for Antimicrobial Susceptibility Testing</source><edition>31st ed.</edition><comment>CLSI supplement M100</comment><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2021</year></element-citation></ref><ref id="B147-antibiotics-11-01378"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leadbetter</surname><given-names>M.R.</given-names></name>
<name><surname>Adams</surname><given-names>S.M.</given-names></name>
<name><surname>Bazzini</surname><given-names>B.</given-names></name>
<name><surname>Fatheree</surname><given-names>P.R.</given-names></name>
<name><surname>Karr</surname><given-names>D.E.</given-names></name>
<name><surname>Krause</surname><given-names>K.M.</given-names></name>
<name><surname>Lam</surname><given-names>B.M.T.</given-names></name>
<name><surname>Linsell</surname><given-names>M.S.</given-names></name>
<name><surname>Nodwell</surname><given-names>M.B.</given-names></name>
<name><surname>Pace</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Hydrophobic Vancomycin Derivatives with Improved ADME Properties: Discovery of Telavancin (TD-6424)</article-title><source>J. Antibiot.</source><year>2004</year><volume>57</volume><fpage>326</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.57.326</pub-id><?supplied-pmid 15303493?><pub-id pub-id-type="pmid">15303493</pub-id></element-citation></ref><ref id="B148-antibiotics-11-01378"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hindy</surname><given-names>J.</given-names></name>
<name><surname>Haddad</surname><given-names>S.F.</given-names></name>
<name><surname>Kanj</surname><given-names>S.S.</given-names></name>
</person-group><article-title>New drugs for methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> skin and soft tissue infections</article-title><source>Curr. Opin. Infect. Dis.</source><year>2021</year><volume>35</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000800</pub-id><?supplied-pmid 34812745?><pub-id pub-id-type="pmid">34812745</pub-id></element-citation></ref><ref id="B149-antibiotics-11-01378"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaftari</surname><given-names>A.M.</given-names></name>
<name><surname>Hachem</surname><given-names>R.</given-names></name>
<name><surname>Jordan</surname><given-names>M.</given-names></name>
<name><surname>Garoge</surname><given-names>K.</given-names></name>
<name><surname>Al Hamal</surname><given-names>Z.</given-names></name>
<name><surname>El Zakhem</surname><given-names>A.</given-names></name>
<name><surname>Viola</surname><given-names>G.M.</given-names></name>
<name><surname>Granwehr</surname><given-names>B.</given-names></name>
<name><surname>Mulanovich</surname><given-names>V.</given-names></name>
<name><surname>Gagel</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Case-control study of telavancin as an alternative treatment for gram-positive bloodstream infections in patients with cancer</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1128/AAC.00617-15</pub-id><?supplied-pmid 26482312?><pub-id pub-id-type="pmid">26482312</pub-id></element-citation></ref><ref id="B150-antibiotics-11-01378"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bassetti</surname><given-names>M.</given-names></name>
<name><surname>Mikulska</surname><given-names>M.</given-names></name>
<name><surname>Righi</surname><given-names>E.</given-names></name>
<name><surname>Nicolini</surname><given-names>L.</given-names></name>
<name><surname>Viscoli</surname><given-names>C.</given-names></name>
</person-group><article-title>The role of telavancin in the treatment of MRSA infections in hospital</article-title><source>Expert Opin. Investig. Drugs</source><year>2009</year><volume>18</volume><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1517/13543780902845630</pub-id></element-citation></ref><ref id="B151-antibiotics-11-01378"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karlowsky</surname><given-names>J.A.</given-names></name>
<name><surname>Nichol</surname><given-names>K.</given-names></name>
<name><surname>Zhanel</surname><given-names>G.G.</given-names></name>
</person-group><article-title>Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>61</volume><fpage>S58</fpage><lpage>S68</lpage><pub-id pub-id-type="doi">10.1093/cid/civ534</pub-id><?supplied-pmid 26316559?><pub-id pub-id-type="pmid">26316559</pub-id></element-citation></ref><ref id="B152-antibiotics-11-01378"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duggar</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Aureomycin: A product of the continuing search for new antibiotics</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1948</year><volume>51</volume><fpage>177</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1948.tb27262.x</pub-id><?supplied-pmid 18112227?><pub-id pub-id-type="pmid">18112227</pub-id></element-citation></ref><ref id="B153-antibiotics-11-01378"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gale</surname><given-names>E.F.</given-names></name>
<name><surname>Folkes</surname><given-names>J.P.</given-names></name>
</person-group><article-title>The assimilation of amino-acids by bacteria. 15. Actions of antibiotics on nucleic acid and protein synthesis in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Biochem. J.</source><year>1953</year><volume>53</volume><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1042/bj0530493</pub-id><?supplied-pmid 13032100?><pub-id pub-id-type="pmid">13032100</pub-id></element-citation></ref><ref id="B154-antibiotics-11-01378"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Epe</surname><given-names>B.</given-names></name>
<name><surname>Woolley</surname><given-names>P.</given-names></name>
</person-group><article-title>The binding of 6-demethylchlortetracycline to 70S, 50S and 30S ribosomal particles: A quantitative study by fluorescence anisotropy</article-title><source>EMBO J.</source><year>1984</year><volume>3</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1984.tb01771.x</pub-id><?supplied-pmid 6423382?><pub-id pub-id-type="pmid">6423382</pub-id></element-citation></ref><ref id="B155-antibiotics-11-01378"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
<name><surname>Roberts</surname><given-names>M.C.</given-names></name>
<name><surname>Werckenthin</surname><given-names>C.</given-names></name>
<name><surname>Pang</surname><given-names>Y.</given-names></name>
<name><surname>Lange</surname><given-names>C.</given-names></name>
</person-group><article-title>Tetracycline resistance in <italic toggle="yes">Staphylococcus</italic> spp. from domestic animals</article-title><source>Vet. Microbiol.</source><year>1998</year><volume>63</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/S0378-1135(98)00234-X</pub-id><pub-id pub-id-type="pmid">9851000</pub-id></element-citation></ref><ref id="B156-antibiotics-11-01378"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stephens</surname><given-names>C.R.</given-names></name>
<name><surname>Beereboom</surname><given-names>J.J.</given-names></name>
<name><surname>Rennhard</surname><given-names>H.H.</given-names></name>
<name><surname>Gordon</surname><given-names>P.N.</given-names></name>
<name><surname>Murai</surname><given-names>K.</given-names></name>
<name><surname>Blackwood</surname><given-names>R.K.</given-names></name>
<name><surname>von Wittenau</surname><given-names>M.S.</given-names></name>
</person-group><article-title>6-Deoxytetracyclines. IV. 1,2 Preparation, C-6 Stereochemistry, and Reactions</article-title><source>J. Am. Chem. Soc.</source><year>1963</year><volume>85</volume><fpage>2643</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1021/ja00900a027</pub-id></element-citation></ref><ref id="B157-antibiotics-11-01378"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>M.L.</given-names></name>
<name><surname>Levy</surname><given-names>S.B.</given-names></name>
</person-group><article-title>The history of the tetracyclines</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2011</year><volume>1241</volume><fpage>17</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06354.x</pub-id><?supplied-pmid 22191524?><pub-id pub-id-type="pmid">22191524</pub-id></element-citation></ref><ref id="B158-antibiotics-11-01378"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>B.S.</given-names></name>
<name><surname>Graber</surname><given-names>C.J.</given-names></name>
<name><surname>Diep</surname><given-names>B.A.</given-names></name>
<name><surname>Basuino</surname><given-names>L.</given-names></name>
<name><surname>Perdreau-Remington</surname><given-names>F.</given-names></name>
<name><surname>Chambers</surname><given-names>H.F.</given-names></name>
</person-group><article-title>doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> clone usa300</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>48</volume><fpage>1483</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1086/598510</pub-id><pub-id pub-id-type="pmid">19374563</pub-id></element-citation></ref><ref id="B159-antibiotics-11-01378"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trzcinski</surname><given-names>K.</given-names></name>
<name><surname>Cooper</surname><given-names>B.S.</given-names></name>
<name><surname>Hryniewicz</surname><given-names>W.</given-names></name>
<name><surname>Dowson</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Expression of resistance to tetracyclines in strains of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2000</year><volume>45</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1093/jac/45.6.763</pub-id><?supplied-pmid 10837427?><pub-id pub-id-type="pmid">10837427</pub-id></element-citation></ref><ref id="B160-antibiotics-11-01378"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaudaux</surname><given-names>P.</given-names></name>
<name><surname>Fleury</surname><given-names>B.</given-names></name>
<name><surname>Gjinovci</surname><given-names>A.</given-names></name>
<name><surname>Huggler</surname><given-names>E.</given-names></name>
<name><surname>Tangomo-Bento</surname><given-names>M.</given-names></name>
<name><surname>Lew</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>3150</fpage><lpage>3152</lpage><pub-id pub-id-type="doi">10.1128/AAC.01612-08</pub-id><pub-id pub-id-type="pmid">19364855</pub-id></element-citation></ref><ref id="B161-antibiotics-11-01378"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Draghi</surname><given-names>D.C.</given-names></name>
<name><surname>Tench</surname><given-names>S.</given-names></name>
<name><surname>Dowzicky</surname><given-names>M.J.</given-names></name>
<name><surname>Sahm</surname><given-names>D.F.</given-names></name>
</person-group><article-title>Baseline in vitro Activity of Tigecycline among Key Bacterial Pathogens Exhibiting Multidrug Resistance</article-title><source>Chemotherapy</source><year>2008</year><volume>54</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1159/000118660</pub-id><?supplied-pmid 18303257?><pub-id pub-id-type="pmid">18303257</pub-id></element-citation></ref><ref id="B162-antibiotics-11-01378"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>F.</given-names></name>
<name><surname>Starosta</surname><given-names>A.L.</given-names></name>
<name><surname>Arenz</surname><given-names>S.</given-names></name>
<name><surname>Sohmen</surname><given-names>D.</given-names></name>
<name><surname>D&#x000f6;nh&#x000f6;fer</surname><given-names>A.</given-names></name>
<name><surname>Wilson</surname><given-names>D.N.</given-names></name>
</person-group><article-title>Tetracycline antibiotics and resistance mechanisms</article-title><source>Biol. Chem.</source><year>2014</year><volume>395</volume><fpage>559</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1515/hsz-2013-0292</pub-id><pub-id pub-id-type="pmid">24497223</pub-id></element-citation></ref><ref id="B163-antibiotics-11-01378"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Honeyman</surname><given-names>L.</given-names></name>
<name><surname>Ismail</surname><given-names>M.</given-names></name>
<name><surname>Nelson</surname><given-names>M.L.</given-names></name>
<name><surname>Bhatia</surname><given-names>B.</given-names></name>
<name><surname>Bowser</surname><given-names>T.E.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Mechiche</surname><given-names>R.</given-names></name>
<name><surname>Ohemeng</surname><given-names>K.</given-names></name>
<name><surname>Verma</surname><given-names>A.K.</given-names></name>
<name><surname>Cannon</surname><given-names>E.P.</given-names></name>
<etal/>
</person-group><article-title>Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>7044</fpage><lpage>7053</lpage><pub-id pub-id-type="doi">10.1128/AAC.01536-15</pub-id><pub-id pub-id-type="pmid">26349824</pub-id></element-citation></ref><ref id="B164-antibiotics-11-01378"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Riordan</surname><given-names>W.</given-names></name>
<name><surname>Green</surname><given-names>S.</given-names></name>
<name><surname>Overcash</surname><given-names>J.S.</given-names></name>
<name><surname>Puljiz</surname><given-names>I.</given-names></name>
<name><surname>Metallidis</surname><given-names>S.</given-names></name>
<name><surname>Gardovskis</surname><given-names>J.</given-names></name>
<name><surname>Garrity-Ryan</surname><given-names>L.</given-names></name>
<name><surname>Das</surname><given-names>A.F.</given-names></name>
<name><surname>Tzanis</surname><given-names>E.</given-names></name>
<name><surname>Eckburg</surname><given-names>P.B.</given-names></name>
<etal/>
</person-group><article-title>Omadacycline for Acute Bacterial Skin and Skin-Structure Infections</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>528</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1800170</pub-id><pub-id pub-id-type="pmid">30726689</pub-id></element-citation></ref><ref id="B165-antibiotics-11-01378"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>S.K.</given-names></name>
<name><surname>Steenbergen</surname><given-names>J.</given-names></name>
<name><surname>Villano</surname><given-names>S.</given-names></name>
</person-group><article-title>Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic</article-title><source>Bioorg. Med. Chem.</source><year>2016</year><volume>24</volume><fpage>6409</fpage><lpage>6419</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.07.029</pub-id><pub-id pub-id-type="pmid">27469981</pub-id></element-citation></ref><ref id="B166-antibiotics-11-01378"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Draper</surname><given-names>M.P.</given-names></name>
<name><surname>Weir</surname><given-names>S.</given-names></name>
<name><surname>Macone</surname><given-names>A.</given-names></name>
<name><surname>Donatelli</surname><given-names>J.</given-names></name>
<name><surname>Trieber</surname><given-names>C.A.</given-names></name>
<name><surname>Tanaka</surname><given-names>S.K.</given-names></name>
<name><surname>Levya</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Mechanism of action of the novel aminomethylcycline antibiotic omadacycline</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1279</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1128/AAC.01066-13</pub-id><pub-id pub-id-type="pmid">24041885</pub-id></element-citation></ref><ref id="B167-antibiotics-11-01378"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Macone</surname><given-names>A.B.</given-names></name>
<name><surname>Caruso</surname><given-names>B.K.</given-names></name>
<name><surname>Leahy</surname><given-names>R.G.</given-names></name>
<name><surname>Donatelli</surname><given-names>J.</given-names></name>
<name><surname>Weir</surname><given-names>S.</given-names></name>
<name><surname>Draper</surname><given-names>M.P.</given-names></name>
<name><surname>Tanaka</surname><given-names>S.K.</given-names></name>
<name><surname>Levy</surname><given-names>S.B.</given-names></name>
</person-group><article-title>In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1127</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1128/AAC.01242-13</pub-id><pub-id pub-id-type="pmid">24295985</pub-id></element-citation></ref><ref id="B168-antibiotics-11-01378"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bodley</surname><given-names>J.W.</given-names></name>
<name><surname>Zieve</surname><given-names>F.J.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Zieve</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Formation of the ribosome-G factor-GDP complex in the presence of fusidic acid</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1969</year><volume>37</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(69)90934-6</pub-id><pub-id pub-id-type="pmid">4900137</pub-id></element-citation></ref><ref id="B169-antibiotics-11-01378"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>N.</given-names></name>
<name><surname>Kinoshita</surname><given-names>T.</given-names></name>
<name><surname>Masukawa</surname><given-names>H.</given-names></name>
</person-group><article-title>Mechanism of protein synthesis inhibition by fusidic acid and related antibiotics</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1968</year><volume>30</volume><fpage>278</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(68)90447-6</pub-id><pub-id pub-id-type="pmid">4296678</pub-id></element-citation></ref><ref id="B170-antibiotics-11-01378"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nagaev</surname><given-names>I.</given-names></name>
<name><surname>Bjorkman</surname><given-names>J.</given-names></name>
<name><surname>Andersson</surname><given-names>D.I.</given-names></name>
<name><surname>Hughes</surname><given-names>D.</given-names></name>
</person-group><article-title>Biological cost and compensatory evolution in fusidic acid-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Mol. Microbiol.</source><year>2001</year><volume>40</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2001.02389.x</pub-id><pub-id pub-id-type="pmid">11309125</pub-id></element-citation></ref><ref id="B171-antibiotics-11-01378"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Neill</surname><given-names>A.J.</given-names></name>
<name><surname>Larsen</surname><given-names>A.R.</given-names></name>
<name><surname>Henriksen</surname><given-names>A.S.</given-names></name>
<name><surname>Chopra</surname><given-names>I.</given-names></name>
</person-group><article-title>A fusidic acid-resistant epidemic strain of <italic toggle="yes">Staphylococcus aureus</italic> carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>3594</fpage><lpage>3597</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.9.3594-3597.2004</pub-id><pub-id pub-id-type="pmid">15328136</pub-id></element-citation></ref><ref id="B172-antibiotics-11-01378"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Brien</surname><given-names>F.G.</given-names></name>
</person-group><article-title>Genetic characterization of the fusidic acid and cadmium resistance determinants of <italic toggle="yes">Staphylococcus aureus</italic> plasmid pUB101</article-title><source>J. Antimicrob. Chemother.</source><year>2002</year><volume>50</volume><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1093/jac/dkf153</pub-id><pub-id pub-id-type="pmid">12205055</pub-id></element-citation></ref><ref id="B173-antibiotics-11-01378"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Neill</surname><given-names>A.J.</given-names></name>
<name><surname>McLaws</surname><given-names>F.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Henriksen</surname><given-names>A.S.</given-names></name>
<name><surname>Chopra</surname><given-names>I.</given-names></name>
</person-group><article-title>Genetic basis of resistance to fusidic acid in <italic toggle="yes">Staphylococci</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>1737</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1128/AAC.01542-06</pub-id><pub-id pub-id-type="pmid">17325218</pub-id></element-citation></ref><ref id="B174-antibiotics-11-01378"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanus</surname><given-names>T.</given-names></name>
<name><surname>Scangarella-Oman</surname><given-names>N.E.</given-names></name>
<name><surname>Dalessandro</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Breton</surname><given-names>J.J.</given-names></name>
<name><surname>Tomayko</surname><given-names>J.F.</given-names></name>
</person-group><article-title>A Randomized, Double-blind, Comparative Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment 1% Versus Oral Linezolid in the Treatment of Secondarily Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant <italic toggle="yes">Staphylococcus</italic> au</article-title><source>Adv. Skin Wound Care</source><year>2014</year><volume>27</volume><fpage>548</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1097/01.ASW.0000456631.20389.ae</pub-id><pub-id pub-id-type="pmid">25396674</pub-id></element-citation></ref><ref id="B175-antibiotics-11-01378"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Mechanisms of fluoroquinolone resistance</article-title><source>Drug Resist. Updates</source><year>1999</year><volume>2</volume><fpage>38</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1054/drup.1998.0068</pub-id></element-citation></ref><ref id="B176-antibiotics-11-01378"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>LeBel</surname><given-names>M.</given-names></name>
</person-group><article-title>Ciprofloxacin: Chemistry, Mechanism of Action, Resistance, Antimicrobial Spectrum, Pharmacokinetics, Clinical Trials, and Adverse Reactions</article-title><source>Pharmacother. J. Hum. Pharmacol. Drug Ther.</source><year>1988</year><volume>8</volume><fpage>3</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.1988.tb04058.x</pub-id></element-citation></ref><ref id="B177-antibiotics-11-01378"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Mode of Action of Fluoroquinolones</article-title><source>Drugs</source><year>1999</year><volume>58</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2165/00003495-199958002-00002</pub-id><pub-id pub-id-type="pmid">10553698</pub-id></element-citation></ref><ref id="B178-antibiotics-11-01378"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drlica</surname><given-names>K.</given-names></name>
</person-group><article-title>Mechanism of fluoroquinolone action</article-title><source>Curr. Opin. Microbiol.</source><year>1999</year><volume>2</volume><fpage>504</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/S1369-5274(99)00008-9</pub-id><pub-id pub-id-type="pmid">10508721</pub-id></element-citation></ref><ref id="B179-antibiotics-11-01378"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papkou</surname><given-names>A.</given-names></name>
<name><surname>Hedge</surname><given-names>J.</given-names></name>
<name><surname>Kapel</surname><given-names>N.</given-names></name>
<name><surname>Young</surname><given-names>B.</given-names></name>
<name><surname>MacLean</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Efflux pump activity potentiates the evolution of antibiotic resistance across <italic toggle="yes">S. aureus</italic> isolates</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3970</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17735-y</pub-id><pub-id pub-id-type="pmid">32769975</pub-id></element-citation></ref><ref id="B180-antibiotics-11-01378"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aeschlimann</surname><given-names>J.R.</given-names></name>
<name><surname>Dresser</surname><given-names>L.D.</given-names></name>
<name><surname>Kaatz</surname><given-names>G.W.</given-names></name>
<name><surname>Rybak</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1999</year><volume>43</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1128/AAC.43.2.335</pub-id><pub-id pub-id-type="pmid">9925528</pub-id></element-citation></ref><ref id="B181-antibiotics-11-01378"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitz</surname><given-names>F.</given-names></name>
</person-group><article-title>Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Antimicrob. Chemother.</source><year>1998</year><volume>41</volume><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1093/jac/41.4.481</pub-id><pub-id pub-id-type="pmid">9598779</pub-id></element-citation></ref><ref id="B182-antibiotics-11-01378"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nilius</surname><given-names>A.M.</given-names></name>
<name><surname>Shen</surname><given-names>L.L.</given-names></name>
<name><surname>Hensey-Rudloff</surname><given-names>D.</given-names></name>
<name><surname>Almer</surname><given-names>L.S.</given-names></name>
<name><surname>Beyer</surname><given-names>J.M.</given-names></name>
<name><surname>Balli</surname><given-names>D.J.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Flamm</surname><given-names>R.K.</given-names></name>
</person-group><article-title>In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone</article-title><source>Antimicrob. Agents Chemother.</source><year>2003</year><volume>47</volume><fpage>3260</fpage><lpage>3269</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.10.3260-3269.2003</pub-id><pub-id pub-id-type="pmid">14506039</pub-id></element-citation></ref><ref id="B183-antibiotics-11-01378"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saravolatz</surname><given-names>L.D.</given-names></name>
<name><surname>Stein</surname><given-names>G.E.</given-names></name>
</person-group><article-title>Delafloxacin: A New Anti&#x02013;methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> Fluoroquinolone</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>68</volume><fpage>1058</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy600</pub-id><pub-id pub-id-type="pmid">30060092</pub-id></element-citation></ref><ref id="B184-antibiotics-11-01378"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iregui</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>Z.</given-names></name>
<name><surname>Malik</surname><given-names>S.</given-names></name>
<name><surname>Landman</surname><given-names>D.</given-names></name>
<name><surname>Quale</surname><given-names>J.</given-names></name>
</person-group><article-title>Emergence of Delafloxacin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> in Brooklyn, New York</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>70</volume><fpage>1758</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz787</pub-id><pub-id pub-id-type="pmid">31412357</pub-id></element-citation></ref><ref id="B185-antibiotics-11-01378"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Remy</surname><given-names>J.M.</given-names></name>
<name><surname>Tow-Keogh</surname><given-names>C.A.</given-names></name>
<name><surname>McConnell</surname><given-names>T.S.</given-names></name>
<name><surname>Dalton</surname><given-names>J.M.</given-names></name>
<name><surname>DeVito</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Activity of delafloxacin against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>: Resistance selection and characterization</article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>2814</fpage><lpage>2820</lpage><pub-id pub-id-type="doi">10.1093/jac/dks307</pub-id><pub-id pub-id-type="pmid">22875850</pub-id></element-citation></ref><ref id="B186-antibiotics-11-01378"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCurdy</surname><given-names>S.</given-names></name>
<name><surname>Lawrence</surname><given-names>L.</given-names></name>
<name><surname>Quintas</surname><given-names>M.</given-names></name>
<name><surname>Woosley</surname><given-names>L.</given-names></name>
<name><surname>Flamm</surname><given-names>R.</given-names></name>
<name><surname>Tseng</surname><given-names>C.</given-names></name>
<name><surname>Cammarata</surname><given-names>S.</given-names></name>
</person-group><article-title>In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible <italic toggle="yes">Staphylococcus aureus</italic> isolates from two phase 3 studies of acute bacterial skin and skin structure infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>2017</fpage><pub-id pub-id-type="doi">10.1128/AAC.00772-17</pub-id></element-citation></ref><ref id="B187-antibiotics-11-01378"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurokawa</surname><given-names>I.</given-names></name>
<name><surname>Kanayama</surname><given-names>S.</given-names></name>
<name><surname>Yamasaki</surname><given-names>O.</given-names></name>
</person-group><article-title>Antimicrobial activity of ozenoxacin and other antimicrobials against <italic toggle="yes">Staphylococcus aureus</italic> strains isolated from clinical skin specimens in Japan in 2019 and 2020</article-title><source>J. Infect. Chemother.</source><year>2022</year><volume>28</volume><fpage>1693</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2022.08.014</pub-id><pub-id pub-id-type="pmid">35988886</pub-id></element-citation></ref><ref id="B188-antibiotics-11-01378"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brogden</surname><given-names>R.N.</given-names></name>
<name><surname>Carmine</surname><given-names>A.A.</given-names></name>
<name><surname>Heel</surname><given-names>R.C.</given-names></name>
<name><surname>Speight</surname><given-names>T.M.</given-names></name>
<name><surname>Avery</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Trimethoprim: A Review of its Antibacterial Activity, Pharmacokinetics and Therapeutic Use in Urinary Tract Infections</article-title><source>Drugs</source><year>1982</year><volume>23</volume><fpage>405</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.2165/00003495-198223060-00001</pub-id><pub-id pub-id-type="pmid">7049657</pub-id></element-citation></ref><ref id="B189-antibiotics-11-01378"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dale</surname><given-names>G.E.</given-names></name>
<name><surname>Broger</surname><given-names>C.</given-names></name>
<name><surname>D&#x02019;Arcy</surname><given-names>A.</given-names></name>
<name><surname>Hartman</surname><given-names>P.G.</given-names></name>
<name><surname>DeHoogt</surname><given-names>R.</given-names></name>
<name><surname>Jolidon</surname><given-names>S.</given-names></name>
<name><surname>Kompis</surname><given-names>I.</given-names></name>
<name><surname>Labhardt</surname><given-names>A.M.</given-names></name>
<name><surname>Langen</surname><given-names>H.</given-names></name>
<name><surname>Locher</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>A single amino acid substitution in <italic toggle="yes">Staphylococcus aureus</italic> dihydrofolate reductase determines trimethoprim resistance 1 1 Edited by T.Richmond</article-title><source>J. Mol. Biol.</source><year>1997</year><volume>266</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0770</pub-id><pub-id pub-id-type="pmid">9054967</pub-id></element-citation></ref><ref id="B190-antibiotics-11-01378"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nurjadi</surname><given-names>D.</given-names></name>
<name><surname>Olalekan</surname><given-names>A.O.</given-names></name>
<name><surname>Layer</surname><given-names>F.</given-names></name>
<name><surname>Shittu</surname><given-names>A.O.</given-names></name>
<name><surname>Alabi</surname><given-names>A.</given-names></name>
<name><surname>Ghebremedhin</surname><given-names>B.</given-names></name>
<name><surname>Schaumburg</surname><given-names>F.</given-names></name>
<name><surname>Hofmann-Eifler</surname><given-names>J.</given-names></name>
<name><surname>Van Genderen</surname><given-names>P.J.J.</given-names></name>
<name><surname>Caumes</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Emergence of trimethoprim resistance gene dfrG in <italic toggle="yes">Staphylococcus aureus</italic> causing human infection and colonization in sub-Saharan Africa and its import to Europe</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>2361</fpage><lpage>2368</lpage><pub-id pub-id-type="doi">10.1093/jac/dku174</pub-id><pub-id pub-id-type="pmid">24855123</pub-id></element-citation></ref><ref id="B191-antibiotics-11-01378"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perreten</surname><given-names>V.</given-names></name>
<name><surname>Kadlec</surname><given-names>K.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
<name><surname>Gronlund Andersson</surname><given-names>U.</given-names></name>
<name><surname>Finn</surname><given-names>M.</given-names></name>
<name><surname>Greko</surname><given-names>C.</given-names></name>
<name><surname>Moodley</surname><given-names>A.</given-names></name>
<name><surname>Kania</surname><given-names>S.A.</given-names></name>
<name><surname>Frank</surname><given-names>L.A.</given-names></name>
<name><surname>Bemis</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>Clonal spread of methicillin-resistant <italic toggle="yes">Staphylococcus pseudintermedius</italic> in Europe and North America: An international multicentre study</article-title><source>J. Antimicrob. Chemother.</source><year>2010</year><volume>65</volume><fpage>1145</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq078</pub-id><pub-id pub-id-type="pmid">20348087</pub-id></element-citation></ref><ref id="B192-antibiotics-11-01378"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nurjadi</surname><given-names>D.</given-names></name>
<name><surname>Sch&#x000e4;fer</surname><given-names>J.</given-names></name>
<name><surname>Friedrich-J&#x000e4;nicke</surname><given-names>B.</given-names></name>
<name><surname>Mueller</surname><given-names>A.</given-names></name>
<name><surname>Neumayr</surname><given-names>A.</given-names></name>
<name><surname>Calvo-Cano</surname><given-names>A.</given-names></name>
<name><surname>Goorhuis</surname><given-names>A.</given-names></name>
<name><surname>Molhoek</surname><given-names>N.</given-names></name>
<name><surname>Lagler</surname><given-names>H.</given-names></name>
<name><surname>Kantele</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Predominance of dfrG as determinant of trimethoprim resistance in imported <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Clin. Microbiol. Infect.</source><year>2015</year><volume>21</volume><fpage>1095.e5</fpage><lpage>1095.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2015.08.021</pub-id></element-citation></ref><ref id="B193-antibiotics-11-01378"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadlec</surname><given-names>K.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
</person-group><article-title>Identification of a novel trimethoprim resistance gene, dfrK, in a methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> ST398 strain and its physical linkage to the tetracycline resistance gene tet (L)</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>776</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1128/AAC.01128-08</pub-id><pub-id pub-id-type="pmid">19015335</pub-id></element-citation></ref><ref id="B194-antibiotics-11-01378"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rouch</surname><given-names>D.A.</given-names></name>
<name><surname>Messerotti</surname><given-names>L.J.</given-names></name>
<name><surname>Loo</surname><given-names>L.S.L.</given-names></name>
<name><surname>Jackson</surname><given-names>C.A.</given-names></name>
<name><surname>Skurray</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Trimethoprim resistance transposon Tn4003 from <italic toggle="yes">Staphylococcus aureus</italic> encodes genes for a dihydrofolate reductase and thymidylate synthetase flanked by three copies of IS257</article-title><source>Mol. Microbiol.</source><year>1989</year><volume>3</volume><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.1989.tb01805.x</pub-id><pub-id pub-id-type="pmid">2548057</pub-id></element-citation></ref><ref id="B195-antibiotics-11-01378"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sekiguchi</surname><given-names>J.I.</given-names></name>
<name><surname>Tharavichitkul</surname><given-names>P.</given-names></name>
<name><surname>Miyoshi-Akiyama</surname><given-names>T.</given-names></name>
<name><surname>Chupia</surname><given-names>V.</given-names></name>
<name><surname>Fujino</surname><given-names>T.</given-names></name>
<name><surname>Araake</surname><given-names>M.</given-names></name>
<name><surname>Irie</surname><given-names>A.</given-names></name>
<name><surname>Morita</surname><given-names>K.</given-names></name>
<name><surname>Kuratsuji</surname><given-names>T.</given-names></name>
<name><surname>Kirikae</surname><given-names>T.</given-names></name>
</person-group><article-title>Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of <italic toggle="yes">Staphylococcus aureus</italic> CM.S2 (IMCJ1454)</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>3948</fpage><lpage>3951</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.9.3948-3951.2005</pub-id><pub-id pub-id-type="pmid">16127079</pub-id></element-citation></ref><ref id="B196-antibiotics-11-01378"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadlec</surname><given-names>K.</given-names></name>
<name><surname>Schwarz</surname><given-names>S.</given-names></name>
</person-group><article-title>Novel ABC Transporter Gene, vga (C), Located on a Multiresistance Plasmid from a Porcine Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> ST398 Strain</article-title><source>Antimicrob. Agents Chemother.</source><year>2009</year><volume>53</volume><fpage>3589</fpage><lpage>3591</lpage><pub-id pub-id-type="doi">10.1128/AAC.00570-09</pub-id><pub-id pub-id-type="pmid">19470508</pub-id></element-citation></ref><ref id="B197-antibiotics-11-01378"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chain</surname><given-names>E.B.</given-names></name>
<name><surname>Mellows</surname><given-names>G.</given-names></name>
</person-group><article-title>Structure of pseudomonic acid, an antibiotic from <italic toggle="yes">Pseudomonas fluorescens</italic></article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1974</year><volume>20</volume><fpage>847</fpage><pub-id pub-id-type="doi">10.1039/c39740000847</pub-id></element-citation></ref><ref id="B198-antibiotics-11-01378"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehtar</surname><given-names>S.</given-names></name>
</person-group><article-title>New strategies for the use of mupirocin for the prevention of serious infection</article-title><source>J. Hosp. Infect.</source><year>1998</year><volume>40</volume><fpage>S39</fpage><lpage>S44</lpage><pub-id pub-id-type="doi">10.1016/S0195-6701(98)90203-1</pub-id><pub-id pub-id-type="pmid">9777532</pub-id></element-citation></ref><ref id="B199-antibiotics-11-01378"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.</given-names></name>
<name><surname>Noble</surname><given-names>W.C.</given-names></name>
<name><surname>Cookson</surname><given-names>B.</given-names></name>
<name><surname>Baird</surname><given-names>D.</given-names></name>
<name><surname>Coia</surname><given-names>J.</given-names></name>
</person-group><article-title>Mupirocin-Resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Lancet</source><year>1987</year><volume>330</volume><fpage>387</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(87)92398-1</pub-id></element-citation></ref><ref id="B200-antibiotics-11-01378"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kavi</surname><given-names>J.</given-names></name>
<name><surname>Andrews</surname><given-names>J.M.</given-names></name>
<name><surname>Wise</surname><given-names>R.</given-names></name>
<name><surname>Smith</surname><given-names>M.D.</given-names></name>
<name><surname>Sanghrajka</surname><given-names>M.</given-names></name>
<name><surname>Lock</surname><given-names>S.</given-names></name>
</person-group><article-title>Mupirocin-Resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Lancet</source><year>1987</year><volume>330</volume><fpage>1472</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(87)91179-2</pub-id></element-citation></ref><ref id="B201-antibiotics-11-01378"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>J.</given-names></name>
<name><surname>Mellows</surname><given-names>G.</given-names></name>
</person-group><article-title>On the mode of action of pseudomonic acid: Inhibition of protein synthesis in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Antibiot.</source><year>1978</year><volume>31</volume><fpage>330</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.31.330</pub-id></element-citation></ref><ref id="B202-antibiotics-11-01378"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurdle</surname><given-names>J.G.</given-names></name>
</person-group><article-title>The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate <italic toggle="yes">Staphylococcus aureus</italic> is not associated with a significant fitness burden</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>53</volume><fpage>102</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh020</pub-id><pub-id pub-id-type="pmid">14657089</pub-id></element-citation></ref><ref id="B203-antibiotics-11-01378"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antonio</surname><given-names>M.</given-names></name>
<name><surname>McFerran</surname><given-names>N.</given-names></name>
<name><surname>Pallen</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2002</year><volume>46</volume><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1128/AAC.46.2.438-442.2002</pub-id><pub-id pub-id-type="pmid">11796355</pub-id></element-citation></ref><ref id="B204-antibiotics-11-01378"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurdle</surname><given-names>J.G.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>A.J.</given-names></name>
<name><surname>Ingham</surname><given-names>E.</given-names></name>
<name><surname>Fishwick</surname><given-names>C.</given-names></name>
<name><surname>Chopra</surname><given-names>I.</given-names></name>
</person-group><article-title>Analysis of mupirocin resistance and fitness in <italic toggle="yes">Staphylococcus aureus</italic> by molecular genetic and structural modeling techniques</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>4366</fpage><lpage>4376</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.11.4366-4376.2004</pub-id><pub-id pub-id-type="pmid">15504866</pub-id></element-citation></ref><ref id="B205-antibiotics-11-01378"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujimura</surname><given-names>S.</given-names></name>
<name><surname>Tokue</surname><given-names>Y.</given-names></name>
<name><surname>Watanabe</surname><given-names>A.</given-names></name>
</person-group><article-title>Isoleucyl-tRNA Synthetase Mutations in <italic toggle="yes">Staphylococcus aureus</italic> Clinical Isolates and In Vitro Selection of Low-Level Mupirocin-Resistant Strains</article-title><source>Antimicrob. Agents Chemother.</source><year>2003</year><volume>47</volume><fpage>3373</fpage><lpage>3374</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.10.3373-3374.2003</pub-id><pub-id pub-id-type="pmid">14506063</pub-id></element-citation></ref><ref id="B206-antibiotics-11-01378"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Udo</surname><given-names>E.E.</given-names></name>
<name><surname>Jacob</surname><given-names>L.E.</given-names></name>
<name><surname>Mathew</surname><given-names>B.</given-names></name>
</person-group><article-title>Genetic analysis of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> expressing high- and low-level mupirocin resistance</article-title><source>J. Med. Microbiol.</source><year>2001</year><volume>50</volume><fpage>909</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-50-10-909</pub-id><pub-id pub-id-type="pmid">11599741</pub-id></element-citation></ref><ref id="B207-antibiotics-11-01378"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seah</surname><given-names>C.</given-names></name>
<name><surname>Alexander</surname><given-names>D.C.</given-names></name>
<name><surname>Louie</surname><given-names>L.</given-names></name>
<name><surname>Simor</surname><given-names>A.</given-names></name>
<name><surname>Low</surname><given-names>D.E.</given-names></name>
<name><surname>Longtin</surname><given-names>J.</given-names></name>
<name><surname>Melano</surname><given-names>R.G.</given-names></name>
</person-group><article-title>MupB, a new high-level mupirocin resistance mechanism in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>1916</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1128/AAC.05325-11</pub-id><pub-id pub-id-type="pmid">22252810</pub-id></element-citation></ref><ref id="B208-antibiotics-11-01378"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hodgson</surname><given-names>J.E.</given-names></name>
<name><surname>Curnock</surname><given-names>S.P.</given-names></name>
<name><surname>Dyke</surname><given-names>K.G.H.</given-names></name>
<name><surname>Morris</surname><given-names>R.</given-names></name>
<name><surname>Sylvester</surname><given-names>D.R.</given-names></name>
<name><surname>Gross</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Molecular characterization of the gene encoding high-level mupirocin resistance in <italic toggle="yes">Staphylococcus aureus</italic> J2870</article-title><source>Antimicrob. Agents Chemother.</source><year>1994</year><volume>38</volume><fpage>1205</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.5.1205</pub-id><?supplied-pmid 8067768?><pub-id pub-id-type="pmid">8067768</pub-id></element-citation></ref><ref id="B209-antibiotics-11-01378"><label>209.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CLSI</collab>
</person-group><source>Performance Standards for Antimicrobial Susceptibility Testing</source><edition>30th ed.</edition><comment>CLSI supplement M100</comment><publisher-name>Clinical and Laboratory Standards Institute</publisher-name><publisher-loc>Wayne, PA, USA</publisher-loc><year>2020</year><isbn>0956-4624</isbn></element-citation></ref><ref id="B210-antibiotics-11-01378"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hendlin</surname><given-names>D.</given-names></name>
<name><surname>Stapley</surname><given-names>E.O.</given-names></name>
<name><surname>Jackson</surname><given-names>M.</given-names></name>
<name><surname>Wallick</surname><given-names>H.</given-names></name>
<name><surname>Miller</surname><given-names>A.K.</given-names></name>
<name><surname>Wolf</surname><given-names>F.J.</given-names></name>
<name><surname>Miller</surname><given-names>T.W.</given-names></name>
<name><surname>Chaiet</surname><given-names>L.</given-names></name>
<name><surname>Kahan</surname><given-names>F.M.</given-names></name>
<name><surname>Foltz</surname><given-names>E.L.</given-names></name>
<etal/>
</person-group><article-title>Phosphonomycin, a new antibiotic produced by strains of <italic toggle="yes">Streptomyces</italic></article-title><source>Science</source><year>1969</year><volume>166</volume><fpage>122</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1126/science.166.3901.122</pub-id><pub-id pub-id-type="pmid">5809587</pub-id></element-citation></ref><ref id="B211-antibiotics-11-01378"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kahan</surname><given-names>F.M.</given-names></name>
<name><surname>Kahan</surname><given-names>J.S.</given-names></name>
<name><surname>Cassidy</surname><given-names>P.J.</given-names></name>
<name><surname>Kropp</surname><given-names>H.</given-names></name>
</person-group><article-title>The mechanism of action of fosfomycin (phosphonomycin)</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1974</year><volume>235</volume><fpage>364</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1974.tb43277.x</pub-id><?supplied-pmid 4605290?><pub-id pub-id-type="pmid">4605290</pub-id></element-citation></ref><ref id="B212-antibiotics-11-01378"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Fu</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
</person-group><article-title>Mutations of the Transporter Proteins GlpT and UhpT Confer Fosfomycin Resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>914</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.00914</pub-id><?supplied-pmid 28579984?><pub-id pub-id-type="pmid">28579984</pub-id></element-citation></ref><ref id="B213-antibiotics-11-01378"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Z.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
</person-group><article-title>Prevalence of Fosfomycin Resistance and Mutations in murA, glpT, and uhpT in Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Strains Isolated from Blood and Cerebrospinal Fluid Samples</article-title><source>Front. Microbiol.</source><year>2016</year><volume>6</volume><fpage>1544</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2015.01544</pub-id><pub-id pub-id-type="pmid">26793179</pub-id></element-citation></ref><ref id="B214-antibiotics-11-01378"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Jian</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>N.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
</person-group><article-title>Mechanisms of high-level fosfomycin resistance in <italic toggle="yes">Staphylococcus aureus</italic> epidemic lineage ST5</article-title><source>J. Antimicrob. Chemother.</source><year>2022</year><volume>77</volume><fpage>2816</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac236</pub-id><?supplied-pmid 35848785?><pub-id pub-id-type="pmid">35848785</pub-id></element-citation></ref><ref id="B215-antibiotics-11-01378"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zeng</surname><given-names>W.</given-names></name>
<name><surname>Wu</surname><given-names>Q.</given-names></name>
<name><surname>Yu</surname><given-names>K.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>T.</given-names></name>
</person-group><article-title>Molecular Mechanisms and Epidemiology of Fosfomycin Resistance in <italic toggle="yes">Staphylococcus aureus</italic> Isolated From Patients at a Teaching Hospital in China</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>1290</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.01290</pub-id><?supplied-pmid 32670230?><pub-id pub-id-type="pmid">32670230</pub-id></element-citation></ref><ref id="B216-antibiotics-11-01378"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Truong-Bolduc</surname><given-names>Q.C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Hooper</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Tet38 Efflux pump contributes to fosfomycin resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e00927-18</fpage><pub-id pub-id-type="doi">10.1128/AAC.00927-18</pub-id><pub-id pub-id-type="pmid">29891612</pub-id></element-citation></ref><ref id="B217-antibiotics-11-01378"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Ji</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Zhuang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>The novel fosfomycin resistance gene fosY is present on a genomic island in CC1 methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Emerg. Microbes Infect.</source><year>2022</year><volume>11</volume><fpage>1166</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2058421</pub-id><?supplied-pmid 35332834?><pub-id pub-id-type="pmid">35332834</pub-id></element-citation></ref><ref id="B218-antibiotics-11-01378"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>P.</given-names></name>
</person-group><article-title>History of the Development of Rifampin</article-title><source>Clin. Infect. Dis.</source><year>1983</year><volume>5</volume><fpage>S402</fpage><lpage>S406</lpage><pub-id pub-id-type="doi">10.1093/clinids/5.Supplement_3.S402</pub-id><?supplied-pmid 6635432?><pub-id pub-id-type="pmid">6635432</pub-id></element-citation></ref><ref id="B219-antibiotics-11-01378"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>R.A.</given-names></name>
<name><surname>Leon</surname><given-names>G.</given-names></name>
<name><surname>Miller</surname><given-names>N.M.</given-names></name>
<name><surname>Reyes</surname><given-names>S.P.</given-names></name>
<name><surname>Thantrong</surname><given-names>C.H.</given-names></name>
<name><surname>Thokkadam</surname><given-names>A.M.</given-names></name>
<name><surname>Lemma</surname><given-names>A.S.</given-names></name>
<name><surname>Sivaloganathan</surname><given-names>D.M.</given-names></name>
<name><surname>Wan</surname><given-names>X.</given-names></name>
<name><surname>Brynildsen</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Rifamycin antibiotics and the mechanisms of their failure</article-title><source>J. Antibiot.</source><year>2021</year><volume>74</volume><fpage>786</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1038/s41429-021-00462-x</pub-id><?supplied-pmid 34400805?><pub-id pub-id-type="pmid">34400805</pub-id></element-citation></ref><ref id="B220-antibiotics-11-01378"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartmann</surname><given-names>G.</given-names></name>
<name><surname>Honikel</surname><given-names>K.O.</given-names></name>
<name><surname>Kn&#x000fc;sel</surname><given-names>F.</given-names></name>
<name><surname>N&#x000fc;esch</surname><given-names>J.</given-names></name>
</person-group><article-title>The specific inhibition of the DNA-directed RNA synthesis by rifamycin</article-title><source>Biochim. Biophys. Acta Nucleic Acids Protein Synth.</source><year>1967</year><volume>145</volume><fpage>843</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/0005-2787(67)90147-5</pub-id></element-citation></ref><ref id="B221-antibiotics-11-01378"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aiba</surname><given-names>Y.</given-names></name>
<name><surname>Katayama</surname><given-names>Y.</given-names></name>
<name><surname>Hishinuma</surname><given-names>T.</given-names></name>
<name><surname>Murakami-Kuroda</surname><given-names>H.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Hiramatsu</surname><given-names>K.</given-names></name>
</person-group><article-title>Mutation of RNA polymerase &#x003b2;-subunit gene promotes heterogeneous-to-homogeneous conversion of &#x003b2;-lactam resistance in methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>4861</fpage><lpage>4871</lpage><pub-id pub-id-type="doi">10.1128/AAC.00720-13</pub-id><?supplied-pmid 23877693?><pub-id pub-id-type="pmid">23877693</pub-id></element-citation></ref><ref id="B222-antibiotics-11-01378"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e1;zquez-Laslop</surname><given-names>N.</given-names></name>
<name><surname>Mankin</surname><given-names>A.S.</given-names></name>
</person-group><article-title>How Macrolide Antibiotics Work</article-title><source>Trends Biochem. Sci.</source><year>2018</year><volume>43</volume><fpage>668</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2018.06.011</pub-id><?supplied-pmid 30054232?><pub-id pub-id-type="pmid">30054232</pub-id></element-citation></ref><ref id="B223-antibiotics-11-01378"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>J.-A.</given-names></name>
</person-group><article-title>Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in a Korean hospital</article-title><source>J. Antimicrob. Chemother.</source><year>2002</year><volume>49</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1093/jac/49.3.489</pub-id><pub-id pub-id-type="pmid">11864949</pub-id></element-citation></ref><ref id="B224-antibiotics-11-01378"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diep</surname><given-names>B.A.</given-names></name>
<name><surname>Chambers</surname><given-names>H.F.</given-names></name>
<name><surname>Graber</surname><given-names>C.J.</given-names></name>
<name><surname>Szumowski</surname><given-names>J.D.</given-names></name>
<name><surname>Miller</surname><given-names>L.G.</given-names></name>
<name><surname>Han</surname><given-names>L.L.</given-names></name>
<name><surname>Chen</surname><given-names>J.H.</given-names></name>
<name><surname>Lin</surname><given-names>F.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
<name><surname>Phan</surname><given-names>T.H.</given-names></name>
<etal/>
</person-group><article-title>Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Clone USA300 in Men Who Have Sex with Men</article-title><source>Ann. Intern. Med.</source><year>2008</year><volume>148</volume><fpage>249</fpage><pub-id pub-id-type="doi">10.7326/0003-4819-148-4-200802190-00204</pub-id><?supplied-pmid 18283202?><pub-id pub-id-type="pmid">18283202</pub-id></element-citation></ref><ref id="B225-antibiotics-11-01378"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martineau</surname><given-names>F.</given-names></name>
<name><surname>Picard</surname><given-names>F.J.</given-names></name>
<name><surname>Lansac</surname><given-names>N.</given-names></name>
<name><surname>M&#x000e9;nard</surname><given-names>C.</given-names></name>
<name><surname>Roy</surname><given-names>P.H.</given-names></name>
<name><surname>Ouellette</surname><given-names>M.</given-names></name>
<name><surname>Bergeron</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Correlation between the Resistance Genotype Determined by Multiplex PCR Assays and the Antibiotic Susceptibility Patterns of <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Staphylococcus epidermidis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.2.231-238.2000</pub-id><?supplied-pmid 10639342?><pub-id pub-id-type="pmid">10639342</pub-id></element-citation></ref><ref id="B226-antibiotics-11-01378"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rubinstein</surname><given-names>E.</given-names></name>
<name><surname>Keynan</surname><given-names>Y.</given-names></name>
</person-group><article-title>Vancomycin Revisited&#x02014;60 Years Later</article-title><source>Front. Public Health</source><year>2014</year><volume>2</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2014.00217</pub-id><?supplied-pmid 25401098?><pub-id pub-id-type="pmid">25401098</pub-id></element-citation></ref><ref id="B227-antibiotics-11-01378"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barna</surname><given-names>J.C.J.</given-names></name>
<name><surname>Williams</surname><given-names>D.H.</given-names></name>
</person-group><article-title>The Structure and Mode of Action of Glycopeptide Antibiotics of the Vancomycin Group</article-title><source>Annu. Rev. Microbiol.</source><year>1984</year><volume>38</volume><fpage>339</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1146/annurev.mi.38.100184.002011</pub-id><?supplied-pmid 6388496?><pub-id pub-id-type="pmid">6388496</pub-id></element-citation></ref><ref id="B228-antibiotics-11-01378"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>P.E.</given-names></name>
</person-group><article-title>Studies on the mode of action of vancomycin</article-title><source>BBA Biochim. Biophys. Acta</source><year>1961</year><volume>52</volume><fpage>403</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/0006-3002(61)90698-9</pub-id><pub-id pub-id-type="pmid">14491721</pub-id></element-citation></ref><ref id="B229-antibiotics-11-01378"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Typas</surname><given-names>A.</given-names></name>
<name><surname>Banzhaf</surname><given-names>M.</given-names></name>
<name><surname>Gross</surname><given-names>C.A.</given-names></name>
<name><surname>Vollmer</surname><given-names>W.</given-names></name>
</person-group><article-title>From the regulation of peptidoglycan synthesis to bacterial growth and morphology</article-title><source>Nat. Rev. Microbiol.</source><year>2012</year><volume>10</volume><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2677</pub-id><?supplied-pmid 22203377?><pub-id pub-id-type="pmid">22203377</pub-id></element-citation></ref><ref id="B230-antibiotics-11-01378"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubrac</surname><given-names>S.</given-names></name>
<name><surname>Boneca</surname><given-names>I.G.</given-names></name>
<name><surname>Poupel</surname><given-names>O.</given-names></name>
<name><surname>Msadek</surname><given-names>T.</given-names></name>
</person-group><article-title>New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Bacteriol.</source><year>2007</year><volume>189</volume><fpage>8257</fpage><lpage>8269</lpage><pub-id pub-id-type="doi">10.1128/JB.00645-07</pub-id><?supplied-pmid 17827301?><pub-id pub-id-type="pmid">17827301</pub-id></element-citation></ref><ref id="B231-antibiotics-11-01378"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubrac</surname><given-names>S.</given-names></name>
<name><surname>Bisicchia</surname><given-names>P.</given-names></name>
<name><surname>Devine</surname><given-names>K.M.</given-names></name>
<name><surname>Msadek</surname><given-names>T.</given-names></name>
</person-group><article-title>A matter of life and death: Cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway</article-title><source>Mol. Microbiol.</source><year>2008</year><volume>70</volume><fpage>1307</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06483.x</pub-id><pub-id pub-id-type="pmid">19019149</pub-id></element-citation></ref><ref id="B232-antibiotics-11-01378"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delaune</surname><given-names>A.</given-names></name>
<name><surname>Poupel</surname><given-names>O.</given-names></name>
<name><surname>Mallet</surname><given-names>A.</given-names></name>
<name><surname>Coic</surname><given-names>Y.-M.</given-names></name>
<name><surname>Msadek</surname><given-names>T.</given-names></name>
<name><surname>Dubrac</surname><given-names>S.</given-names></name>
</person-group><article-title>Peptidoglycan Crosslinking Relaxation Plays an Important Role in <italic toggle="yes">Staphylococcus aureus</italic> WalKR-Dependent Cell Viability</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17054</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017054</pub-id><?supplied-pmid 21386961?><pub-id pub-id-type="pmid">21386961</pub-id></element-citation></ref><ref id="B233-antibiotics-11-01378"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herbert</surname><given-names>S.</given-names></name>
<name><surname>Bera</surname><given-names>A.</given-names></name>
<name><surname>Nerz</surname><given-names>C.</given-names></name>
<name><surname>Kraus</surname><given-names>D.</given-names></name>
<name><surname>Peschel</surname><given-names>A.</given-names></name>
<name><surname>Goerke</surname><given-names>C.</given-names></name>
<name><surname>Meehl</surname><given-names>M.</given-names></name>
<name><surname>Cheung</surname><given-names>A.</given-names></name>
<name><surname>G&#x000f6;tz</surname><given-names>F.</given-names></name>
</person-group><article-title>Molecular Basis of Resistance to Muramidase and Cationic Antimicrobial Peptide Activity of Lysozyme in <italic toggle="yes">Staphylococci</italic></article-title><source>PLoS Pathog.</source><year>2007</year><volume>3</volume><elocation-id>e102</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0030102</pub-id><pub-id pub-id-type="pmid">17676995</pub-id></element-citation></ref><ref id="B234-antibiotics-11-01378"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
<name><surname>Moellering</surname><given-names>R.C.</given-names></name>
<name><surname>Wennersten</surname><given-names>C.</given-names></name>
<name><surname>Venkataraman</surname><given-names>L.</given-names></name>
<name><surname>Novick</surname><given-names>R.P.</given-names></name>
<name><surname>Gold</surname><given-names>H.S.</given-names></name>
</person-group><article-title>Accessory gene regulator (agr) locus in geographically diverse <italic toggle="yes">Staphylococcus aureus</italic> isolates with reduced susceptibility to vancomycin</article-title><source>Antimicrob. Agents Chemother.</source><year>2002</year><volume>46</volume><fpage>1492</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1128/AAC.46.5.1492-1502.2002</pub-id><pub-id pub-id-type="pmid">11959587</pub-id></element-citation></ref><ref id="B235-antibiotics-11-01378"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howden</surname><given-names>B.P.</given-names></name>
<name><surname>Davies</surname><given-names>J.K.</given-names></name>
<name><surname>Johnson</surname><given-names>P.D.R.</given-names></name>
<name><surname>Stinear</surname><given-names>T.P.</given-names></name>
<name><surname>Grayson</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Reduced vancomycin susceptibility in <italic toggle="yes">Staphylococcus aureus</italic>, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications</article-title><source>Clin. Microbiol. Rev.</source><year>2010</year><volume>23</volume><fpage>99</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1128/CMR.00042-09</pub-id><pub-id pub-id-type="pmid">20065327</pub-id></element-citation></ref><ref id="B236-antibiotics-11-01378"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;nch</surname><given-names>D.</given-names></name>
<name><surname>Engels</surname><given-names>I.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>A.</given-names></name>
<name><surname>Reder-Christ</surname><given-names>K.</given-names></name>
<name><surname>Falkenstein-Paul</surname><given-names>H.</given-names></name>
<name><surname>Bierbaum</surname><given-names>G.</given-names></name>
<name><surname>Grein</surname><given-names>F.</given-names></name>
<name><surname>Bendas</surname><given-names>G.</given-names></name>
<name><surname>Sahl</surname><given-names>H.G.</given-names></name>
<name><surname>Schneider</surname><given-names>T.</given-names></name>
</person-group><article-title>Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1128/AAC.02663-14</pub-id><?supplied-pmid 25403671?><pub-id pub-id-type="pmid">25403671</pub-id></element-citation></ref><ref id="B237-antibiotics-11-01378"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arthur</surname><given-names>M.</given-names></name>
<name><surname>Molinas</surname><given-names>C.</given-names></name>
<name><surname>Depardieu</surname><given-names>F.</given-names></name>
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
</person-group><article-title>Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in <italic toggle="yes">Enterococcus faecium</italic> BM4147</article-title><source>J. Bacteriol.</source><year>1993</year><volume>175</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1128/jb.175.1.117-127.1993</pub-id><pub-id pub-id-type="pmid">8380148</pub-id></element-citation></ref><ref id="B238-antibiotics-11-01378"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lambert</surname><given-names>P.</given-names></name>
</person-group><article-title>Bacterial resistance to antibiotics: Modified target sites</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>1471</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2005.04.003</pub-id><?supplied-pmid 15964098?><pub-id pub-id-type="pmid">15964098</pub-id></element-citation></ref><ref id="B239-antibiotics-11-01378"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sievert</surname><given-names>D.M.</given-names></name>
<name><surname>Rudrik</surname><given-names>J.T.</given-names></name>
<name><surname>Patel</surname><given-names>J.B.</given-names></name>
<name><surname>McDonald</surname><given-names>L.C.</given-names></name>
<name><surname>Wilkins</surname><given-names>M.J.</given-names></name>
<name><surname>Hageman</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Vancomycin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> in the United States, 2002&#x02013;2006</article-title><source>Clin. Infect. Dis.</source><year>2008</year><volume>46</volume><fpage>668</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1086/527392</pub-id><?supplied-pmid 18257700?><pub-id pub-id-type="pmid">18257700</pub-id></element-citation></ref><ref id="B240-antibiotics-11-01378"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melo-Cristino</surname><given-names>J.</given-names></name>
<name><surname>Resina</surname><given-names>C.</given-names></name>
<name><surname>Manuel</surname><given-names>V.</given-names></name>
<name><surname>Lito</surname><given-names>L.</given-names></name>
<name><surname>Ramirez</surname><given-names>M.</given-names></name>
</person-group><article-title>First case of infection with vancomycin-resistant <italic toggle="yes">Staphylococcus aureus</italic> in Europe</article-title><source>Lancet</source><year>2013</year><volume>382</volume><fpage>205</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61219-2</pub-id></element-citation></ref><ref id="B241-antibiotics-11-01378"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Birmingham</surname><given-names>M.C.</given-names></name>
<name><surname>Rayner</surname><given-names>C.R.</given-names></name>
<name><surname>Meagher</surname><given-names>A.K.</given-names></name>
<name><surname>Flavin</surname><given-names>S.M.</given-names></name>
<name><surname>Batts</surname><given-names>D.H.</given-names></name>
<name><surname>Schentag</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program</article-title><source>Clin. Infect. Dis.</source><year>2003</year><volume>36</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1086/345744</pub-id><pub-id pub-id-type="pmid">12522747</pub-id></element-citation></ref><ref id="B242-antibiotics-11-01378"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barber</surname><given-names>K.E.</given-names></name>
<name><surname>Smith</surname><given-names>J.R.</given-names></name>
<name><surname>Raut</surname><given-names>A.</given-names></name>
<name><surname>Rybak</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Evaluation of tedizolid against <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Enterococci</italic> with reduced susceptibility to vancomycin, daptomycin or linezolid</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>152</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv302</pub-id><pub-id pub-id-type="pmid">26476277</pub-id></element-citation></ref><ref id="B243-antibiotics-11-01378"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perlaza-Jim&#x000e9;nez</surname><given-names>L.</given-names></name>
<name><surname>Tan</surname><given-names>K.-S.</given-names></name>
<name><surname>Piper</surname><given-names>S.J.</given-names></name>
<name><surname>Johnson</surname><given-names>R.M.</given-names></name>
<name><surname>Bamert</surname><given-names>R.S.</given-names></name>
<name><surname>Stubenrauch</surname><given-names>C.J.</given-names></name>
<name><surname>Wright</surname><given-names>A.</given-names></name>
<name><surname>Lupton</surname><given-names>D.</given-names></name>
<name><surname>Lithgow</surname><given-names>T.</given-names></name>
<name><surname>Belousoff</surname><given-names>M.J.</given-names></name>
</person-group><article-title>A Structurally Characterized <italic toggle="yes">Staphylococcus aureus</italic> Evolutionary Escape Route from Treatment with the Antibiotic Linezolid</article-title><source>Microbiol. Spectr.</source><year>2022</year><volume>10</volume><fpage>e00583-22</fpage><pub-id pub-id-type="doi">10.1128/spectrum.00583-22</pub-id></element-citation></ref><ref id="B244-antibiotics-11-01378"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Humphries</surname><given-names>R.M.</given-names></name>
<name><surname>Pollett</surname><given-names>S.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
</person-group><article-title>A current perspective on daptomycin for the clinical microbiologist</article-title><source>Clin. Microbiol. Rev.</source><year>2013</year><volume>26</volume><fpage>759</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1128/CMR.00030-13</pub-id><pub-id pub-id-type="pmid">24092854</pub-id></element-citation></ref><ref id="B245-antibiotics-11-01378"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arbeit</surname><given-names>R.D.</given-names></name>
<name><surname>Maki</surname><given-names>D.</given-names></name>
<name><surname>Tally</surname><given-names>F.P.</given-names></name>
<name><surname>Campanaro</surname><given-names>E.</given-names></name>
<name><surname>Eisenstein</surname><given-names>B.I.</given-names></name>
</person-group><article-title>The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections</article-title><source>Clin. Infect. Dis.</source><year>2004</year><volume>38</volume><fpage>1673</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.1086/420818</pub-id><pub-id pub-id-type="pmid">15227611</pub-id></element-citation></ref><ref id="B246-antibiotics-11-01378"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grein</surname><given-names>F.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>A.</given-names></name>
<name><surname>Scherer</surname><given-names>K.M.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Ludwig</surname><given-names>K.C.</given-names></name>
<name><surname>Kl&#x000f6;ckner</surname><given-names>A.</given-names></name>
<name><surname>Strach</surname><given-names>M.</given-names></name>
<name><surname>Sahl</surname><given-names>H.</given-names></name>
<name><surname>Kubitscheck</surname><given-names>U.</given-names></name>
<name><surname>Schneider</surname><given-names>T.</given-names></name>
</person-group><article-title>Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1455</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15257-1</pub-id><pub-id pub-id-type="pmid">32193379</pub-id></element-citation></ref><ref id="B247-antibiotics-11-01378"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silverman</surname><given-names>J.A.</given-names></name>
<name><surname>Oliver</surname><given-names>N.</given-names></name>
<name><surname>Andrew</surname><given-names>T.</given-names></name>
<name><surname>Tongchuan</surname><given-names>L.I.</given-names></name>
</person-group><article-title>Resistance studies with daptomycin</article-title><source>Antimicrob. Agents Chemother.</source><year>2001</year><volume>45</volume><fpage>1799</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.6.1799-1802.2001</pub-id><?supplied-pmid 11353628?><pub-id pub-id-type="pmid">11353628</pub-id></element-citation></ref><ref id="B248-antibiotics-11-01378"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabat</surname><given-names>A.J.</given-names></name>
<name><surname>Tinelli</surname><given-names>M.</given-names></name>
<name><surname>Grundmann</surname><given-names>H.</given-names></name>
<name><surname>Akkerboom</surname><given-names>V.</given-names></name>
<name><surname>Monaco</surname><given-names>M.</given-names></name>
<name><surname>Del Grosso</surname><given-names>M.</given-names></name>
<name><surname>Errico</surname><given-names>G.</given-names></name>
<name><surname>Pantosti</surname><given-names>A.</given-names></name>
<name><surname>Friedrich</surname><given-names>A.W.</given-names></name>
</person-group><article-title>Daptomycin resistant <italic toggle="yes">Staphylococcus aureus</italic> clinical strain with novel non-synonymous mutations in the mprF and vraS genes: A new insight into daptomycin resistance</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2705</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02705</pub-id><pub-id pub-id-type="pmid">30459746</pub-id></element-citation></ref><ref id="B249-antibiotics-11-01378"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>T.</given-names></name>
<name><surname>Yeaman</surname><given-names>M.R.</given-names></name>
<name><surname>Sakoulas</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>S.-J.</given-names></name>
<name><surname>Proctor</surname><given-names>R.A.</given-names></name>
<name><surname>Sahl</surname><given-names>H.-G.</given-names></name>
<name><surname>Schrenzel</surname><given-names>J.</given-names></name>
<name><surname>Xiong</surname><given-names>Y.Q.</given-names></name>
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Failures in Clinical Treatment of <italic toggle="yes">Staphylococcus aureus</italic> Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding</article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1128/AAC.00719-07</pub-id><?supplied-pmid 17954690?><pub-id pub-id-type="pmid">17954690</pub-id></element-citation></ref><ref id="B250-antibiotics-11-01378"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Hal</surname><given-names>S.J.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Gosbell</surname><given-names>I.B.</given-names></name>
</person-group><article-title>Emergence of daptomycin resistance following vancomycin-unresponsive <italic toggle="yes">Staphylococcus aureus</italic> bacteraemia in a daptomycin-na&#x000ef;ve patient&#x02014;A review of the literature</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2011</year><volume>30</volume><fpage>603</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1007/s10096-010-1128-3</pub-id><?supplied-pmid 21191627?><pub-id pub-id-type="pmid">21191627</pub-id></element-citation></ref><ref id="B251-antibiotics-11-01378"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capone</surname><given-names>A.</given-names></name>
<name><surname>Cafiso</surname><given-names>V.</given-names></name>
<name><surname>Campanile</surname><given-names>F.</given-names></name>
<name><surname>Parisi</surname><given-names>G.</given-names></name>
<name><surname>Mariani</surname><given-names>B.</given-names></name>
<name><surname>Petrosillo</surname><given-names>N.</given-names></name>
<name><surname>Stefani</surname><given-names>S.</given-names></name>
</person-group><article-title>In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> severe infections previously treated with glycopeptides</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2016</year><volume>35</volume><fpage>625</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1007/s10096-016-2581-4</pub-id><pub-id pub-id-type="pmid">26815434</pub-id></element-citation></ref><ref id="B252-antibiotics-11-01378"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x000e6;k</surname><given-names>K.T.</given-names></name>
<name><surname>Th&#x000f8;gersen</surname><given-names>L.</given-names></name>
<name><surname>Mogenssen</surname><given-names>R.G.</given-names></name>
<name><surname>Mellergaard</surname><given-names>M.</given-names></name>
<name><surname>Thomsen</surname><given-names>L.E.</given-names></name>
<name><surname>Petersen</surname><given-names>A.</given-names></name>
<name><surname>Skov</surname><given-names>S.</given-names></name>
<name><surname>Cameron</surname><given-names>D.R.</given-names></name>
<name><surname>Peleg</surname><given-names>A.Y.</given-names></name>
<name><surname>Frees</surname><given-names>D.</given-names></name>
</person-group><article-title>Stepwise decrease in daptomycin susceptibility in clinical <italic toggle="yes">Staphylococcus aureus</italic> isolates associated with an initial mutation in rpoB and a Compensatory Inactivation of the clpX Gene</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>6983</fpage><lpage>6991</lpage><pub-id pub-id-type="doi">10.1128/AAC.01303-15</pub-id><pub-id pub-id-type="pmid">26324273</pub-id></element-citation></ref><ref id="B253-antibiotics-11-01378"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ernst</surname><given-names>C.M.</given-names></name>
<name><surname>Slavetinsky</surname><given-names>C.J.</given-names></name>
<name><surname>Kuhn</surname><given-names>S.</given-names></name>
<name><surname>Hauser</surname><given-names>J.N.</given-names></name>
<name><surname>Nega</surname><given-names>M.</given-names></name>
<name><surname>Mishra</surname><given-names>N.N.</given-names></name>
<name><surname>Gekeler</surname><given-names>C.</given-names></name>
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
<name><surname>Peschel</surname><given-names>A.</given-names></name>
</person-group><article-title>Gain-of-function mutations in the phospholipid flippase mprf confer specific daptomycin resistance</article-title><source>MBio</source><year>2018</year><volume>9</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1128/mBio.01659-18</pub-id><?supplied-pmid 30563904?><pub-id pub-id-type="pmid">30563904</pub-id></element-citation></ref><ref id="B254-antibiotics-11-01378"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ernst</surname><given-names>C.M.</given-names></name>
<name><surname>Staubitz</surname><given-names>P.</given-names></name>
<name><surname>Mishra</surname><given-names>N.N.</given-names></name>
<name><surname>Yang</surname><given-names>S.-J.</given-names></name>
<name><surname>Hornig</surname><given-names>G.</given-names></name>
<name><surname>Kalbacher</surname><given-names>H.</given-names></name>
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
<name><surname>Kraus</surname><given-names>D.</given-names></name>
<name><surname>Peschel</surname><given-names>A.</given-names></name>
</person-group><article-title>The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000660</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000660</pub-id><pub-id pub-id-type="pmid">19915718</pub-id></element-citation></ref><ref id="B255-antibiotics-11-01378"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertsche</surname><given-names>U.</given-names></name>
<name><surname>Yang</surname><given-names>S.J.</given-names></name>
<name><surname>Kuehner</surname><given-names>D.</given-names></name>
<name><surname>Wanner</surname><given-names>S.</given-names></name>
<name><surname>Mishra</surname><given-names>N.N.</given-names></name>
<name><surname>Roth</surname><given-names>T.</given-names></name>
<name><surname>Nega</surname><given-names>M.</given-names></name>
<name><surname>Schneider</surname><given-names>A.</given-names></name>
<name><surname>Mayer</surname><given-names>C.</given-names></name>
<name><surname>Grau</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Increased Cell Wall Teichoic Acid Production and D-alanylation Are Common Phenotypes among Daptomycin-Resistant Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) Clinical Isolates</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e67398</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0067398</pub-id><pub-id pub-id-type="pmid">23785522</pub-id></element-citation></ref><ref id="B256-antibiotics-11-01378"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>L.</given-names></name>
<name><surname>Alder</surname><given-names>J.D.</given-names></name>
<name><surname>Silverman</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Genetic changes that correlate with reduced susceptibility to daptomycin in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2006</year><volume>50</volume><fpage>2137</fpage><lpage>2145</lpage><pub-id pub-id-type="doi">10.1128/AAC.00039-06</pub-id><pub-id pub-id-type="pmid">16723576</pub-id></element-citation></ref><ref id="B257-antibiotics-11-01378"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>N.N.</given-names></name>
<name><surname>Bayer</surname><given-names>A.S.</given-names></name>
<name><surname>Weidenmaier</surname><given-names>C.</given-names></name>
<name><surname>Grau</surname><given-names>T.</given-names></name>
<name><surname>Wanner</surname><given-names>S.</given-names></name>
<name><surname>Stefani</surname><given-names>S.</given-names></name>
<name><surname>Cafiso</surname><given-names>V.</given-names></name>
<name><surname>Bertuccio</surname><given-names>T.</given-names></name>
<name><surname>Yeaman</surname><given-names>M.R.</given-names></name>
<name><surname>Nast</surname><given-names>C.C.</given-names></name>
<etal/>
</person-group><article-title>Phenotypic and Genotypic Characterization of Daptomycin-Resistant Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Strains: Relative Roles of mprF and dlt Operons</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e107426</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0107426</pub-id><pub-id pub-id-type="pmid">25226591</pub-id></element-citation></ref><ref id="B258-antibiotics-11-01378"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Cha</surname><given-names>D.J.</given-names></name>
<name><surname>Lai</surname><given-names>Y.</given-names></name>
<name><surname>Villaruz</surname><given-names>A.E.</given-names></name>
<name><surname>Sturdevant</surname><given-names>D.E.</given-names></name>
<name><surname>Otto</surname><given-names>M.</given-names></name>
</person-group><article-title>The antimicrobial peptide-sensing system aps of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Mol. Microbiol.</source><year>2007</year><volume>66</volume><fpage>1136</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2007.05986.x</pub-id><pub-id pub-id-type="pmid">17961141</pub-id></element-citation></ref><ref id="B259-antibiotics-11-01378"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meehl</surname><given-names>M.</given-names></name>
<name><surname>Herbert</surname><given-names>S.</given-names></name>
<name><surname>G&#x000f6;tz</surname><given-names>F.</given-names></name>
<name><surname>Cheung</surname><given-names>A.</given-names></name>
</person-group><article-title>Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>2679</fpage><lpage>2689</lpage><pub-id pub-id-type="doi">10.1128/AAC.00209-07</pub-id><?supplied-pmid 17502406?><pub-id pub-id-type="pmid">17502406</pub-id></element-citation></ref><ref id="B260-antibiotics-11-01378"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diekema</surname><given-names>D.J.</given-names></name>
<name><surname>Pfaller</surname><given-names>M.A.</given-names></name>
<name><surname>Schmitz</surname><given-names>F.J.</given-names></name>
<name><surname>Smayevsky</surname><given-names>J.</given-names></name>
<name><surname>Bell</surname><given-names>J.</given-names></name>
<name><surname>Jones</surname><given-names>R.N.</given-names></name>
<name><surname>Beach</surname><given-names>M.</given-names></name>
</person-group><article-title>Survey of Infections Due to <italic toggle="yes">Staphylococcus</italic> Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillanc</article-title><source>Clin. Infect. Dis.</source><year>2001</year><volume>32</volume><fpage>S114</fpage><lpage>S132</lpage><pub-id pub-id-type="doi">10.1086/320184</pub-id><?supplied-pmid 11320452?><pub-id pub-id-type="pmid">11320452</pub-id></element-citation></ref><ref id="B261-antibiotics-11-01378"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burgold-Voigt</surname><given-names>S.</given-names></name>
<name><surname>Monecke</surname><given-names>S.</given-names></name>
<name><surname>Simbeck</surname><given-names>A.</given-names></name>
<name><surname>Holzmann</surname><given-names>T.</given-names></name>
<name><surname>Kieninger</surname><given-names>B.</given-names></name>
<name><surname>Liebler-Tenorio</surname><given-names>E.M.</given-names></name>
<name><surname>Braun</surname><given-names>S.D.</given-names></name>
<name><surname>Collatz</surname><given-names>M.</given-names></name>
<name><surname>Diezel</surname><given-names>C.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Characterisation and Molecular Analysis of an Unusual Chimeric Methicillin Resistant <italic toggle="yes">Staphylococcus Aureus</italic> Strain and its Bacteriophages</article-title><source>Front. Genet.</source><year>2021</year><volume>12</volume><fpage>1823</fpage><pub-id pub-id-type="doi">10.3389/fgene.2021.723958</pub-id><?supplied-pmid 34868203?><pub-id pub-id-type="pmid">34868203</pub-id></element-citation></ref><ref id="B262-antibiotics-11-01378"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaatz</surname><given-names>G.W.</given-names></name>
<name><surname>Seo</surname><given-names>S.M.</given-names></name>
<name><surname>Ruble</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Efflux-mediated fluoroquinolone resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>1086</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.5.1086</pub-id><pub-id pub-id-type="pmid">8517696</pub-id></element-citation></ref><ref id="B263-antibiotics-11-01378"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yun</surname><given-names>H.J.</given-names></name>
<name><surname>Min</surname><given-names>Y.H.</given-names></name>
<name><surname>Lim</surname><given-names>J.A.</given-names></name>
<name><surname>Kang</surname><given-names>J.W.</given-names></name>
<name><surname>Kim</surname><given-names>S.Y.</given-names></name>
<name><surname>Kim</surname><given-names>M.J.</given-names></name>
<name><surname>Jeong</surname><given-names>J.H.</given-names></name>
<name><surname>Choi</surname><given-names>Y.J.</given-names></name>
<name><surname>Kwon</surname><given-names>H.J.</given-names></name>
<name><surname>Jung</surname><given-names>Y.H.</given-names></name>
<etal/>
</person-group><article-title>In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic</article-title><source>Antimicrob. Agents Chemother.</source><year>2002</year><volume>46</volume><fpage>3071</fpage><lpage>3074</lpage><pub-id pub-id-type="doi">10.1128/AAC.46.9.3071-3074.2002</pub-id><pub-id pub-id-type="pmid">12183275</pub-id></element-citation></ref><ref id="B264-antibiotics-11-01378"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schindler</surname><given-names>B.D.</given-names></name>
<name><surname>Kaatz</surname><given-names>G.W.</given-names></name>
</person-group><article-title>Multidrug efflux pumps of Gram-positive bacteria</article-title><source>Drug Resist. Updates</source><year>2016</year><volume>27</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2016.04.003</pub-id></element-citation></ref><ref id="B265-antibiotics-11-01378"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poole</surname><given-names>K.</given-names></name>
</person-group><article-title>Efflux pumps as antimicrobial resistance mechanisms</article-title><source>Ann. Med.</source><year>2007</year><volume>39</volume><fpage>162</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1080/07853890701195262</pub-id><pub-id pub-id-type="pmid">17457715</pub-id></element-citation></ref><ref id="B266-antibiotics-11-01378"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ubukata</surname><given-names>K.</given-names></name>
<name><surname>Itoh-Yamashita</surname><given-names>N.</given-names></name>
<name><surname>Konno</surname><given-names>M.</given-names></name>
</person-group><article-title>Cloning and expression of the norA gene for fluoroquinolone resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1989</year><volume>33</volume><fpage>1535</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.9.1535</pub-id><pub-id pub-id-type="pmid">2817852</pub-id></element-citation></ref><ref id="B267-antibiotics-11-01378"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neyfakh</surname><given-names>A.A.</given-names></name>
<name><surname>Borsch</surname><given-names>C.M.</given-names></name>
<name><surname>Kaatz</surname><given-names>G.W.</given-names></name>
</person-group><article-title>Fluoroquinolone resistance protein NorA of <italic toggle="yes">Staphylococcus aureus</italic> is a multidrug efflux transporter</article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>128</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.1.128</pub-id><pub-id pub-id-type="pmid">8431010</pub-id></element-citation></ref><ref id="B268-antibiotics-11-01378"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshida</surname><given-names>H.</given-names></name>
<name><surname>Bogaki</surname><given-names>M.</given-names></name>
<name><surname>Nakamura</surname><given-names>S.</given-names></name>
<name><surname>Ubukata</surname><given-names>K.</given-names></name>
<name><surname>Konno</surname><given-names>M.</given-names></name>
</person-group><article-title>Nucleotide sequence and characterization of the <italic toggle="yes">Staphylococcus aureus</italic> norA gene, which confers resistance to quinolones</article-title><source>J. Bacteriol.</source><year>1990</year><volume>172</volume><fpage>6942</fpage><lpage>6949</lpage><pub-id pub-id-type="doi">10.1128/jb.172.12.6942-6949.1990</pub-id><pub-id pub-id-type="pmid">2174864</pub-id></element-citation></ref><ref id="B269-antibiotics-11-01378"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paul</surname><given-names>M.</given-names></name>
<name><surname>Bishara</surname><given-names>J.</given-names></name>
<name><surname>Yahav</surname><given-names>D.</given-names></name>
<name><surname>Goldberg</surname><given-names>E.</given-names></name>
<name><surname>Neuberger</surname><given-names>A.</given-names></name>
<name><surname>Ghanem-Zoubi</surname><given-names>N.</given-names></name>
<name><surname>Dickstein</surname><given-names>Y.</given-names></name>
<name><surname>Nseir</surname><given-names>W.</given-names></name>
<name><surname>Dan</surname><given-names>M.</given-names></name>
<name><surname>Leibovici</surname><given-names>L.</given-names></name>
</person-group><article-title>Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant <italic toggle="yes">Staphylococcus aureus</italic>: Randomised controlled trial</article-title><source>BMJ</source><year>2015</year><volume>350</volume><fpage>h2219</fpage><pub-id pub-id-type="doi">10.1136/bmj.h2219</pub-id><?supplied-pmid 25977146?><pub-id pub-id-type="pmid">25977146</pub-id></element-citation></ref><ref id="B270-antibiotics-11-01378"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elwell</surname><given-names>L.P.</given-names></name>
<name><surname>Wilson</surname><given-names>H.R.</given-names></name>
<name><surname>Knick</surname><given-names>V.B.</given-names></name>
<name><surname>Keith</surname><given-names>B.R.</given-names></name>
</person-group><article-title>In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>1986</year><volume>29</volume><fpage>1092</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1128/AAC.29.6.1092</pub-id><?supplied-pmid 3488022?><pub-id pub-id-type="pmid">3488022</pub-id></element-citation></ref><ref id="B271-antibiotics-11-01378"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frei</surname><given-names>C.R.</given-names></name>
<name><surname>Miller</surname><given-names>M.L.</given-names></name>
<name><surname>Lewis</surname><given-names>J.S.</given-names></name>
<name><surname>Lawson</surname><given-names>K.A.</given-names></name>
<name><surname>Hunter</surname><given-names>J.M.</given-names></name>
<name><surname>Oramasionwu</surname><given-names>C.U.</given-names></name>
<name><surname>Talbert</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Trimethoprim-Sulfamethoxazole or Clindamycin for Community-Associated MRSA (CA-MRSA) Skin Infections</article-title><source>J. Am. Board Fam. Med.</source><year>2010</year><volume>23</volume><fpage>714</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.3122/jabfm.2010.06.090270</pub-id><?supplied-pmid 21057066?><pub-id pub-id-type="pmid">21057066</pub-id></element-citation></ref><ref id="B272-antibiotics-11-01378"><label>272.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Woods</surname><given-names>D.D.</given-names></name>
</person-group><source>The Relation of p-Aminobenzoic Acid to the Mechanism of the Action of Sulphanilamide</source><publisher-name>Wiley-Blackwell</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>1940</year><volume>Volume 21</volume></element-citation></ref><ref id="B273-antibiotics-11-01378"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hitchings</surname><given-names>G.H.</given-names></name>
</person-group><article-title>Mechanism of Action of Trimethoprim-Sulfamethoxazole&#x02014;I</article-title><source>J. Infect. Dis.</source><year>1973</year><volume>128</volume><fpage>S433</fpage><lpage>S436</lpage><pub-id pub-id-type="doi">10.1093/infdis/128.Supplement_3.S433</pub-id></element-citation></ref><ref id="B274-antibiotics-11-01378"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalkut</surname><given-names>G.</given-names></name>
</person-group><article-title>Sulfonamides and Trimethoprim</article-title><source>Cancer Invest.</source><year>1998</year><volume>16</volume><fpage>612</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.3109/07357909809032892</pub-id><?supplied-pmid 9844622?><pub-id pub-id-type="pmid">9844622</pub-id></element-citation></ref><ref id="B275-antibiotics-11-01378"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chernyshev</surname><given-names>A.</given-names></name>
<name><surname>Fleischmann</surname><given-names>T.</given-names></name>
<name><surname>Kohen</surname><given-names>A.</given-names></name>
</person-group><article-title>Thymidyl biosynthesis enzymes as antibiotic targets</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2007</year><volume>74</volume><fpage>282</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1007/s00253-006-0763-1</pub-id><?supplied-pmid 17216455?><pub-id pub-id-type="pmid">17216455</pub-id></element-citation></ref><ref id="B276-antibiotics-11-01378"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Proctor</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Role of Folate Antagonists in the Treatment of Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> Infection</article-title><source>Clin. Infect. Dis.</source><year>2008</year><volume>46</volume><fpage>584</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">18197761</pub-id></element-citation></ref><ref id="B277-antibiotics-11-01378"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khamash</surname><given-names>D.F.</given-names></name>
<name><surname>Voskertchian</surname><given-names>A.</given-names></name>
<name><surname>Tamma</surname><given-names>P.D.</given-names></name>
<name><surname>Akinboyo</surname><given-names>I.C.</given-names></name>
<name><surname>Carroll</surname><given-names>K.C.</given-names></name>
<name><surname>Milstone</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric <italic toggle="yes">Staphylococcus aureus</italic> Infections</article-title><source>J. Pediatric Infect. Dis. Soc.</source><year>2019</year><volume>8</volume><fpage>351</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1093/jpids/piy062</pub-id><pub-id pub-id-type="pmid">30011009</pub-id></element-citation></ref><ref id="B278-antibiotics-11-01378"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Acree</surname><given-names>M.E.</given-names></name>
<name><surname>Morgan</surname><given-names>E.</given-names></name>
<name><surname>David</surname><given-names>M.Z.</given-names></name>
</person-group><article-title>S. aureus infections in chicago, 2006&#x02013;2014: Increase in CA MSSA and decrease in MRSA incidence</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2017</year><volume>38</volume><fpage>1226</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1017/ice.2017.177</pub-id><pub-id pub-id-type="pmid">28903801</pub-id></element-citation></ref><ref id="B279-antibiotics-11-01378"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harris</surname><given-names>T.</given-names></name>
<name><surname>Bowen</surname><given-names>A.</given-names></name>
<name><surname>Holt</surname><given-names>D.</given-names></name>
<name><surname>Sarovich</surname><given-names>D.</given-names></name>
<name><surname>Stevens</surname><given-names>K.</given-names></name>
<name><surname>Currie</surname><given-names>B.</given-names></name>
<name><surname>Howden</surname><given-names>B.</given-names></name>
<name><surname>Carapetis</surname><given-names>J.</given-names></name>
<name><surname>Giffard</surname><given-names>P.</given-names></name>
<name><surname>Tong</surname><given-names>S.</given-names></name>
</person-group><article-title>Investigation of trimethoprim/sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant <italic toggle="yes">Staphylococcus Aureus</italic> clone reveals discrepant resistance reporting</article-title><source>Clin. Microbiol. Infect.</source><year>2018</year><volume>24</volume><fpage>1027</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2018.04.020</pub-id><pub-id pub-id-type="pmid">29723570</pub-id></element-citation></ref><ref id="B280-antibiotics-11-01378"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>T.</given-names></name>
<name><surname>Ito</surname><given-names>R.</given-names></name>
<name><surname>Kawamura</surname><given-names>M.</given-names></name>
<name><surname>Fujimura</surname><given-names>S.</given-names></name>
</person-group><article-title>The Risk of Emerging Resistance to Trimethoprim/Sulfamethoxazole in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Infect. Drug Resist.</source><year>2022</year><volume>15</volume><fpage>4779</fpage><lpage>4784</lpage><pub-id pub-id-type="doi">10.2147/IDR.S375588</pub-id><?supplied-pmid 36039323?><pub-id pub-id-type="pmid">36039323</pub-id></element-citation></ref><ref id="B281-antibiotics-11-01378"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>S.O.</given-names></name>
<name><surname>Lyon</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Genetics of antimicrobial resistance in <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Future Microbiol.</source><year>2009</year><volume>4</volume><fpage>565</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.2217/fmb.09.30</pub-id><pub-id pub-id-type="pmid">19492967</pub-id></element-citation></ref><ref id="B282-antibiotics-11-01378"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frey</surname><given-names>K.M.</given-names></name>
<name><surname>Lombardo</surname><given-names>M.N.</given-names></name>
<name><surname>Wright</surname><given-names>D.L.</given-names></name>
<name><surname>Anderson</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> dihydrofolate reductase</article-title><source>J. Struct. Biol.</source><year>2010</year><volume>170</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2009.12.011</pub-id><pub-id pub-id-type="pmid">20026215</pub-id></element-citation></ref><ref id="B283-antibiotics-11-01378"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oefner</surname><given-names>C.</given-names></name>
<name><surname>Bandera</surname><given-names>M.</given-names></name>
<name><surname>Haldimann</surname><given-names>A.</given-names></name>
<name><surname>Laue</surname><given-names>H.</given-names></name>
<name><surname>Schulz</surname><given-names>H.</given-names></name>
<name><surname>Mukhija</surname><given-names>S.</given-names></name>
<name><surname>Parisi</surname><given-names>S.</given-names></name>
<name><surname>Weiss</surname><given-names>L.</given-names></name>
<name><surname>Lociuro</surname><given-names>S.</given-names></name>
<name><surname>Dale</surname><given-names>G.E.</given-names></name>
</person-group><article-title>Increased hydrophobic interactions of iclaprim with <italic toggle="yes">Staphylococcus aureus</italic> dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity</article-title><source>J. Antimicrob. Chemother.</source><year>2009</year><volume>63</volume><fpage>687</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1093/jac/dkp024</pub-id><?supplied-pmid 19211577?><pub-id pub-id-type="pmid">19211577</pub-id></element-citation></ref><ref id="B284-antibiotics-11-01378"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramsey</surname><given-names>M.A.</given-names></name>
<name><surname>Bradley</surname><given-names>S.F.</given-names></name>
<name><surname>Kauffman</surname><given-names>C.A.</given-names></name>
<name><surname>Morton</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in Staphylococcal isolates</article-title><source>Antimicrob. Agents Chemother.</source><year>1996</year><volume>40</volume><fpage>2820</fpage><lpage>2823</lpage><pub-id pub-id-type="doi">10.1128/AAC.40.12.2820</pub-id><?supplied-pmid 9124848?><pub-id pub-id-type="pmid">9124848</pub-id></element-citation></ref><ref id="B285-antibiotics-11-01378"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramsey</surname><given-names>M.A.</given-names></name>
<name><surname>Bradley</surname><given-names>S.F.</given-names></name>
<name><surname>Kauffman</surname><given-names>C.A.</given-names></name>
<name><surname>Morton</surname><given-names>T.M.</given-names></name>
<name><surname>Patterson</surname><given-names>J.E.</given-names></name>
<name><surname>Reagan</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Characterization of Mupirocin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> from Different Geographic Areas</article-title><source>Antimicrob. Agents Chemother.</source><year>1998</year><volume>42</volume><fpage>1305</fpage><pub-id pub-id-type="doi">10.1128/AAC.42.5.1305</pub-id><?supplied-pmid 9593176?><pub-id pub-id-type="pmid">9593176</pub-id></element-citation></ref><ref id="B286-antibiotics-11-01378"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bongiorno</surname><given-names>D.</given-names></name>
<name><surname>Mongelli</surname><given-names>G.</given-names></name>
<name><surname>Stefani</surname><given-names>S.</given-names></name>
<name><surname>Campanile</surname><given-names>F.</given-names></name>
</person-group><article-title>Burden of Rifampicin- and Methicillin-Resistant <italic toggle="yes">Staphylococcus aureus</italic> in Italy</article-title><source>Microb. Drug Resist.</source><year>2018</year><volume>24</volume><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1089/mdr.2017.0299</pub-id><pub-id pub-id-type="pmid">29185859</pub-id></element-citation></ref><ref id="B287-antibiotics-11-01378"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peleg</surname><given-names>A.Y.</given-names></name>
<name><surname>Miyakis</surname><given-names>S.</given-names></name>
<name><surname>Ward</surname><given-names>D.V.</given-names></name>
<name><surname>Earl</surname><given-names>A.M.</given-names></name>
<name><surname>Rubio</surname><given-names>A.</given-names></name>
<name><surname>Cameron</surname><given-names>D.R.</given-names></name>
<name><surname>Pillai</surname><given-names>S.</given-names></name>
<name><surname>Moellering</surname><given-names>R.C.</given-names></name>
<name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Whole Genome Characterization of the Mechanisms of Daptomycin Resistance in Clinical and Laboratory Derived Isolates of <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e28316</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0028316</pub-id><?supplied-pmid 22238576?><pub-id pub-id-type="pmid">22238576</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="antibiotics-11-01378-f001"><label>Figure 1</label><caption><p>Timeline of the key non-&#x003b2;-lactam antibiotics deployment and the first reported cases of <italic toggle="yes">S. aureus</italic> resistance identified.</p></caption><graphic xlink:href="antibiotics-11-01378-g001" position="float"/></fig><fig position="float" id="antibiotics-11-01378-f002"><label>Figure 2</label><caption><p>Schematic representation of the mechanisms of antibiotic resistance in <italic toggle="yes">S. aureus</italic>. (i) Target modification: change in the structure or composition of the target site in a bacterial cell can stop the antibiotic to bind, thus shielding it from the antibiotic. Modification of the bacterial ribosome by 23S ribosomal RNA (rRNA) methyltransferase (encoded by <italic toggle="yes">erm</italic> genes) leads to a conformational change in the ribosome target [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>], thereby preventing the binding of erythromycin to the ribosomal target. (ii) Mutation of target: mutations in the target can prevent the antibiotic from binding, or if it binds, preventing it from inhibiting the target. Mutation in the DNA topoisomerase IV subunit A (encoded by <italic toggle="yes">grlA</italic> gene) and an essential enzyme DNA gyrase subunit A (encoded by <italic toggle="yes">gyrA</italic> gene) is the main contributor to fluoroquinolone resistance in <italic toggle="yes">S. aureus</italic> [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>]. (iii) Drug inactivation by enzymes: several <italic toggle="yes">S. aureus</italic> enzymes modify the structure of antibiotics or break them down to make them inactive. The bifunctional aminoglycoside-modifying enzyme (AME) AAC(6&#x02032;)/APH(2&#x02033;) (encoded by <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) genes) confers resistance to aminoglycosides via acetyltransferase and phosphotransferase activities [<xref rid="B36-antibiotics-11-01378" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-11-01378" ref-type="bibr">37</xref>]. (iv) Decreased antibiotic uptake or efflux: decrease in the permeability of cell membrane to drugs makes it more difficult to pass through or activation of an efflux pump that removes antibiotics from the bacterial cell. The <italic toggle="yes">norA, qacA</italic>/<italic toggle="yes">B,</italic> and <italic toggle="yes">smr</italic> (<italic toggle="yes">qacC/D</italic>) genes encoding multidrug efflux pump proteins are found mainly in <italic toggle="yes">S. aureus</italic> clinical isolates and mediate resistance to fluoroquinolones, tetracyclines, and reduced susceptibility to certain antiseptics [<xref rid="B38-antibiotics-11-01378" ref-type="bibr">38</xref>,<xref rid="B39-antibiotics-11-01378" ref-type="bibr">39</xref>].</p></caption><graphic xlink:href="antibiotics-11-01378-g002" position="float"/></fig><table-wrap position="float" id="antibiotics-11-01378-t001"><object-id pub-id-type="pii">antibiotics-11-01378-t001_Table 1</object-id><label>Table 1</label><caption><p>Mechanisms of action of non-&#x003b2;-lactam antibiotics active against <italic toggle="yes">S. aureus</italic> and molecular basis of antibiotic resistance.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic Class/ <break/>Primary Agent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approve Year and Use</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Target and <break/>Mechanisms of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Resistance Genes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism(s) of Resistance</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Macrolides </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythromycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1952 [<xref rid="B66-antibiotics-11-01378" ref-type="bibr">66</xref>].<break/>SSTI<break/>
<break/>(Resistance 1955) [<xref rid="B67-antibiotics-11-01378" ref-type="bibr">67</xref>] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythromycin binds to bacterial 23S rRNA in the 50S ribosomal subunit and stops protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and assembly of the 50S ribosomal subunit [<xref rid="B68-antibiotics-11-01378" ref-type="bibr">68</xref>,<xref rid="B69-antibiotics-11-01378" ref-type="bibr">69</xref>].<break/>The target site for macrolides is nucleotides A2058 and A2059 located in the V region of 23S rRNA and, rarely, nucleotide A752 located in domain II [<xref rid="B70-antibiotics-11-01378" ref-type="bibr">70</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">ermA</italic> [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>], <italic toggle="yes">ermB</italic>, <italic toggle="yes">ermC</italic> [<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>], <italic toggle="yes">ermY</italic> [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>],<break/><italic toggle="yes">msr</italic>(F) [<xref rid="B71-antibiotics-11-01378" ref-type="bibr">71</xref>],<break/><italic toggle="yes">msrA</italic> [<xref rid="B72-antibiotics-11-01378" ref-type="bibr">72</xref>],<break/><italic toggle="yes">msrB</italic>,<break/><italic toggle="yes">ereA</italic>, <italic toggle="yes">ereB,</italic><break/><italic toggle="yes">mphB, mphC</italic> [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Modification of the bacterial ribosome by 23S rRNA methyltransferase (encoded by <italic toggle="yes">erm</italic> genes) prevents the binding of erythromycin to ribosomal target [<xref rid="B31-antibiotics-11-01378" ref-type="bibr">31</xref>,<xref rid="B32-antibiotics-11-01378" ref-type="bibr">32</xref>].<break/>(ii) Active efflux of macrolides from cells by ATP-binding-cassette family (ABC-F) transporters (encoded by <italic toggle="yes">msr</italic><italic toggle="yes">A</italic> and <italic toggle="yes">msr</italic><italic toggle="yes">B</italic> genes) protects ribosomes from inhibition [<xref rid="B72-antibiotics-11-01378" ref-type="bibr">72</xref>,<xref rid="B73-antibiotics-11-01378" ref-type="bibr">73</xref>].<break/>(iii) Enzymatic hydrolysis of 14- and 15-membered lactone ring of macrolides by esterase (encoded by <italic toggle="yes">ere</italic> genes) prevents its binding to the antibiotic target site [<xref rid="B74-antibiotics-11-01378" ref-type="bibr">74</xref>].<break/>(iv) Phosphotransferases (encoded by <italic toggle="yes">mph</italic> genes) introduce phosphate to the 2&#x02032;-hydroxyl group of the 14-, 15-, and 16-membered lactone rings of macrolides amino sugar, which interferes with the interaction of the antibiotic with nucleotide A2058 [<xref rid="B52-antibiotics-11-01378" ref-type="bibr">52</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modification of the bacterial ribosome and active efflux from the bacterial cell are important mechanisms of macrolide resistance in <italic toggle="yes">S. aureus</italic>.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lincosamides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discovered in 1966.<break/>SSTI caused by CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>]<break/>
<break/>(Resistance 1968) [<xref rid="B30-antibiotics-11-01378" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clindamycin binds to bacterial 23S rRNA in the 50S ribosomal subunit and impedes both the assembly of ribosomes and the translation process [<xref rid="B75-antibiotics-11-01378" ref-type="bibr">75</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">ermA</italic>, <italic toggle="yes">ermB</italic>, <italic toggle="yes">ermC</italic> [<xref rid="B76-antibiotics-11-01378" ref-type="bibr">76</xref>]<break/><italic toggle="yes">cfr</italic> [<xref rid="B41-antibiotics-11-01378" ref-type="bibr">41</xref>,<xref rid="B42-antibiotics-11-01378" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) The rRNA methylase (encoded by <italic toggle="yes">erm</italic> genes) methylates an adenosine nucleotide within the peptidyl transferase center, resulting in the C-8 methylation of A2503 (m<sup>8</sup>A2503) [<xref rid="B77-antibiotics-11-01378" ref-type="bibr">77</xref>].<break/>(ii) The acquired <italic toggle="yes">cfr</italic> gene encoded rRNA methyltransferase methylates an adenine residue of the 23S rRNA in the 50S ribosomal subunit [<xref rid="B41-antibiotics-11-01378" ref-type="bibr">41</xref>], resulting in altered antibiotic binding sites within the ribosome.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aminoglycosides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gentamicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 1971. Bacterial meningitis, sepsis of newborns, septicemia, UTI<break/>
<break/>(Resistance 1975) [<xref rid="B78-antibiotics-11-01378" ref-type="bibr">78</xref>,<xref rid="B79-antibiotics-11-01378" ref-type="bibr">79</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gentamicin binds to the A-site on the 16S rRNA helix at the mRNA-tRNA decoding center of bacterial 30S ribosome subunit [<xref rid="B80-antibiotics-11-01378" ref-type="bibr">80</xref>,<xref rid="B81-antibiotics-11-01378" ref-type="bibr">81</xref>], causing the inhibition and inaccurate induction of translation, disrupting protein synthesis [<xref rid="B82-antibiotics-11-01378" ref-type="bibr">82</xref>,<xref rid="B83-antibiotics-11-01378" ref-type="bibr">83</xref>,<xref rid="B84-antibiotics-11-01378" ref-type="bibr">84</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;) <break/><italic toggle="yes">aadD</italic> (AG <italic toggle="yes">O</italic>-adenyltransferase) [<xref rid="B85-antibiotics-11-01378" ref-type="bibr">85</xref>]<break/><italic toggle="yes">ant</italic>(4&#x02032;) (AG <italic toggle="yes">O</italic>-nucleotidyltransferase(4&#x02032;))<break/><italic toggle="yes">ant</italic>(9) (<italic toggle="yes">AG O</italic>-nucleotidyltransferase(9))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The bifunctional AMEs inactivate aminoglycosides by acetylating, phosphorylating, or adenylating amino or hydroxyl groups [<xref rid="B51-antibiotics-11-01378" ref-type="bibr">51</xref>,<xref rid="B85-antibiotics-11-01378" ref-type="bibr">85</xref>]<break/>Gentamicin, tobramycin and kanamycin resistance is generally mediated by a bifunctional AME AAC(6&#x02032;)-APH(2&#x02033;) (encoded by <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;<italic toggle="yes">)</italic> gene<italic toggle="yes">)</italic> that specifies 6&#x02032;-acetyltransferase [AAC(6&#x02032;)] and/or 2&#x02033;-phosphotransferase [APH(2&#x02033;)] aminoglycoside modifying activities [<xref rid="B36-antibiotics-11-01378" ref-type="bibr">36</xref>,<xref rid="B37-antibiotics-11-01378" ref-type="bibr">37</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;<italic toggle="yes">)</italic> gene is most prevalent in aminoglycoside resistant <italic toggle="yes">S. aureus</italic> [<xref rid="B86-antibiotics-11-01378" ref-type="bibr">86</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arbekacin<break/>(not used clinically in the U.S.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japanese PMDA 1990 [<xref rid="B87-antibiotics-11-01378" ref-type="bibr">87</xref>].<break/>Pneumonia and sepsis due to MRSA. <break/>
<break/>(Resistance 1979) [<xref rid="B88-antibiotics-11-01378" ref-type="bibr">88</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arbekacin binds to both 50S and the 30S ribosomal subunits, resulting in codon misreading and inhibition of translation [<xref rid="B89-antibiotics-11-01378" ref-type="bibr">89</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">aac</italic>(<italic toggle="yes">6</italic>&#x02032;)-<italic toggle="yes">aph</italic>(<italic toggle="yes">2</italic>&#x02033;) [<xref rid="B88-antibiotics-11-01378" ref-type="bibr">88</xref>,<xref rid="B90-antibiotics-11-01378" ref-type="bibr">90</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) A single base alteration (G1126A) of <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;<italic toggle="yes">)</italic> gene resulted in one amino acid substitution S376N in AAC(6&#x02032;)/APH(2&#x02033;), which leads to arbekacin resistance in MRSA strain PRC104 [<xref rid="B90-antibiotics-11-01378" ref-type="bibr">90</xref>].<break/>(ii) &#x003b2;-lactam-inducible arbekacin resistance was reported in MRSA strain by the integration of Tn4001-IS257 hybrid structure containing <italic toggle="yes">aac(6</italic>&#x02032;<italic toggle="yes">)/aph(2</italic>&#x02033;<italic toggle="yes">)</italic> gene cointegrated into a region downstream of <italic toggle="yes">blaZ</italic> gene [<xref rid="B91-antibiotics-11-01378" ref-type="bibr">91</xref>].(iii) The AAC(6&#x02032;)/APH(2&#x02033;) modify arbekacin by 6&#x02032;-<italic toggle="yes">N</italic>-acetylation and/or 2&#x02033;-<italic toggle="yes">O</italic>-phosphorylation of AGs that contain 6&#x02032;-NH<sub>2</sub> and/or 2&#x02033;-OH [<xref rid="B37-antibiotics-11-01378" ref-type="bibr">37</xref>,<xref rid="B92-antibiotics-11-01378" ref-type="bibr">92</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arbekacin is not inactivated by AMEs (3&#x02032;)(APH), (4&#x02032;)(AAD), or AAD(2&#x02033;) and has a weak affinity to (6&#x02032;-IV) (AAC) [<xref rid="B93-antibiotics-11-01378" ref-type="bibr">93</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycopeptides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell wall synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1958.<break/>Bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, sepsis, and complicated SSTI due to HA-MRSA and CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>].<break/>
<break/>(Resistance VISA in 1996 [<xref rid="B28-antibiotics-11-01378" ref-type="bibr">28</xref>] and VRSA in 2002 [<xref rid="B94-antibiotics-11-01378" ref-type="bibr">94</xref>])</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin bind to D-Ala-D-Ala termini moieties of Lipid II precursor of peptidoglycan through a series of hydrogen bonds, leading to conformational alteration that prevents incorporation of NAM- and NAG-peptide subunits to the growing peptidoglycan chain and consequent transpeptidation [<xref rid="B95-antibiotics-11-01378" ref-type="bibr">95</xref>,<xref rid="B96-antibiotics-11-01378" ref-type="bibr">96</xref>,<xref rid="B97-antibiotics-11-01378" ref-type="bibr">97</xref>]. This alters membrane integrity and increases permeability, leading to bacterial death.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">vanA</italic> [<xref rid="B97-antibiotics-11-01378" ref-type="bibr">97</xref>,<xref rid="B98-antibiotics-11-01378" ref-type="bibr">98</xref>]<break/>
<break/>Mutations in <italic toggle="yes">walKR, vraSR</italic>, <italic toggle="yes">graSR,</italic> and <italic toggle="yes">clpP</italic><break/>
<break/>Mutation in <italic toggle="yes">rpoB</italic> [<xref rid="B99-antibiotics-11-01378" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-11-01378" ref-type="bibr">100</xref>]<break/>
<break/>SNPs in <italic toggle="yes">capB</italic> (E58K) and <italic toggle="yes">lytN</italic> (I16V) gene [<xref rid="B101-antibiotics-11-01378" ref-type="bibr">101</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) VRSA: The Tn<italic toggle="yes">1546</italic>-borne <italic toggle="yes">vanA</italic> gene cluster encodes 9 proteins (D-Ala:D-Lac ligases) that modify D-Ala-D-Ala termini of peptidoglycan chains to D-Ala-D-Lactate, thereby inhibiting target binding by vancomycin [<xref rid="B102-antibiotics-11-01378" ref-type="bibr">102</xref>,<xref rid="B103-antibiotics-11-01378" ref-type="bibr">103</xref>].<break/>(ii) VISA: Mutations in TCSs like essential <italic toggle="yes">WalKR</italic> [<xref rid="B104-antibiotics-11-01378" ref-type="bibr">104</xref>,<xref rid="B105-antibiotics-11-01378" ref-type="bibr">105</xref>,<xref rid="B106-antibiotics-11-01378" ref-type="bibr">106</xref>,<xref rid="B107-antibiotics-11-01378" ref-type="bibr">107</xref>], <italic toggle="yes">VraSR</italic> [<xref rid="B108-antibiotics-11-01378" ref-type="bibr">108</xref>,<xref rid="B109-antibiotics-11-01378" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-11-01378" ref-type="bibr">110</xref>], and <italic toggle="yes">GraSR</italic> [<xref rid="B107-antibiotics-11-01378" ref-type="bibr">107</xref>,<xref rid="B109-antibiotics-11-01378" ref-type="bibr">109</xref>,<xref rid="B110-antibiotics-11-01378" ref-type="bibr">110</xref>,<xref rid="B111-antibiotics-11-01378" ref-type="bibr">111</xref>,<xref rid="B112-antibiotics-11-01378" ref-type="bibr">112</xref>] affect cell wall biosynthesis, resulting in reduced susceptibility to vancomycin.<break/>(iii) Mutation in <italic toggle="yes">rpoB</italic> (encoding RNA polymerase subunit B) [<xref rid="B99-antibiotics-11-01378" ref-type="bibr">99</xref>,<xref rid="B100-antibiotics-11-01378" ref-type="bibr">100</xref>].<break/>(iv) Mutation in TCS <italic toggle="yes">walKR</italic> and proteolytic regulatory gene <italic toggle="yes">clpP</italic> leads to raised vancomycin resistance in laboratory VISA strain N315LR5P1 [<xref rid="B113-antibiotics-11-01378" ref-type="bibr">113</xref>].<break/>(v) SNPs in <italic toggle="yes">capB</italic> (E58K) gene (encoding tyrosine kinase) and <italic toggle="yes">lytN</italic> (I16V) gene (encoding <italic toggle="yes">N</italic>-acetylmuramyl-L-alanine amidase) cause increased <italic toggle="yes">S. aureus</italic> resistance to vancomycin in the absence of <italic toggle="yes">van</italic> genes [<xref rid="B101-antibiotics-11-01378" ref-type="bibr">101</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VRSA is mediated by the <italic toggle="yes">vanA</italic> gene cluster, which is transferred from vancomycin-resistant Enterococcus [<xref rid="B114-antibiotics-11-01378" ref-type="bibr">114</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teicoplanin <break/>(formerly known as teichomycin A2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1988.<break/>Approved in Europe for SSTI, pneumonia, and sepsis [<xref rid="B115-antibiotics-11-01378" ref-type="bibr">115</xref>]. <break/>Never approved for use in the U.S.<break/>
<break/>(Resistance 2000) [<xref rid="B116-antibiotics-11-01378" ref-type="bibr">116</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Teicoplanin inhibits peptidoglycan polymerization, leading to the inhibition of bacterial cell-wall synthesis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">tcaRAB</italic> [<xref rid="B117-antibiotics-11-01378" ref-type="bibr">117</xref>,<xref rid="B118-antibiotics-11-01378" ref-type="bibr">118</xref>], <italic toggle="yes">tcaA</italic> [<xref rid="B119-antibiotics-11-01378" ref-type="bibr">119</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) The <italic toggle="yes">tcaRAB</italic> operon may be involved in increased teicoplanin resistance in <italic toggle="yes">S. aureus</italic> [<xref rid="B118-antibiotics-11-01378" ref-type="bibr">118</xref>].<break/>(ii) Mutation in <italic toggle="yes">tcaRAB</italic> may influence the transcription of the cell wall biosynthesis gene and may contribute to increasing teicoplanin resistance [<xref rid="B117-antibiotics-11-01378" ref-type="bibr">117</xref>].<break/>(iii) The <italic toggle="yes">tcaA</italic> gene within <italic toggle="yes">tcaRAB</italic> plays a relevant role in teicoplanin resistance in <italic toggle="yes">S. aureus</italic> clinical isolates [<xref rid="B119-antibiotics-11-01378" ref-type="bibr">119</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BSAC recommended breakpoint for teicoplanin are susceptible (MIC &#x02264; 2 mg/L) and resistant (MIC &#x0003e; 2 mg/L).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oxazolidinones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linezolid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2000.<break/>ABSSSI, pneumonia, BJI, catheter- related bacteremia [<xref rid="B120-antibiotics-11-01378" ref-type="bibr">120</xref>]<break/>
<break/>(Resistance 2001) [<xref rid="B121-antibiotics-11-01378" ref-type="bibr">121</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linezolid binds to bacterial 23S rRNA in the 50S ribosome subunit, thereby preventing the formation of functional 70S ribosomal initiation complex with 30S subunit, mRNA, initiation factors, and <italic toggle="yes">N</italic>-formylmethionyl-tRNA (tRNA<sup>fMet</sup>) [<xref rid="B122-antibiotics-11-01378" ref-type="bibr">122</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">cfr</italic> [<xref rid="B123-antibiotics-11-01378" ref-type="bibr">123</xref>]<break/>Mutations in <italic toggle="yes">23S rRNA</italic> [<xref rid="B121-antibiotics-11-01378" ref-type="bibr">121</xref>,<xref rid="B124-antibiotics-11-01378" ref-type="bibr">124</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Acquisition of <italic toggle="yes">cfr</italic> gene encoding 23S rRNA methyltransferase [<xref rid="B125-antibiotics-11-01378" ref-type="bibr">125</xref>], which modifies adenosine at position 2503 in 23S rRNA in the large ribosomal subunit [<xref rid="B126-antibiotics-11-01378" ref-type="bibr">126</xref>].<break/>(ii) The T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA [<xref rid="B127-antibiotics-11-01378" ref-type="bibr">127</xref>].<break/>(iii) Mutations G2576T, G2576T, G2447T in domain V of 23S rRNA [<xref rid="B121-antibiotics-11-01378" ref-type="bibr">121</xref>,<xref rid="B124-antibiotics-11-01378" ref-type="bibr">124</xref>] and amino acid changes in ribosomal proteins L3 and L4 [<xref rid="B128-antibiotics-11-01378" ref-type="bibr">128</xref>] lead to conformational changes in the ribosome.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tedizolid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2014; E.U. EMA 2015.ABSSSI and pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tedizolid binds to 23S rRNA in the 50S ribosome subunit and prevents the formation of 70S ribosomal initial complex, resulting in inhibition of bacterial protein synthesis [<xref rid="B129-antibiotics-11-01378" ref-type="bibr">129</xref>,<xref rid="B130-antibiotics-11-01378" ref-type="bibr">130</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">cfr</italic><break/><italic toggle="yes">rplC</italic>, <italic toggle="yes">rplD, rplV</italic>,<break/><italic toggle="yes">rpoB</italic> [<xref rid="B131-antibiotics-11-01378" ref-type="bibr">131</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Mutations in domain V region of 23S rRNA target confer resistance to tedizolid.<break/>(ii) Mutations in ribosomal proteins L3, L4, and L22 (encoded by <italic toggle="yes">rplC</italic>, <italic toggle="yes">rplD</italic>, and <italic toggle="yes">rplV</italic> genes<italic toggle="yes">,</italic> respectively) and the 23S rRNA target [<xref rid="B132-antibiotics-11-01378" ref-type="bibr">132</xref>].<break/>(iii) Mutation in <italic toggle="yes">rpoB</italic> corresponding to amino acid substitution D449N [<xref rid="B131-antibiotics-11-01378" ref-type="bibr">131</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutation in L3, L4, and L22 also mediate PhLOPSa (phenicol, lincosamide, oxazolidinone, pleuromutilin, and streptogramin A) resistance.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contezolid </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NMPA of China 2021 [<xref rid="B133-antibiotics-11-01378" ref-type="bibr">133</xref>].<break/>Complicated SSTI, ABSSSI<break/>
<break/>(Resistance 2021) [<xref rid="B134-antibiotics-11-01378" ref-type="bibr">134</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contezolid binds to the 23S rRNA region adjacent to the peptidyl transferase center of the 50S ribosomal subunit and prevents the formation of a functional 70S initiation complex, thereby interfering with bacterial protein synthesis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">cfr, optrA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contezolid exhibited limited activity against strains with linezolid resistance genes <italic toggle="yes">cfr</italic> and <italic toggle="yes">optrA</italic> [<xref rid="B134-antibiotics-11-01378" ref-type="bibr">134</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contezolid has reduced hematologic toxicity compared to linezolid</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipopeptides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell wall synthesis<break/>Cell membrane </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daptomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2003. Bacteremia, ABSSSI<break/>(Nonsusceptible 2004) [<xref rid="B135-antibiotics-11-01378" ref-type="bibr">135</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daptomycin complexes with Ca<sup>2+</sup> to form oligomers that insert into bacterial membranes, resulting in depolarization, permeabilization, leakage of ions, and ultimately bacterial death [<xref rid="B136-antibiotics-11-01378" ref-type="bibr">136</xref>].<break/>Daptomycin disrupts the localization of cell wall synthesis enzymes such as MurG, further interfering with cell wall synthesis [<xref rid="B137-antibiotics-11-01378" ref-type="bibr">137</xref>,<xref rid="B138-antibiotics-11-01378" ref-type="bibr">138</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">mprF, dltA</italic> [<xref rid="B139-antibiotics-11-01378" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-11-01378" ref-type="bibr">140</xref>]<italic toggle="yes">, yycH, yycI</italic> [<xref rid="B141-antibiotics-11-01378" ref-type="bibr">141</xref>], <italic toggle="yes">rpoB</italic> [<xref rid="B99-antibiotics-11-01378" ref-type="bibr">99</xref>]<italic toggle="yes">, walKR,</italic>
<italic toggle="yes">vraSR</italic>, <italic toggle="yes">graSR</italic> [<xref rid="B142-antibiotics-11-01378" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-11-01378" ref-type="bibr">143</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Alteration of the surface charge of cells due to mutation in <italic toggle="yes">mprF</italic> gene (encoding phosphatidylglycerol lysyltransferase) which leads to lysinylation of PG and translocation of lysyl-PG [<xref rid="B144-antibiotics-11-01378" ref-type="bibr">144</xref>].<break/>(ii) Mutation in TCSs <italic toggle="yes">walKR,</italic>
<italic toggle="yes">vraSR</italic>, and <italic toggle="yes">graSR</italic> which are involved in cell wall synthesis and permeability are associated with daptomycin susceptibility in <italic toggle="yes">S. aureus</italic> [<xref rid="B142-antibiotics-11-01378" ref-type="bibr">142</xref>,<xref rid="B143-antibiotics-11-01378" ref-type="bibr">143</xref>].<break/>(iii) Mutation in <italic toggle="yes">rpoB</italic> gene (encoding RNA polymerase) confers dual heteroresistance to daptomycin and vancomycin [<xref rid="B99-antibiotics-11-01378" ref-type="bibr">99</xref>].<break/>(iv) Mutations in <italic toggle="yes">yycH</italic> and <italic toggle="yes">yycI</italic> genes lead to the loss of protein functions essential for cell wall synthesis [<xref rid="B141-antibiotics-11-01378" ref-type="bibr">141</xref>].<break/>(v) <italic toggle="yes">dltA</italic> gene overexpression leads to electrostatic repulsion and indirectly reduces autolysin, resulting in daptomycin nonsusceptibility [<xref rid="B139-antibiotics-11-01378" ref-type="bibr">139</xref>,<xref rid="B140-antibiotics-11-01378" ref-type="bibr">140</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> strains with MIC &#x02264; 1 &#x003bc;g/mL are referred as daptomycin-susceptible (DAP-S) [<xref rid="B145-antibiotics-11-01378" ref-type="bibr">145</xref>] and MIC &#x0003e;1 &#x003bc;g/mL as daptomycin-non susceptible [<xref rid="B146-antibiotics-11-01378" ref-type="bibr">146</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipoglycopeptides</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell wall synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Telavancin<break/>(derivative of vancomycin. Addition of the hydrophobic side chain and hydrophilic group results in enhanced activity [<xref rid="B147-antibiotics-11-01378" ref-type="bibr">147</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2009 and 2013 [<xref rid="B148-antibiotics-11-01378" ref-type="bibr">148</xref>].<break/>Complicated SSTI, pneumonia, BJI, ABSSSI, bacteremia [<xref rid="B149-antibiotics-11-01378" ref-type="bibr">149</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan synthesis, like vancomycin. Additionally, it depolarizes the bacterial cell membrane and disrupts its functional integrity [<xref rid="B150-antibiotics-11-01378" ref-type="bibr">150</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The <italic toggle="yes">vanA</italic>-mediated telavancin resistance is rare in MRSA [<xref rid="B151-antibiotics-11-01378" ref-type="bibr">151</xref>].<break/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracyclines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracycline </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1948 [<xref rid="B152-antibiotics-11-01378" ref-type="bibr">152</xref>]<break/>SSTI<break/>
<break/>(Resistance 1953) [<xref rid="B44-antibiotics-11-01378" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracycline binds to bacterial 30S ribosomal subunit and prevents the aminoacyl tRNA from binding to A site of the rRNA, resulting in inhibition of translation. To some extent, it also binds to the bacterial 50S ribosomal subunit [<xref rid="B44-antibiotics-11-01378" ref-type="bibr">44</xref>,<xref rid="B153-antibiotics-11-01378" ref-type="bibr">153</xref>,<xref rid="B154-antibiotics-11-01378" ref-type="bibr">154</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">tetM, tetO</italic>, <italic toggle="yes">tetK</italic> [<xref rid="B155-antibiotics-11-01378" ref-type="bibr">155</xref>]<italic toggle="yes">, tetS/M, tetA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Ribosomal protection: the <italic toggle="yes">tetM</italic> and <italic toggle="yes">tetO</italic> genes encode enzymes that destabilize the interaction between tetracyclines and their cellular target ribosome [<xref rid="B44-antibiotics-11-01378" ref-type="bibr">44</xref>,<xref rid="B45-antibiotics-11-01378" ref-type="bibr">45</xref>].<break/>(ii) Active efflux: the <italic toggle="yes">tetK</italic> gene encodes efflux protein that couples the tetracycline with proton motive force to pump it out from the cell against the concentration gradient [<xref rid="B44-antibiotics-11-01378" ref-type="bibr">44</xref>,<xref rid="B155-antibiotics-11-01378" ref-type="bibr">155</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The <italic toggle="yes">tetK</italic> gene is normally found <italic toggle="yes">in S. aureus</italic>.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxycycline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 1967 [<xref rid="B156-antibiotics-11-01378" ref-type="bibr">156</xref>,<xref rid="B157-antibiotics-11-01378" ref-type="bibr">157</xref>].<break/>UTI, SSTI [<xref rid="B27-antibiotics-11-01378" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxycycline inhibits bacterial protein synthesis by preventing the association of aminoacyl tRNA with the ribosome, an MoA similar to tetracycline.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">tetK</italic> [<xref rid="B158-antibiotics-11-01378" ref-type="bibr">158</xref>,<xref rid="B159-antibiotics-11-01378" ref-type="bibr">159</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active efflux by <italic toggle="yes">tetK</italic> encoded efflux [<xref rid="B158-antibiotics-11-01378" ref-type="bibr">158</xref>,<xref rid="B159-antibiotics-11-01378" ref-type="bibr">159</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tigecycline </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2005.ABSSSI, pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tigecycline inhibits protein synthesis, an MoA similar to tetracycline but with enhanced binding.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">tetM, tetO, tetX</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The oxygen-dependent destruction of tigecycline is catalyzed by the enzyme TetX [<xref rid="B160-antibiotics-11-01378" ref-type="bibr">160</xref>,<xref rid="B161-antibiotics-11-01378" ref-type="bibr">161</xref>,<xref rid="B162-antibiotics-11-01378" ref-type="bibr">162</xref>].<break/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tigecycline retains activity against both <italic toggle="yes">tetM</italic> and <italic toggle="yes">tetO.</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omadacycline<break/>(derived from tetracycline) [<xref rid="B163-antibiotics-11-01378" ref-type="bibr">163</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2018.ABSSSI, SSTI [<xref rid="B164-antibiotics-11-01378" ref-type="bibr">164</xref>], pneumonia (CA-associated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omadacycline binds to bacterial 30S ribosomal subunit and inhibits protein synthesis, an MoA similar to tetracycline with enhanced binding like tigecycline [<xref rid="B165-antibiotics-11-01378" ref-type="bibr">165</xref>].<break/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resistance mechanism not reported.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unaffected by the presence of <italic toggle="yes">tetK</italic> active efflux gene and ribosomal protection <italic toggle="yes">tetM</italic> or <italic toggle="yes">tetO</italic> gene [<xref rid="B166-antibiotics-11-01378" ref-type="bibr">166</xref>,<xref rid="B167-antibiotics-11-01378" ref-type="bibr">167</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fusidane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fusidic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1962.<break/>ABSSSI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fusidic acid binds to elongation factor G (EF-G) on the ribosome, thereby preventing the release of EF-G-guanosine diphosphate complex and delaying bacterial protein synthesis by inhibiting the next stage in translation [<xref rid="B168-antibiotics-11-01378" ref-type="bibr">168</xref>,<xref rid="B169-antibiotics-11-01378" ref-type="bibr">169</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">fusA</italic> [<xref rid="B170-antibiotics-11-01378" ref-type="bibr">170</xref>]<italic toggle="yes">, fusB</italic> [<xref rid="B171-antibiotics-11-01378" ref-type="bibr">171</xref>,<xref rid="B172-antibiotics-11-01378" ref-type="bibr">172</xref>], <italic toggle="yes">fusc, fusD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Mutations in chromosomal <italic toggle="yes">fusA</italic> (encoding ribosomal translocase and translation elongation factor EF-G) [<xref rid="B170-antibiotics-11-01378" ref-type="bibr">170</xref>] or <italic toggle="yes">fusE</italic> genes confer high-level resistance to fusidic acid.<break/>(ii) Mutation in acquired genes <italic toggle="yes">fusB</italic> (encoding an inducible protein that protects an in vitro translation) [<xref rid="B171-antibiotics-11-01378" ref-type="bibr">171</xref>,<xref rid="B172-antibiotics-11-01378" ref-type="bibr">172</xref>] and <italic toggle="yes">fusD</italic> genes mediate low-level resistance.<break/>These mutations affect the elongation factor EF-6.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The <italic toggle="yes">fusc</italic> and <italic toggle="yes">fusD</italic> are homologs of <italic toggle="yes">fusB</italic> [<xref rid="B173-antibiotics-11-01378" ref-type="bibr">173</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pleuromutilin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retapamulin<break/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2007.<break/>Impetigo [<xref rid="B174-antibiotics-11-01378" ref-type="bibr">174</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retapamulin binds to domain V of 23S rRNA on the 50S ribosome subunit, thereby blocking peptide formation directly by interfering with substrate binding.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">23S rRNA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resistance to retapamulin occurs due to mutations in the genes encoding 23S rRNA methyltransferase.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retapamulin is a semisynthetic derivative of pleuromutilin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluoroquinolones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA replication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-antibiotics-11-01378" ref-type="bibr">46</xref>,<xref rid="B175-antibiotics-11-01378" ref-type="bibr">175</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin<break/>(2<sup>nd</sup>-generation fluoroquinolone)<break/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 1987.UTI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin target bacterial DNA topoisomerase IV and DNA gyrase, thus preventing it from supercoiling the bacterial DNA [<xref rid="B176-antibiotics-11-01378" ref-type="bibr">176</xref>], which leads to inhibition of DNA replication [<xref rid="B177-antibiotics-11-01378" ref-type="bibr">177</xref>,<xref rid="B178-antibiotics-11-01378" ref-type="bibr">178</xref>].<break/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">gyrA</italic> [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>]<italic toggle="yes">, grlA</italic> [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>]<italic toggle="yes">, flqA</italic> (formerly <italic toggle="yes">ofx/cfx</italic>) [<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>], <italic toggle="yes">norA</italic> [<xref rid="B58-antibiotics-11-01378" ref-type="bibr">58</xref>,<xref rid="B179-antibiotics-11-01378" ref-type="bibr">179</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Mutation in the genes <italic toggle="yes">grlA</italic> (encoding DNA topoisomerase IV subunit A) [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>,<xref rid="B46-antibiotics-11-01378" ref-type="bibr">46</xref>], <italic toggle="yes">gyrA</italic> (encoding DNA gyrase subunit A) [<xref rid="B33-antibiotics-11-01378" ref-type="bibr">33</xref>,<xref rid="B34-antibiotics-11-01378" ref-type="bibr">34</xref>,<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>], and <italic toggle="yes">flqA</italic> (linked to DNA topoisomerase IV) [<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>].<break/>(ii) Mutations in the gene <italic toggle="yes">norA</italic> (encoding a membrane-associated active efflux pump NorA) [<xref rid="B58-antibiotics-11-01378" ref-type="bibr">58</xref>,<xref rid="B180-antibiotics-11-01378" ref-type="bibr">180</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated <italic toggle="yes">norA</italic> expression potentiates evolution by increasing the fitness benefit provided by a mutation in DNA topoisomerase [<xref rid="B179-antibiotics-11-01378" ref-type="bibr">179</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Levofloxacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 1996.<break/>RTI, UTI, SSTI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Levofloxacin inhibits bacterial DNA replication, an MoA similar to ciprofloxacin.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">gyrA, grlA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Mutation in the genes <italic toggle="yes">grlA</italic> and <italic toggle="yes">gyrA</italic> [<xref rid="B181-antibiotics-11-01378" ref-type="bibr">181</xref>].<break/>(ii) Mutations in the gene <italic toggle="yes">norA</italic> [<xref rid="B180-antibiotics-11-01378" ref-type="bibr">180</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delafloxacin<break/>(previously referred to as ABT-492) [<xref rid="B182-antibiotics-11-01378" ref-type="bibr">182</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2017 [<xref rid="B183-antibiotics-11-01378" ref-type="bibr">183</xref>]; E.U. EMA 2019. <break/>SSTI, ABSSSI<break/>
<break/>(Resistance 2017) [<xref rid="B184-antibiotics-11-01378" ref-type="bibr">184</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delafloxacin inhibits bacterial DNA replication by blocking both DNA topoisomerase IV and DNA gyrase, an MoA similar to ciprofloxacin [<xref rid="B182-antibiotics-11-01378" ref-type="bibr">182</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">grlA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Point mutations in the <italic toggle="yes">grlA</italic> [<xref rid="B185-antibiotics-11-01378" ref-type="bibr">185</xref>,<xref rid="B186-antibiotics-11-01378" ref-type="bibr">186</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delafloxacin is not active substrate for <italic toggle="yes">S. aureus</italic> efflux pumps [<xref rid="B185-antibiotics-11-01378" ref-type="bibr">185</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quinolones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA replication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ozenoxacin<break/>(topical quinolone without fluorine at C6-position)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. FDA 2017.Japanese PMDA 2016 [<xref rid="B187-antibiotics-11-01378" ref-type="bibr">187</xref>].<break/>SSTI (impetigo) caused by MRSA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ozenoxacin inhibits bacterial DNA replication by dual-targeting activity against DNA topoisomerase IV and DNA gyrase [<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">grlA, grlB</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutations in QRDR regions of <italic toggle="yes">grlA</italic> and <italic toggle="yes">gyrA</italic> are the primary cause of decreased susceptibility to ozenoxacin [<xref rid="B35-antibiotics-11-01378" ref-type="bibr">35</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low MIC of ozenoxacin was observed for MSSA and MRSA strains with reduced susceptibility to nadifloxacin [<xref rid="B187-antibiotics-11-01378" ref-type="bibr">187</xref>]. </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyrimidine/ <break/>Sulfonamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Folate synthesis (DNA synthesis and protein synthesis)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trimethoprim&#x02013;Sulfamethoxazole (TMP-SMX)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UTI, SSTI, and BJI due to CA-MRSA [<xref rid="B29-antibiotics-11-01378" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMP binds and inhibits the dihydrofolate reductase, thereby preventing the conversion of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF) [<xref rid="B188-antibiotics-11-01378" ref-type="bibr">188</xref>]. THF is an essential precursor of the thymidine synthesis pathway and interference with this pathway results in inhibition of bacterial DNA synthesis.<break/>SMX inhibits bacterial dihydropteroate synthase, an enzyme involved upstream in the thymidine synthesis pathway, resulting in the inhibition of folic acid biosynthesis [<xref rid="B188-antibiotics-11-01378" ref-type="bibr">188</xref>]. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">dfrA</italic>, <italic toggle="yes">dfrB</italic> [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>], <italic toggle="yes">dfrD</italic> [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>], <italic toggle="yes">dfrG</italic> [<xref rid="B190-antibiotics-11-01378" ref-type="bibr">190</xref>], <italic toggle="yes">dfrK,</italic>
<italic toggle="yes">dfrS1</italic> [<xref rid="B191-antibiotics-11-01378" ref-type="bibr">191</xref>,<xref rid="B192-antibiotics-11-01378" ref-type="bibr">192</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) The acquisition of <italic toggle="yes">dfrA</italic> gene (encoding DHFR) and mutation of the chromosomal <italic toggle="yes">dfrB</italic> gene (encoding SaDHFR) are considered key determinants of TMP-SMX resistance [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>,<xref rid="B193-antibiotics-11-01378" ref-type="bibr">193</xref>,<xref rid="B194-antibiotics-11-01378" ref-type="bibr">194</xref>,<xref rid="B195-antibiotics-11-01378" ref-type="bibr">195</xref>].<break/>(ii) Point mutation in the <italic toggle="yes">dfrB</italic> gene resulted in a single amino acid substitution Phe98Tyr of SaDHFR, which was associated with TMP-SMX resistance in <italic toggle="yes">S. aureus</italic> [<xref rid="B189-antibiotics-11-01378" ref-type="bibr">189</xref>].<break/>(iii) Transposon-located <italic toggle="yes">dfrA</italic> gene mediates TMP resistance [<xref rid="B194-antibiotics-11-01378" ref-type="bibr">194</xref>,<xref rid="B196-antibiotics-11-01378" ref-type="bibr">196</xref>].<break/>(iv) The <italic toggle="yes">dfrG</italic> gene (encoding DHFR) mainly mediates the TMP resistance in <italic toggle="yes">S. aureus</italic> clinical isolates [<xref rid="B190-antibiotics-11-01378" ref-type="bibr">190</xref>,<xref rid="B195-antibiotics-11-01378" ref-type="bibr">195</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other classes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mupirocin <break/>(previously pseudomonic acid)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discovered in 1971 [<xref rid="B197-antibiotics-11-01378" ref-type="bibr">197</xref>] while marketed for clinical use in the UK in 1985 and US in 1988 [<xref rid="B198-antibiotics-11-01378" ref-type="bibr">198</xref>].<break/>SSTI, nasal carriage of <italic toggle="yes">S. aureus</italic><break/>
<break/>(Resistance 1987) [<xref rid="B199-antibiotics-11-01378" ref-type="bibr">199</xref>,<xref rid="B200-antibiotics-11-01378" ref-type="bibr">200</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mupirocin binds to bacterial isoleucyl transfer RNA (tRNA) synthetase, leading to depletion of isoleucyl&#x02013;tRNA and accumulation of the corresponding uncharged tRNA. This results in the inhibition of protein and RNA synthesis [<xref rid="B201-antibiotics-11-01378" ref-type="bibr">201</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">ileS</italic> [<xref rid="B202-antibiotics-11-01378" ref-type="bibr">202</xref>,<xref rid="B203-antibiotics-11-01378" ref-type="bibr">203</xref>,<xref rid="B204-antibiotics-11-01378" ref-type="bibr">204</xref>]<italic toggle="yes">, mupA</italic> [<xref rid="B205-antibiotics-11-01378" ref-type="bibr">205</xref>,<xref rid="B206-antibiotics-11-01378" ref-type="bibr">206</xref>], and <italic toggle="yes">mupB</italic> [<xref rid="B207-antibiotics-11-01378" ref-type="bibr">207</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Mutations in the chromosomal <italic toggle="yes">ileS</italic> gene (encoding native isoleucyl t-RNA synthetase) result in V588F or V631F alterations [<xref rid="B202-antibiotics-11-01378" ref-type="bibr">202</xref>,<xref rid="B203-antibiotics-11-01378" ref-type="bibr">203</xref>,<xref rid="B204-antibiotics-11-01378" ref-type="bibr">204</xref>], which lead to low-level mupirocin resistance [<xref rid="B205-antibiotics-11-01378" ref-type="bibr">205</xref>].<break/>(ii) Acquisition of the plasmid-encoded <italic toggle="yes">mupA</italic> gene (encoding eukaryotic-like isoleucyl&#x02013;tRNA synthetase variant) [<xref rid="B208-antibiotics-11-01378" ref-type="bibr">208</xref>] confers high-level resistance to mupirocin [<xref rid="B205-antibiotics-11-01378" ref-type="bibr">205</xref>,<xref rid="B206-antibiotics-11-01378" ref-type="bibr">206</xref>].<break/>(iii) Acquisition of the plasmid-encoded <italic toggle="yes">mupB</italic> gene (encoding eukaryotic-like isoleucyl&#x02013;tRNA synthetase variant) confers high-level resistance to mupirocin [<xref rid="B207-antibiotics-11-01378" ref-type="bibr">207</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-level mupirocin resistance (MIC 8&#x02013;256&#x02009;&#x003bc;g/mL) and high-level resistance (MIC &#x02265;&#x02009;512&#x02009;&#x003bc;g/mL) [<xref rid="B209-antibiotics-11-01378" ref-type="bibr">209</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fosfomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discovered in 1969 [<xref rid="B210-antibiotics-11-01378" ref-type="bibr">210</xref>]. <break/>UTI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fosfomycin deactivates the enzyme UDP-<italic toggle="yes">N</italic>-acetylglucosamine enolpyruvyl transferase (MurA) and catalyzes the addition of phosphoenolpyruvate to UDP-<italic toggle="yes">N</italic>-acetylglucosamine (UDP-GlcNAc) to form UDP-<italic toggle="yes">N</italic>-acetylmuramic acid (UDP-MurNAc), thereby inhibiting bacterial cell-wall synthesis [<xref rid="B211-antibiotics-11-01378" ref-type="bibr">211</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">fosB</italic> [<xref rid="B54-antibiotics-11-01378" ref-type="bibr">54</xref>], <italic toggle="yes">glpT</italic> and <italic toggle="yes">uhpT</italic> [<xref rid="B212-antibiotics-11-01378" ref-type="bibr">212</xref>,<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>,<xref rid="B214-antibiotics-11-01378" ref-type="bibr">214</xref>], <italic toggle="yes">murA</italic> [<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>,<xref rid="B215-antibiotics-11-01378" ref-type="bibr">215</xref>] <italic toggle="yes">tet38</italic> [<xref rid="B216-antibiotics-11-01378" ref-type="bibr">216</xref>], <italic toggle="yes">fosY</italic> [<xref rid="B217-antibiotics-11-01378" ref-type="bibr">217</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Thiol-S-transferase (encoded by <italic toggle="yes">fosB</italic> gene) catalyzes the inactivation of fosfomycin [<xref rid="B53-antibiotics-11-01378" ref-type="bibr">53</xref>,<xref rid="B54-antibiotics-11-01378" ref-type="bibr">54</xref>].<break/>(ii) Mutations in fosfomycin uptake transporter proteins GlpT (Trp137/Arg) (encoded by <italic toggle="yes">glpT</italic> gene) [<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>] and UhpT (encoded by <italic toggle="yes">uhpT</italic> genes) [<xref rid="B214-antibiotics-11-01378" ref-type="bibr">214</xref>] reduce the permeability and subsequently prevent fosfomycin from invading the bacterium [<xref rid="B212-antibiotics-11-01378" ref-type="bibr">212</xref>,<xref rid="B213-antibiotics-11-01378" ref-type="bibr">213</xref>].<break/>(iii) Mutation in target enzyme UDP-<italic toggle="yes">N</italic>-acetylglucosamine enolpyruvyl transferase (encoded by <italic toggle="yes">murA</italic> gene) reduces its affinity for fosfomycin [<xref rid="B215-antibiotics-11-01378" ref-type="bibr">215</xref>].<break/>(iv) The major facilitator superfamily efflux transporter Tet38 (encoded by <italic toggle="yes">tet38</italic> gene) contributes to fosfomycin resistance [<xref rid="B216-antibiotics-11-01378" ref-type="bibr">216</xref>].<break/>(v) FosY protein, a putative bacillithiol transferase enzyme (encoded by <italic toggle="yes">fosY</italic> gene) confers resistance to fosfomycin in CC1 <italic toggle="yes">S. aureus</italic> [<xref rid="B217-antibiotics-11-01378" ref-type="bibr">217</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discovered in 1965, introduced for therapy in Italy in 1968, and approved in the United States in 1971 [<xref rid="B218-antibiotics-11-01378" ref-type="bibr">218</xref>].<break/>Endocarditis; BJI [<xref rid="B27-antibiotics-11-01378" ref-type="bibr">27</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampin inhibits transcription (RNA synthesis) by binding to the &#x003b2;-subunit of the bacterial DNA-dependent RNA polymerase [<xref rid="B219-antibiotics-11-01378" ref-type="bibr">219</xref>,<xref rid="B220-antibiotics-11-01378" ref-type="bibr">220</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">rpoB</italic> [<xref rid="B43-antibiotics-11-01378" ref-type="bibr">43</xref>,<xref rid="B221-antibiotics-11-01378" ref-type="bibr">221</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(i) Mutations in the RRDR region of <italic toggle="yes">rpoB</italic> gene (encoding RNA polymerase) resulted in amino acid substitutions of Gln468/Arg, His481/Tyr, and Arg484/His and are associated with high-level resistance to rifampicin [<xref rid="B43-antibiotics-11-01378" ref-type="bibr">43</xref>].<break/>(ii) Mutation in the <italic toggle="yes">rpoB</italic> (N967I) gene causes the substitution Asn967/Ile in the &#x003b2;-subunit of RNA polymerase [<xref rid="B221-antibiotics-11-01378" ref-type="bibr">221</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CLSI breakpoint of rifampicin susceptibility is &#x02264;1 &#x003bc;g/mL [<xref rid="B146-antibiotics-11-01378" ref-type="bibr">146</xref>].</td></tr></tbody></table><table-wrap-foot><fn><p>&#x02013;: not studied or reported, AAC: aminoglycoside acetyltransferase, ABSSSI: acute bacterial skin and skin structure infection, AG: aminoglycoside, AMEs: aminoglycoside-modifying enzymes, ANT: aminoglycoside nucleotidyltransferase, APH: aminoglycoside phosphotransferase, BJI: bone and joint infections, BSAC: British Society for Antimicrobial Chemotherapy, CLSI: Clinical and Laboratory Standards Institute, E.U. EMA: European Union European Medicine Agency, Japanese PMDA: Japanese Pharmaceutical and Medical Devices Agency, MRSA: methicillin-resistant <italic toggle="yes">S. aureus</italic>, MSSA: methicillin-sensitive <italic toggle="yes">S. aureus</italic>, PG: peptidoglycan, QRDR: quinolone-resistance-determining region, RRDR: rifampin-resistance-determining region, rRNA: ribosomal RNA, SaPI: <italic toggle="yes">S. aureus</italic> pathogenicity island, SMX: sulfamethoxazole, SSTI: skin and soft tissue infections, TCSs: two-component regulatory systems, TMP: trimethoprim, U.S. FDA: U.S. Food and Drug Administration, UTI: urinary tract infection, VISA: vancomycin intermediate-resistant <italic toggle="yes">S. aureus</italic>, VRSA: vancomycin-resistant <italic toggle="yes">S. aureus.</italic></p></fn></table-wrap-foot></table-wrap></floats-group></article>